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Introduction
In this thesis, the outline and the results of the fi rst part of the Peripheral 
Neuropathy outcome measures Standardisation (PeriNomS) study are described. 
The PeriNomS study aims to improve and standardise the assessment of patients 
with immune-mediated neuropathies. These disorders are potentially treatable 
with immuno-modulating agents, therefore, proper outcome measures are needed 
to detect clinically important improvement or deterioration over time. 
Immune-mediated neuropathies include Guillain-Barré syndrome (GBS), chronic 
infl ammatory demyelinating polyneuropathy (CIDP), polyneuropathy associated 
with monoclonal gammopathy of undetermined signifi cance (MGUSP), and 
multifocal motor neuropathy (MMN). Electrophysiological examination in these 
patients generally reveals features of a demyelinating polyneuropathy, although a 
subgroup of GBS patients may have predominantly axonal features (acute motor 
axonal neuropathy (AMAN)). Diagnostic criteria for all these neuropathies have 
been formulated.1-4 From a clinical, electrophysiological, and immunological 
point of view there is increasing evidence that these illnesses represent part of a 
continuum, mainly separated by their extent of neuromuscular dysfunction, the 
evolution of weakness over time, and their response to treatment (table 1). In the 
following, a brief overview of these neuropathies is given with particular emphasis 
on their clinical presentation. 
Guillain-Barré syndrome (GBS)
The diagnosis of GBS is generally not diffi cult to establish.4, 5 Hallmark is the 
combination of rapidly progressive symmetrical weakness in arms and legs with 
or without sensory disturbances and decreased or absent tendon refl exes. By 
defi nition, maximum weakness is reached within 4 weeks, but often already within 2 
weeks.6, 7 Cranial nerve involvement, especially bilateral weakness of facial muscles, 
autonomic dysfunction and pain are other clinical features supporting the diagnosis. 
GBS is most often preceded by an infection (diarrhoea or a respiratory infection). 
Diagnostic criteria for GBS were originally developed to aid epidemiological fi eld 
studies.7, 8 Recently, the Brighton group suggested new criteria, however, their 
primary aim was proper case defi nition to analyse immunisation safety data.9 GBS 
is a heterogeneous disease with a monophasic course of disease; some patients are 
only mildly affected and recover quickly, whereas others are completely paralysed 
within 24 hours and remain bedbound for months. About 25% of GBS patients 
admitted to the hospital need mechanical ventilation mainly due to weakness of 
the respiratory muscles. Despite treatment 3-10% of patients die, 20% are unable 
to walk after six months and between 25 and 85% still have residual signs and 
symptoms after 2-7 years.10 Weakness has demonstrated to have the strongest 
impact on ability limitations and participation restrictions.11 Cerebrospinal fl uid 
(CSF) examination typically shows increased protein levels (often not in the fi rst 
week, but in about 90% in the second week after onset of disease). The most 
important reason however to perform CSF analysis is to investigate whether the 
cell count is normal (as it generally is in GBS), or whether it is increased (which 
should suspect for example neuroborreliosis). With electromyography (EMG) it is 
possible to characterise the pattern of GBS as either more demyelinating (acute 
infl ammatory demyelinating polyradiculoneuropathy (AIDP)) or axonal (AMAN).12 
Patients with an intermediate ‘subacute’ time course have also been reported as 
having a subacute infl ammatory demyelinating polyneuropathy (SAIDP) reaching 
their nadir between 4 to 8 weeks of onset.13 About 10% of patients with GBS have 
‘treatment-related fl uctuations’, a fl uctuating course after initial improvement or 
stabilisation after treatment with intravenous immunoglobulins (IVIg). About 5% 
of patients initially diagnosed as GBS turn out to progress to CIDP, acute onset 
CIDP (A-CIDP).14 Benefi cial effects of IVIg as well as plasma exchange have been 
demonstrated for GBS patients.15-17 In many centres IVIg is the preferred treatment 
because of its greater convenience, availability and side-effect profi le.
Chronic inflammatory demyelinating polyneuropathy (CIDP)
Patients with CIDP usually have symmetrical distal and proximal weakness that 
generally predominates over sensory defi cit. Sensory-motor pattern is most commonly 
seen, although pure motor or pure sensory patterns have been reported.1, 18, 19 
Arefl exia is common. CIDP patients usually have a chronic onset of a progressive 
or relapsing phase over a period of more than 2 months.20, 21 Thereafter weakness 
may progress or may be stable during months or years, or the patients may improve 
spontaneously followed by a relapsing-remitting course.22 In general, motor 
impairment has a stronger impact on daily and social functioning than sensory 
defi cit.11
Up to 16% of all patients with CIDP however do have an acute onset (A-CIDP), 
initially resembling the course of GBS. A-CIDP instead of GBS should be considered 
if a patient deteriorates again after 8 weeks from onset or if ≥3 treatment-related 
fl uctuations occur.14 Compared to GBS, the diagnosis of CIDP, in general is much 
more diffi cult to make. The American Academy of Neurology (AAN) research criteria 
for CIDP are rather restrictive, many patients diagnosed with CIDP by clinicians 
do not meet these research criteria.20 The European Federation of Neurological 
Societies/Peripheral Nerve Society (EFNS/PNS) criteria including clinical and 
electrodiagnostic criteria were designed to overcome this limitation.21 Prior to 
making the diagnosis of CIDP, it is essential to rule out other causes of chronic 
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polyneuropathies (or make them at least unlikely), such as hereditary neuropathies, 
vasculitis, cryoglobulinemia and multiple myeloma. Dyck and associates stated 
that the clinical diagnosis of CIDP could only be made in the absence of a 
systemic disease.23 However, it seems that CIDP can also occur in the setting of 
some concurrent diseases. Associations with diabetes, hepatitis C, HIV infection 
and AIDS, lymphoma, organ transplant, connective tissue disorders, melanoma 
or monoclonal gammopathy of undetermined signifi cance (MGUS) have been 
mentioned.24 It is still a matter of debate whether the diagnosis of CIDP can be 
made in the presence of MGUS. In general it is accepted to diagnose a patient 
with CIDP in the presence of an IgA or IgG monoclonal paraprotein but not in the 
presence of an IgM paraprotein with antibodies to myelin-associated glycoprotein. 
Electrophysiological tests are mandatory in the EFNS/PNS criteria for CIDP and 
include evidence for demyelination with features such as conduction blocks, 
dispersion of the compound muscle action potential, increased distal latencies, or 
slowed conduction velocities.25 Cerebrospinal fl uid generally shows an increased 
protein level without a cellular reaction. IVIg, corticosteroids and treatment with 
plasma exchange are proven effective treatments and exert short-term or long-term 
clinical improvement in two-thirds of patients.26-28 A recent ‘negative’ trial with 
methotrexate (MTX) raised the question whether some included patients might 
have had inactive disease and, therefore, were unlikely to respond to a new therapy 
like MTX beforehand.29 This stresses the need to periodically taper or discontinue 
maintenance treatment for CIDP to avoid over-treatment. Especially in these 
patients, proper outcome measures would be very helpful to determine subtle 
clinically relevant changes over time.
Polyneuropathy associated with monoclonal gammopathy 
of undetermined significance (MGUSP)
A clone of plasma cells in the bone marrow may produce a monoclonal gammopathy 
that can be detected by investigating peripheral blood. This proliferative process 
can be low grade as in monoclonal gammopathy of undetermined signifi cance 
(MGUS) or it can be ‘malignant’ as in multiple myeloma or M. Waldenström. IgA 
and IgG monoclonal gammopathies are associated with idiopathic CIDP. In general, 
patients with MGUS-related CIDP are somewhat older at onset of symptoms and on 
average have more frequent sensory loss with less severe weakness, despite similar 
motor conduction fi ndings when compared to CIDP patients without MGUS. About 
half of the patients with polyneuropathy and an IgM monoclonal gammopathy 
have antibodies against myelin-associated glycoprotein (MAG). These ‘IgM anti-
MAG positive MGUSP’ patients characteristically present with slowly progressive, 
symmetric, predominantly distal sensory impairment with ataxia and little or no 
weakness.3 Since MGUS has an annual risk of 1% to transform to malignancy regular 
haematological screenings are recommended. Immuno-modulating treatment may 
be considered in patients with signifi cant chronic or progressive disability, although 
none are proven effective. It is uncertain whether Rituximab has a benefi cial effect 
in IgM anti-MAG positive MGUSP. Although several recent trials (including the 
yet unpublished full results of a randomised controlled trial from France) did not 
fi nd improvement on the selected primary outcome measures after Rituximab in 
IgM-anti-MAG positive MGUSP, improvement was found on secondary outcome 
measures.30, 31 This stresses the need to select a proper set of outcome measures 
for future clinical studies.
Multifocal motor neuropathy (MMN)
MMN is an infrequent, chronic disease and diagnosis is based on clinical, 
laboratory and electrophysiological characteristics.2 Most patients with MMN have 
a slowly progressive or stepwise progression of asymmetric, predominantly distal 
weakness in the distribution of two or more peripheral nerves, for more than one 
month. Sensory symptoms are generally absent except for minor vibration sense 
abnormalities in the lower limbs. Other supportive features are predominantly 
upper limb involvement, decreased or absent tendon refl exes, absence of cranial 
involvement, the presence of cramps and fasciculations in the affected limb and 
response to immuno-modulatory treatment. The electrophysiological hallmark 
of MMN is persistent motor conduction block with reduction of the motor nerve 
conduction velocity only over the affected areas. Laboratory fi ndings may reveal 
anti-ganglioside GM1 IgM antibodies in 30-80% of MMN patients. However these 
antibodies are not specifi c for MMN. Clinically, MMN is also described as an 
asymmetrical pure motor variant of CIDP with multifocal motor conduction blocks. 
Especially, during the evolution of MMN the multifocal character may gradually 
evolve in a more or less symmetrical pattern, clinically resembling the motor form 
of CIDP. Neuropathological studies have also linked MMN to CIDP.32, 33 A multifocal 
acquired demyelinating sensory and motor neuropathy with conduction blocks 
(MADSAM or Lewis Sumner syndrome) has also been reported, hence fulfi lling 
the intermediate clinical pattern between CIDP and MMN.34, 35 IVIg is currently the 
standard treatment for patients with MMN.2, 36
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Table 1. C
haracteristics of typical G
B
S, C
ID
P, IgM
 anti-M
A
G
 M
G
U
SP and M
M
N
G
B
S
C
ID
P
IgM
 anti-M
A
G
 M
G
U
SP
M
M
N
C
linical 
features
•
 Sym
m
etric w
eakness of all 
extrem
ities
•
 C
an be very severe (20
-25%
 
needs artifi cial ventilation)
•
 A
bsent or reduced tendon 
refl exes
•
 W
ith or w
ithout sensory 
dysfunction
•
 C
ranial nerves m
ay be 
affected
•
 Som
etim
es autonom
ic 
dysfunction
•
 O
ften pain
•
 Sym
m
etric proxim
al and 
distal w
eakness of all 
extrem
ities
•
 A
bsent or reduced tendon 
refl exes
•
 O
ften sensory dysfunction
•
 C
ranial nerves m
ay be 
affected
•
 Sym
m
etric, predom
inantly 
distal sensory im
pairm
ent, 
often w
ith ataxia
•
 G
enerally little or no 
w
eakness
•
 Trem
or m
ay be present
•
 A
sym
m
etric, predom
inantly 
distal w
eakness in the 
distribution of tw
o or m
ore 
peripheral nerves (often 
starting in upper lim
b)
•
 N
o sensory disturbances
•
 N
o upper m
otor neuron signs
•
 A
bsent or reduced tendon 
refl exes in affected lim
b
•
 A
bsence of cranial nerve 
involvem
ent
C
ourse of 
disease
•
 R
apidly progressive onset
•
 M
axim
um
 w
eakness w
ithin 
4 w
eeks
•
 D
eterioration continues > 
2 m
onths from
 onset
•
 O
ften m
onophasic w
ith 
stepw
ise progression
•
 Som
etim
es relapsing w
ith 
spontaneous rem
issions
•
 Slow
ly progressive onset
•
 C
hronic, duration over 6 
m
onths
•
 Slow
ly progressive or stepw
ise 
progressive onset
•
 C
hronic, duration usually over 
6 m
onths
A
dditional 
investigation
•
 EM
G
: dem
yelinating (e.g., 
A
ID
P) or axonal (e.g., 
A
M
A
N
)
•
 C
SF: increased protein level, 
norm
al cell count 
•
 EM
G
: dem
yelinating, 
m
eeting specifi c 
electrophysiological 
criteria for C
ID
P
•
 C
SF: increased protein 
level, norm
al cell count 
•
 EM
G
: dem
yelinating features 
sim
ilar to C
ID
P 
•
 Proven M
G
U
S
•
 IgM
 paraprotein: test for 
antibodies to M
A
G
•
 C
SF: som
etim
es increased 
protein level, norm
al cell 
count 
•
 EM
G
: m
otor conduction 
blocks
•
 A
nti-G
M
1 IgM
 antibodies in 
30
-80
%
 of M
M
N
 patients
•
 C
SF: protein level < 1 g/l, 
norm
al cell count 
Treatm
ent
•
 IV
Ig
•
 Plasm
a exchange
•
 IV
Ig
•
 Plasm
a exchange
•
 C
orticosteroids
•
 Im
m
unosuppressive or 
im
m
uno-m
odulating agents, 
(no proven effective drugs in 
R
C
Ts)
•
 IV
Ig
Legend to table 1. G
B
S= G
uillain-B
arré syndrom
e, C
ID
P= chronic infl am
m
atory dem
yelinating polyneuropathy, anti-M
A
G
= antibodies against m
yelin-associated 
glycoprotein, M
G
U
S= m
onoclonal gam
m
opathy of undeterm
ined signifi cance, M
G
U
SP= polyneuropathy associated w
ith M
G
U
S, M
M
N
= m
ultifocal m
otor 
neuropathy, EM
G
=electrom
yography, A
ID
P= acute infl am
m
atory dem
yelinating polyradiculoneuropathy, A
M
A
N
= acute m
otor axonal neuropathy, C
SF= cer-
ebrospinal fl uid, IV
Ig= intravenous im
m
unoglobulins, R
C
Ts= random
ised controlled trials
Challenges in assessing outcome
In clinical trials involving patients with immune-mediated neuropathies outcome has 
been assessed using varying defi nitions of treatment response. Furthermore, many 
different outcome measures have been used, which may hamper comparison of trial 
results.37 Therefore, the PeriNomS study was designed to improve and standardise 
assessment of patients with these conditions. The clinimetric essentials of selected 
outcome measures are being evaluated and compared to select a minimum core 
set of outcome measures for the future. This thesis also discusses the defi nition of 
treatment response by demonstrating the use of the concept of minimum clinically 
Important difference (MCID) in CIDP and the use of variable individual standard 
errors derived from Rasch-built interval scales in defi ning a responder.38 
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Abstract 
Peripheral neurological disorders like neuropathies may cause impairments (such 
as weakness and sensory defi cits) which may lead to problems in daily life and social 
functioning with a possible decrement in quality of life expectations. Choosing the 
proper outcome measure to evaluate the therapeutic effi cacy of an intervention at 
one of these levels of outcome should therefore be considered as fundamental to 
the design of randomised trials in peripheral neurological disorders. However, these 
choices are not only dependent of the proposed research purposes, but also, and 
perhaps more importantly, of the fulfi lment of the scientifi c needs of these measures. 
With an increasing demand for accuracy, a thorough and comprehensive evaluation 
of an outcome measure is needed to determine its simplicity, communicability, 
validity, reliability, and responsiveness before being clinically applicable; techniques 
which are being captured by the science of clinimetrics. Most neurologists are still 
unfamiliar with these rigorous methodological essentials or overlook some of them 
in their trial preparations because these are considered time consuming and mind 
numbing. 
This review will highlight, against the background of the international 
classifi cation framework and clinimetric needs for outcome measures, the selected 
scales applied in published randomised controlled trials in patients with Guillain-
Barré syndrome, chronic infl ammatory demyelinating polyradiculoneuropathy, 
multifocal motor neuropathy, and gammopathy related neuropathies. The need for 
comparison responsiveness studies between equally valid and reliable measures 
and to standardise their use is emphasised in these conditions. Finally, specifi c 
recommendations are given to move from classic to modern clinimetric approaches 
when constructing, evaluating, and selecting outcome measures using new 
methods like Rasch analysis, accentuating the need for shifting towards a more 
modern era.
Introduction
The American Academy of Neurology, the American Association of Electrodiagnostic 
Medicine, and the American Academy of Physical Medicine and Rehabilitation 
recently stated that the combination of neuropathic symptoms, signs, and 
electrodiagnostic fi ndings should provide the most accurate diagnosis of distal 
symmetric peripheral neuropathies (PN). However, the recommendations hardly 
addressed the (lack of) standardisation of assessment of symptoms and signs.1 
Moreover, the translation of symptoms and signs in these conditions to limitations 
in daily activities and social participation with possible decrement in quality of 
life expectations was not addressed. Neither was the need for standardisation of 
assessing outcome at these various levels referred. It is therefore not surprising 
that an overwhelming assortment of scales have been applied in clinical therapeutic 
trials in PN.2 Some scales were introduced before they had been fully clinimetrically 
tested. Others consisted of a mixture of different clinical modalities.3-5 Flawed 
measures threaten the signifi cance of trials that use them and impede comparison 
of results. 
With an increasing demand for accuracy, selected outcome measures need to be 
clinimetrically well evaluated meeting the demands of being simple, communicable, 
valid, reliable, and responsive.3-5 Moreover, outcome measures should be 
unambiguously constructed to represent only one of the outcome levels according 
to the international classifi cation by the World Health Organisation (WHO) and 
quality of life concept.6-8 These aspects are considered cardinal features in the 
evaluation of outcome measures. 
This paper provides an overview of all selected outcome measures applied in clinical 
randomised trials of patients with an immune-mediated neuropathies like Guillain-
Barré syndrome (GBS), chronic infl ammatory demyelinating polyradiculoneuropathy 
(CIDP), multifocal motor neuropathy (MMN), and monoclonal gammopathy of 
undetermined signifi cance related neuropathy (MGUSP). The signifi cance of these 
selected outcome measures will be refl ected against the background of their levels 
of representation in accordance with the WHO framework and their fulfi lment of 
clinimetric essentials. Finally, recommendations will be given, emphasising the 
need to standardise their use and to adopt the modern rather than the classical 
clinimetric approach when constructing outcome measures for peripheral nerve 
diseases.
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International classification of outcome 
measures – the WHO principles and quality of life concept
The ‘consequences’ of chronic illnesses have gained signifi cant attention due to their 
life-long management needs. In particular, the management of these conditions 
became the goal and the use of outcome measures became the standard for 
measuring the performance of health care delivery and its effectiveness. Therefore, 
in 1980 the WHO published a framework, the International Classifi cation of 
Impairments, Disabilities, and Handicaps (ICIDH), to structure outcome measures 
used in evaluating the consequences of illnesses.7 This international classifi cation 
was renewed in 2001 as the International Classifi cation of Functioning, Disability, 
and Health (ICF), providing more information on the relationship between the 
various levels of outcome from a more multidimensional point of view taking the 
possible infl uence of environmental and personal factors on health conditions 
into account.8 Figure 1 provides the structure of the ICF. The ICF is organised 
in two parts. The fi rst part recognises two main components of functioning and 
disability, namely: a) an impairment component comprising ‘body function’ and 
‘body structures’, and b) an activities and participation component providing a 
complete set of domains for aspects of daily and social functioning. In the second 
part, the impact of environmental and personal factors is presented, thus showing 
a dynamic interaction between health and environmental and personal factors. The 
ICF serves as a conceptual framework to bring together the physiological, personal 
and societal aspects of consequences related to health conditions.8 
Another aspect to take into consideration is the assessment of outcome from 
the ‘patient’s own perspective’, a concept captured in ‘quality of life’ assessment.6 
Quality of life is defi ned as the patient’s reaction to the discrepancy between actual 
and expected achievements arising as a consequence of illness. At least four 
dimensions should be included in a quality of life assessment. These dimensions 
are physical, functional, psychological, and social health. The physical health 
dimension refers primarily to disease- and treatment-rela ted symptoms. Functional 
health comprises self-care, mobility, and physical activity level, as well as the capacity 
to carry out various roles in relation to family and work. Cognitive func tioning, 
emotional status, and general perceptions of health, well-being, life satisfaction, 
and happiness are the central components of the psychological health domain. 
Social functioning inclu des the assessment of qualitative and quantitative aspects 
of social contacts and interactions.6 Hence, in the preparation of any randomised 
study, it is essential to fi rst determine which level will be of primary interest to 
answer the research question(s) and secondly to choose an outcome measure 
that represents that particular level of outcome and which has demonstrated good 
clinimetric soundness. 
Figure 1. International Classifi cation of Functioning, Disability and Health (ICF)
Legend to fi gure 1. The following defi nitions are provided for the various components of the 
ICF: Body functions: physiological and psychological functions of body systems; an example is 
weakness or fatigue; Body structures: anatomical parts of the body such as organs, limbs and 
their components; examples are structures of the peripheral nervous system; Impairments are 
considered problems in body function or structure as a signifi cant deviation or loss; Activity: the 
execution of a task or action by an individual; Participation: the involvement of an individual in a 
life situation. Environmental factors are extrinsic to (outside of) the individual (e.g., the attitude 
of society, architectural characteristics, the legal system). Personal factors are intrinsic to (inside 
of) the individual and describe on how the consequences of a health status is experienced (e.g., 
gender, age, fi tness, lifestyle, habits, coping styles, social background, education, life experience).8
Scientific evaluation of outcome measures in immune-
mediated neuropathies: the clinimetric essentials
For proper measurement in clinical practice, outcome measures should fulfi l all 
‘clinimetric’ properties prior to their use. The term ‘clinimetrics’ was introduced by 
Alvan R. Feinstein in 1987 to indicate a set of methods, strategies, and principles 
for evaluating and constructing outcome measures.3 He stated in his introduction 
that ‘… patients and clinicians ... may not realize how often they communicate with 
clinimetric indexes … like severe pain, a slight fatigue, a great improvement …’, and that 
‘… these expressions are seldom regarded as acts of measurement’. Investigation of 
outcome measures involves the evaluation of their clinical applicability and scientifi c 
soundness. These entities are captured in the various clinimetric properties like 
simplicity, communicability, validity, reliability, and responsiveness.3-5 The strength 
of each of these properties should be extensively determined. 
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A clinical useful scale should fulfi l the following requirements:
Simplicity
An outcome measure should be simple, none-time consuming with little special 
training. Many outcome measures are impractical because they require too much 
time to administer or score. A measure should wherever possible be simple, 
particularly if more than one person is going to use the measure. Simplicity will 
improve the patient (and user) compliance, and will increase reliability.
Communicability
An outcome measure should provide results that easily can be interpreted by others 
(refl ecting good communicability). A measure should give results that are easily and 
unambiguously understood by others. The construction of outcome measures 
should also contain unambiguously interpretable items.
Validity
An outcome measure should be valid. A valid scale is one that measures what it 
purports to measure and therefore provides the information required. In other words: 
It should accurately describe the underlying phenomenon or disease. Various types 
of validity are described:
Face validity refers to the apparent sensibility of the measure and its components. 
It simply indicates whether, on the face of it, the scale appears to be assessing the 
desired qualities. This validity form represents the subjective judgment based on 
a review of the measure itself by one or more experts, and rarely are any empirical 
approaches used. The GBS disability score has obvious face validity for the 
assessment of mobility.9
Content validity is closely related to the face validity concept. It consists of a 
judgment by experts evaluating whether an outcome measure captures all the 
relevant or important contents or domains of an illness. The GBS disability scale 
(also known as Hughes’ functional grading scale or f-score) is a 7-point disability 
scale ranging from no symptoms (zero points) to death (six points).9 This scale 
would be a content valid measure for lower limb function in neuropathies, because 
it is strongly based upon mobility. These two forms of validity are also entitled as 
‘the validity forms by assumption’, meaning that a measure assesses outcome in a 
certain way because an expert says it does.3-5 
Construct validity is demonstrated by examining the relations between a newly created 
test and other tests to show that the new test measures the same ‘construct’. In 
practice, evidence for construct validity is gathered by undertaking a series of 
studies to determine:
• Convergent validity – the extent to which a measure correlates with other measures 
of related entities. 
• Discriminant validity – the extent to which a measure does not correlate with 
measures of different entities. 
• Divergent validity – the extent to which a measure correlates with measures of 
opposite entities (e.g., correlation between fatigue versus vitality scales). 
Criterion-related validity is demonstrated by examining the accuracy of a test 
compared with a particular standard, the criterion (‘gold standard’). There are two 
types of criterion-related validity:
• Concurrent validity – the extent to which a new measure correlates with another 
widely accepted validated measure or the opinion of experts. This is generally 
applied in cases of no ‘real’ gold standard.
• Predictive validity – if we thought that the GBS disability score values at 4 weeks 
of follow-up in patients with GBS could predict degree of disability at 6 months, 
data collected at these two instances in time must be correlated. 
Reliability
An outcome measure should be reliable. A reliable measure is one that produces 
results that are accurate, consistent, stable over time, and reproducible. A patient 
whose condition has not changed should always receive the same score apart from 
random variation. There are three different types of reliability:
Internal consistency (Interitem consistency) is the extent to which items comprising a 
scale measure the same concept – that is, a measure of the homogeneity of the 
scale. There are a number of ways to calculate these correlations, of which the 
Cronbach’s alpha is the most widely used.10 After relatedness of items has been 
excluded with factor analysis, an alpha ≥ 0.7 is considered having a good internal 
consistency, but this value alone will not suffi ce in determining the reliability of an 
outcome measure.
Observer reliability is the agreement between observers or within an individual 
observer. There are two types: 
• Interobserver reliability – the agreement between observations made by two or 
more raters on the same patient or group of patients.
• Intraobserver reliability – the agreement between observations made by the same 
rater on two different occasions on the same patient or group of patients.
Test-retest reliability is the agreement between observations made by the same 
patient on two different occasions. 
The concepts of validity and reliability can be explained using the example of 
‘shooting at a target’. Someone learning archery must fi rst learn to hit the centre of 
the target, and then to do this consistently (fi gure 2). 
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Overview of applied outcome measures in randomised 
clinical trials in patients with immune-mediated 
neuropathies
Methods
A systematic search was performed using the search engines of Medline, EMBASE, 
Cochrane Neuromuscular Disease Group (period: January 1976 to March 2008) 
to detect all randomised clinical studies in patients with GBS, CIDP, MMN, 
and MGUSP. Selection was based on the following keywords: Guillain-Barré 
syndrome, GBS, chronic infl ammatory demyelinating poly(radiculo)neuropathy, 
CIDP, infl ammatory (poly)(radiculo)neuropathy, immune-mediated polyneuritis, 
gammopathy, dysimmune, paraprotein(a)emia, and monoclonal gammopathy of 
undetermined signifi cance polyneuropathy, controlled clinical trial and randomised 
controlled trials. Studies included in this review were selected independently by 
two authors (SvN and IM). All measures, primary and secondary, used to evaluate 
the effect of therapeutic interventions were categorised according to the renewed 
WHO international classifi cation and are presented in the tables 1A – 1D.8, 15 Various 
quality-control meetings were performed to improve categorisation.
Figure 2. The concept of validity and reliability explained by the example of shooting on 
a target
Legend to fi gure 2. Validity is represented by the aim of shooting; in other words, how close the 
shots come to the centre of the target. Good validity meaning a bias of approximately zero distance 
(panel A). Reliability is represented by how close consecutive shots fall to each other wherever they 
land. Good reliability means a small variance. The white arrows in panel B are more scattered (= 
lower reliability) compared with the black arrows. However, the validity of the black arrows in panel 
B is low, since they do not hit the aiming spot (centre of the target).
Responsiveness
An outcome measure should be responsive to changes over time in the underlying 
condition, yet relatively insensitive to minor symptom and sign fl uctuations. Whereas 
validity and reliability form the clinimetric foundation of a rating scale, the ability of 
a measure to detect clinically meaningful changes over time is crucial. For clinicians 
and researchers, such a measure should discriminate between irrelevant changes 
(normal fl uctuations in the activity of an illness; ‘noise’) and clinically meaningful 
changes on which a treatment policy can be based (‘signal’), an ability addressed as 
‘responsiveness’. A statistic and heuristic approach in examining responsiveness 
of a measure has been proposed.11
• Statistical responsiveness captures the ability of an instrument to measure 
any change, irrespective of its relevance. Techniques that capture statistical 
responsiveness are the effect size, standardised response mean, Guyatt’s 
responsiveness ratio in cases of parametric statistics, and the Schmitz’ 
distribution-free responsiveness score for non-parametric data.12-14
• Heuristic techniques are based upon comparing changes as assessed by a scale 
with an external indicator, for example the grades of judgment by the patients 
of their clinical condition compared to the last consultation visit (e.g., grade 1: 
improved; grade 2: stable; grade 3: deteriorated).
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Impairment measures
Muscle strength measures
Muscle strength
Hand grip strength
MRC sumscore
Strength recovery
Time to onset of motor recovery
Sensory measures
Sensory scale
Sensory symptoms
Other measures
Time to recover
Forced vital capacity
Functional test
Reduction of time to cease artifi cial 
ventilation
Time to discontinuation of ventilation
Numeric pain rating scale
Ramsey sedation score
Cranial nerve (dys)function
Respiratory function
Vegetative symptoms
Pain
Arm function
Fatigue severity scale
Fatigue impact scale
Hospital anxiety and depression scale
year authors
1984
1985
1987
1992
2004
1995
1997
1992
2004
1976
1985
1985
1993
1997
2002
2002
2004
2005
2005
2005
2005
2005
2006
2006
2006
Osterman et al.16
Mendell et al.17
Farkkila et al.18
Van der Meché et al.19 
Van Koningsveld et al.20 
Gürses et al.21
French cooperative group 
on PE in GBS22
Van der Meché et al.19
Van Koningsveld et al.20
Swick and McQuillen23
Mendell et al.17
Mendell et al.17
GBS steroid trial group24
PSGBS Trial group25
Pandey et al.26
Pandey et al.26
Van Koningsveld et al.20
Korinthenberg et al.27
Korinthenberg et al.27
Korinthenberg et al.27
Korinthenberg et al.27
Korinthenberg et al.27
Garssen et al.28
Garssen et al.28
Garssen et al.28 
Activity and participation measures
GBS disability score 1978
1984
1985
1988
1992
1993
1996
1996
Hughes et al.9
Greenwood et al.29
GBS study group30 
Shukla et al.31
Van der Meché et al.19 
GBS steroid trial group24 
Bril et al.32
Haupt et al.33 
Activity and participation measures
GBS disability score
Time to recover ability to do manual work
Nine point disability grade
Time to recover walking with assistance
Time to recover unaided walking
Time to walk unaided
Rotterdam handicap scale
year authors
1996
1997
2001 
2000
2001
2003
2004
2005
2007
1978
1996
1984
1987 + 1997
2001
1995
1997
2006
Singh and Gupta34 
PSGBS Trial group25 
Wollinsky et al.35 
Nomura et al.36
Wang et al.37 
Pritchard et al.38 
Van Koningsveld et al.20 
Korinthenberg et al.27 
Garssen et al.39 
Hughes et al.9
Bril et al.32
Osterman et al.16
French cooperative group 
on PE in GBS22, 40
Raphael et al.41
Gürses et al.21
PSGBS Trial group25
Garssen et al.28 
Quality of life measures
SF-36
EuroQol-5D
2006
2006
Garssen et al.28 
Garssen et al.28 
Table 1A. Outcome measures used in randomised trials in patients with GBS Table 1A. (Continued)
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Table 1B. Outcome measures used in randomised trials in patients with CIDP Table 1C. Outcome measures used in randomised trials in patients with MMN 
Table 1D. Outcome measures used in randomised trials in patients with MGUSP
Legend to tables 1A-1D. MRC=Medical Research Council, INCAT=Infl ammatory Neuropathy Cause 
and Treatment, NIS=neuropathy impairment score, SF-36=short form 36-item health survey.
Impairment measures
Muscle strength measures
MRC sumscore 
Jamar dynamometer
Expanded MRC sumscore
Average muscle score
Vigorimeter
Sensory measures
INCAT sensory sumscore
Composite and other measures
NIS
Forced vital capacity
year authors
1993 
2001
2008
1996
1996
1999
2001
2001
2008
2001
2008
1985
1996
1996 
2001
Vermeulen et al.42
Hughes et al.43
Hughes et al.44 
Hahn et al.45
Hahn et al.46
Hadden et al.47
Mendell et al.48 
Hughes et al.43
Hughes et al.44 
Hughes et al.43
Hughes et al.44 
Dyck et al.49
Hahn et al.46
Hahn et al.45
Mendell et al.48 
Activity and participation measures 
Rankin scale
Functional clinical grading scale
Ten meters walking test
Nine hole pegboard test
Ambulation index
Functional independence measure
Hammersmith motor ability
Guy’s neurological disability scale
GBS disability score
Rotterdam Handicap scale
INCAT Overall disability sumscore
1990
1993
2001
1996
1996
1999
2001
1999
2001
1999
1999
1999
1999
2001
2001
2001
2008
Van Doorn et al.50 
Vermeulen et al.42
Hughes et al.43
Hahn et al.45
Hahn et al.46
Hadden et al.47
Hughes et al.43
Hadden et al.47
Hughes et al.43
Hadden et al.47
Hadden et al.47
Hadden et al.47
Hadden et al.47
Mendell et al.48 
Hughes et al.43
Hughes et al.43
Hughes et al.44 
Quality of life measures
EuroQol-5D
SF-36
1999
2001
Hadden et al.47
Hughes et al.43
Impairment measures
Muscle strength measures
Manual muscle strength testing
Hand-held dynamometry
Jamar dynamometer
Subjective rating of strength
MRC score
Grip strength
Composite measures
NIS
year authors
1995
2007
1995
2007
2000
2000
2001
2007
2000
Van den Berg et al.51
Piepers et al.52
Van den Berg et al.51
Piepers et al.52
Federico et al.53
Federico et al.53
Léger et al.54
Piepers et al.52
Federico et al.53
Activity and participation measures
Rankin scale
Subjective rating of functionality
Self-evaluation scale
Nine hole pegboard test
Guy’s disability arm grade
1995
2000
2001
2007
2007
2007
Van den Berg et al.51
Federico et al.53
Léger et al.54
Piepers et al.52
Piepers et al.52
Piepers et al.52
Impairment measures
Muscle strength measures
Manual muscle strength testing
MRC sumscore
Sensory measures
Sensory score
Subjective assessment of sensation
INCAT sensory sumscore
Vibration threshold
Sensory scale testing
Ataxia tapping test
Composite measures
NIS
year authors
1996
2007
2001
1996
1997
2001
2001
2007
2007
1991
1995
1997
Dalakas et al.55
Niermeijer et al.56
Comi et al.57
Dalakas et al.55
Mariette et al.58
Comi et al.57
Comi et al.57
Niermeijer et al.56
Niermeijer et al.56
Dyck et al.59
Oksenhendler et al.60
Mariette et al.58
Activity and participation measures
Neuromuscular symptom score
INCAT overall disability sumscore
Ten meters walking test
Nine hole pegboard test
Rotterdam handicap scale
Rivermead mobility index
Rankin scale
1996
2001
2001
2001
2001
2007
2007
Dalakas et al.55
Comi et al.57
Comi et al.57
Comi et al.57
Comi et al.57
Niermeijer et al.56
Niermeijer et al.56
Quality of life measures
SF-36 2001
2007
Comi et al.57
Niermeijer et al.56
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Results
There was a 100% match on selected randomised clinical studies in these conditions 
by the two authors that performed the search. In patients with GBS, most impairment 
scales were based on the MRC grading.61 Of these, only the MRC sumscore has 
demonstrated the complete clinimetric arsenal of being simple, valid, reliable, and 
responsive.62 Some impairment measures were based on neurological examination 
fi ndings. Of the fatigue scales used, the fatigue severity scale has demonstrated 
its simplicity, communicability, validity, and reliability in patients with immune-
mediated neuropathies.63 To date, no responsiveness studies using this scale have 
been conducted. At the activity and participation level, most outcome measures 
captured mobility aspects of which the GBS disability score have been most widely 
used. This scale has a strong face and content validity for mobility aspects, but 
fails in assessing arm functionality. All clinimetric properties of this scale have been 
demonstrated. Surprisingly, only three randomised studies in GBS have addressed 
arm function, but all failed in providing the scientifi c soundness of these outcome 
measures before their use (see table 1A).9, 27, 32
In patients with CIDP, the neuropathy impairment score (NIS; formerly named 
neuropathy disability score) has been most widely used.64 The validity, reliability, 
and responsiveness of this composite score have been demonstrated. However, the 
NIS has a poor communicability, since it is composed by various neurological items 
like different sensory modalities, strength assessment, and tendon refl ex fi ndings. 
The complexity of such a score makes interpretation of changes in the fi nal score 
diffi cult. Moreover, the signifi cance of possible changes in tendon refl ex scores has 
been questioned, since these changes are hardly translated into functional defi cit. 
At the activity and participation level, a variety of outcome measures have been 
applied, most of these being strongly directed towards mobility. Surprisingly, only the 
Infl ammatory Neuropathy Cause and Treatment (INCAT) overall disability sumscore 
(ODSS) has provided a ‘true general outcome’ (defi ned as functional arms + legs 
information) in patients with immune-mediated polyneuropathies and has recently 
demonstrated its effi cacy in the largest trial ever conducted in patients with CIDP 
being treated with intravenous immunoglobulin (see table 1B).44, 65 
Although not listed, the overall neuropathy limitations scale (ONLS) is currently 
being applied in an ongoing CIDP trial. The ONLS also addresses arms and legs 
functionality and has demonstrated good scientifi c soundness.66
In MMN and MGUSP the same pattern of great variety of outcome measures is 
listed (tables 1C and 1D). Moreover, some outcome measures have been introduced 
without being fi rst clinimetrically evaluated. An example of the latter is the recently 
reported randomised trial by Niermeijer et al. (2007) who examined the effi cacy of 
intermittent cyclophosphamide with prednisone in patients with MGUSP.56 These 
researchers chose the Rivermead mobility index (RMI) to capture possible effi cacy 
as the primary endpoint, but have failed to examine whether this outcome measure 
would have been communicable, valid, reliable, and last but not least responsive to 
capture relevant changes over time in this condition. As a result, while impairment 
measures with good clinimetric soundness demonstrated relevant improvement 
over time, the RMI did not.56 A more appropriate activity and participation scale 
might have captured changes at this level, thus changing the fi nal results of this 
trial.
Surprisingly, only a limited number of trials in patients with immune-mediated 
neuropathies have addressed the concept of quality of life. The EuroQol-5D and the 
SF-36 have been applied in these studies.28, 43, 47, 56, 57 Both scales have demonstrated 
their scientifi c soundness in these conditions, but the SF-36 has been examined 
more extensively and has shown its complementary qualities to traditional outcome 
measures.67
Positioning outcome measures in immune-mediated 
neuropathies: where do we stand now and what are the future 
needs? 
Recognising the need to standardise the use of outcome measures 
As the tables illustrate, an overwhelming collection of outcome measures has been 
applied in these conditions, which hamper comparison between the obtained results. 
Surprisingly, only recently attention was directed towards standardisation of the use 
of outcome measures at all levels of outcome in infl ammatory polyneuropathies.2, 68
At the 2004 meeting in the Netherlands, general consensus regarding the use of 
various outcome measures was reached. However, further recommendations 
were made to enhance the clinimetric comparability between the various selected 
outcome measures and some of these are briefl y highlighted: 
• In diseases such as in MMN, outcome measures need to be evaluated or 
developed covering each of the ICF domains.
• In diseases in which symptoms are prominent, such as painful neuropathy, the 
use of symptom-based outcome measures should be considered.
• Evaluators should be trained in the application of the selected instruments 
before the start of each study.
• Research should be conducted to compare the responsiveness of valid and 
reliable outcome measures recommended in different patient populations. 
In GBS, CIDP, and gammopathy related neuropathies, comparison is needed 
between MRC sumscore versus NIS motor subset and between INCAT sensory 
sumscore versus NIS sensory subset.62, 64, 69 
• Assessment of both quality of life with SF-36 and health utility with the EuroQol 
should be considered.70, 71 
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Shifting from classic to modern clinimetric approach
By consensus among the INCAT group, the activity and participation level was 
proposed as the main level of measuring therapeutic response and the ODSS was 
proposed as a preferential outcome measure for treatment trials of these conditions, 
since it covers not only mobility disturbances, but also upper limb dysfunction2. 
Also, the ODSS has good clinimetric properties, especially greater responsiveness 
and has demonstrated a higher proportion of variance of disability explained by 
impairment qualities.72 In addition to these fi ndings, higher associations were found 
between ODSS and outcome assessed from patients’ perceptions in immune-
related polyneuropathies than in other commonly used disability scales.73
Despite these fi ndings, all disability measures (including the ODSS) used in 
immune-mediated polyneuropathies (see tables 1A-1D), are criticised based on the 
following:
• The construction of these ordinal (or Likert) outcome measures is based on 
the classic test theory which recruits items arbitrarily without weighting or 
standardisation.
• Patients are requested to complete all the items in a classic outcome measure, 
even though some may be inappropriate for their level of ability. Hence, it was 
suggested that classically derived tests are only suitable for group studies but 
not suitable for individual patient assessments.
• Under classic test theory, the patient’s raw test score would be the sum of the 
scores received on the items in the test. The sumscore assumes that all items 
have equal relevance and weights regarding the functionality of patients and 
that given differences in sumscore have equal meaning. Therefore, classic test 
theory hampers the comparison between patients with different degrees of 
functionality.
• Hundreds of multi-item disability scales have been developed for various chronic 
illnesses in the last decades. Unfortunately in defi ning these scales, researchers 
have not attempted to defi ne these outcome measures from the patient’s 
perspective. 
• It is questioned whether so many scales are necessary, since activity and 
participation limitations are considered relatively independent of underlying 
illnesses. 
• A large pool of disability scales hampers comparison of the results of clinical trials, 
since the clinical importance of score changes on all scales is unknown.74, 75
It is clear that a new calibrated linearly weighted interval disability measure is needed 
using modern scientifi c methods. The Rasch technology and item response theory 
(IRT) are increasingly being recognised and applied as modern test methods.76, 77
These statistical techniques attempt to transform ordinal scores, that are scale 
dependent and of limited accuracy, into interval measures that are scale independent 
and suitably accurate for individual patient assessment. In essence, these methods 
model the probability of an individual’s response to an item. They are based on a 
logical assumption: individuals with high ability to perform a task should have an 
increased probability, relative to individuals with low levels, of getting a better score 
on any item.76, 77 Using these new techniques would give a true refl ection of disease 
impact, differences between individuals and groups, and treatment effects. The 
ability to generate interval measures, independent of the rating scale used, enables 
scales measuring the same health construct to be equated on the same linear 
ruler. This is the basis for comparisons of studies, systematic reviews, and meta-
analyses. Moreover, the process of scale equating generates a pool of commonly 
calibrated items, which form an item bank. Item banks are fl exible measurement 
methods because any subset of items can be selected from the bank to generate 
an accurate score.78 With these techniques, investigators are no longer wedded to 
defi ned scales and can simply select the most appropriate group of items for their 
study. Alternatively, a fi xed defi ned group of items can be selected for general use 
in a particular illness. This would be, for example, of great interest when choosing 
items that can be used in a clinical trial evaluating improvement in patients with 
mild forms of GBS. 
The use of Rasch technology is suggested rather than traditional methods and IRT 
for very specifi c reasons: the aim of a Rasch analysis is to determine the extent to 
which the observed rating scale data satisfy the requirements of the mathematical 
measurement model. When the observed data satisfy these requirements, within 
reason, scores generated by ordinal rating scales can be transformed into interval 
level measurements. In contrast, IRT models are derived to explain data.79, 80 It is 
now up to the neurology community to learn the Rasch theory and practice of it, 
and to present it in an understandable way.
New international clinimetric study in immune-mediated neuropathies 
Based on the above, it is concluded that consensus regarding the use of a specifi c 
core set of outcome measures is urgently needed to improve the assessment of 
new drug studies in these PN forms. Therefore, the international multi-centre 
Peripheral Neuropathy outcome measures Standardisation (PeriNomS) study 
has been conceived as part of the Infl ammatory Neuropathy Consortium (INC) 
aiming to evaluate equally valid and reliable outcome measures of interest through 
comparative responsiveness. The construction of a linearly weighted interval 
activity and participation multi-item scale based on Rasch methodology will also be 
part of the PeriNomS study.
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Conclusion
This review has shown the diversity of selected outcome measures in published 
randomised controlled trials in patients with immune-mediated neuropathies. 
Choosing proper outcome measures to evaluate the therapeutic effi cacy of an 
intervention should be considered for the design of randomised trials in peripheral 
neurological disorders. The selected outcome measures need to fulfi l the clinimetric 
essentials like being simple, communicable, valid, reliable, and responsive. Because 
ordinally driven outcome measures have serious weaknesses, we propose to move 
from classic to modern clinimetric approach when constructing, evaluating, and 
selecting outcome measures. The Rasch analysis method is preferred for this 
purpose. Finally, there is a strong plea for standardisation and the use of a core set 
of outcome measures at every level of outcome in all randomised trials in immune-
mediated neuropathies, promoting comparability of the obtained results.
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Background
Different methods have been used to study patients with immune-mediated 
neuropathies.1 The Infl ammatory Neuropathy Cause and Treatment (INCAT) group, 
a network of European neurologists with special interest in immune-mediated 
neuropathies, published a series of papers and a thesis dealing with the clinimetric 
aspects of outcome measures used in these disorders, especially in Guillain-Barré 
syndrome (GBS), chronic infl ammatory demyelinating polyneuropathies (CIDP), and 
monoclonal gammopathy of undetermined signifi cance related polyneuropathies 
(MGUSP).2 To evaluate outcome in these disorders, often used outcome measures, 
selected by literature review, experts’ opinions and patients’ suggestions, were 
critically viewed by members of the INCAT group. Outcome measures represent 
different levels of outcome based on the International Classifi cation of Functioning, 
Disability and Health (ICF) and on the quality of life concept, focussing more on 
patients’ perspectives.3, 4 The selected measures were categorised accordingly, 
where needed new outcome measures were created to fi ll the gaps. These measures 
were, if necessary, subsequently analysed to determine their clinimetric properties 
like being simple, valid, reliable, and responsive to changes over time (table 1, for 
further details see chapter 1.2).5 
Table 1: Concise description of essential clinimetric properties
simple little special training or instructions needed, not time 
consuming
communicable easily understood by others
valid measures what it supposes to measure
reliable reproducible, consistent over time
responsive measures relevant changes over time
Eventually, a set of clinimetrically well-evaluated outcome measures that represented 
various levels of outcome (impairment, disability, handicap, and quality of life) was 
presented, a big step forward.2 These INCAT studies formed a base for a clinimetric-
oriented workshop that was conducted in December 2004 in the Netherlands and 
was coordinated by the European Neuromuscular Centre (ENMC).6 Furthermore, 
at a workshop on outcome measures in peripheral neuropathies held at the 
Peripheral Nerve Society (PNS) congress (Italy, 2005), the PNS scientifi c committee 
strongly pleaded for further standardisation. It is increasingly being recognised that 
consensus regarding the use of a neuropathy-specifi c core set of proper outcome 
measures is urgently needed to improve assessment during follow-up of patients 
with these disorders in daily clinical practice and, to evaluate their response to 
treatment. Therefore, the international multi-centre Peripheral Neuropathy 
outcome measures Standardisation (PeriNomS) study has been conceived as part 
of the Infl ammatory Neuropathy Consortium (INC). INC (that succeeded INCAT) 
is a standing committee of the PNS, a worldwide network of neurologists who 
are committed to improving and advancing the investigation and treatment of 
immune-mediated neuropathies.
Aims
The PeriNomS study aims to expand the clinimetric knowledge on outcome 
measures at selected levels of outcome (pathology, impairment, activity, 
participation, and quality of life). 
Ultimate goal: the presentation of an internationally supported standardised 
neuropathy-specifi c minimum core set of high quality outcome measures to be 
used in daily clinical practice and in future follow-up studies and clinical trials 
in patients with immune-mediated neuropathies, particularly in patients with 
GBS, CIDP, MMN and IgM-MGUSP.
Study design
The PeriNomS study can be divided into a cross-sectional and a longitudinal part: 
The cross-sectional part, conducted in the Netherlands, focuses on examining the 
reliability and validity modalities of the selected outcome measures. For this part, 
122 patients with an immune-mediated neuropathy and a stable clinical condition 
have been examined two times. During the fi rst visit two examiners performed their 
scores independently and consecutively (usually within 2 hours) (inter-observer 
reliability). Within 2-4 weeks, one of the investigators re-examined the patient 
(intra-observer reliability) without having access to previous results. Additionally, 11 
questionnaires about impairment, activity limitation and quality of life (test-retest) 
are available for further evaluation.
The longitudinal part is still being performed worldwide to obtain responsiveness 
data that may help to differentiate between comparable valid and reliable outcome 
measures. Therefore, newly diagnosed patients and patients with a relapse of their 
neuropathy (n≥140) are being examined 3 times (in MMN and MGUSP) or 5 times 
(in GBS and CIDP) during one-year follow up. All patients were examined at onset, 
3 and 12 months. Patients with GBS and CIDP were additionally examined at 1 
and 6 months because their diseases have a (sub)acute onset and usually a less 
indolent course compared to MMN and MGUSP.
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Figure 1.  PeriNomS study design
Patients
Cross-sectional patients
A total of 102 clinically stable patients have been included, 30 with GBS, 30 with 
CIDP, 20 with MGUSP, and 22 with MMN, all meeting the international criteria 
for their diagnosis.7-10 A stable clinical condition was defi ned as: 1) an unchanged 
clinical functionality as declared by the patient to the best of his/her knowledge over 
2 months prior to the study and during the study (stable condition at second visit 
compared to entry), and 2) no clear objective changes at neurological examination 
by the researcher when compared with recorded fi ndings during the last 2 months 
before study entry (if available). All patients had residual signs and symptoms due 
to their illness representing a broad range of activity limitations. Patients with CIDP 
and MMN receiving (interval) treatment could be included as long as their clinical 
condition was stable (see defi nition above). Only IgM anti-MAG positive MGUSP 
patients were included. Patients with a clinical course and diagnosis compatible 
with CIDP and IgG MGUS were included as CIDP. Patients were excluded if having 
a concomitant disease or using medication like, e.g., diabetes, renal insuffi ciency, 
(prior) treatment with chemotherapy, alcohol abuse (more than 5 IU/day) that might 
interfere with general nervous system as well as physical functioning. Patients were 
recruited and investigated by trained investigators at the outpatient clinics of the 
university hospitals of Rotterdam, Maastricht and Utrecht, the Netherlands.
Longitudinal patients
Over 140 patients have already been included. We strive for at least 50 GBS, 
50 CIDP, 20 MGUSP and 20 MMN meeting the international criteria for their 
diagnosis.7-10 Patients have to be newly diagnosed or have to experience a 
clinical relapse or a new (multi)focal nerve lesion due to their CIDP/MMN 
(no medication for at least 2 months). As for the cross-sectional patients, 
only IgM anti-MAG positive MGUSP patients were included and IgG MGUS 
patients with a clinical course and diagnosis compatible with CIDP were 
included as CIDP. Also, patients were excluded if having concomitant diseases 
or using medication like, e.g., diabetes, renal insuffi ciency, (prior) treatment with 
chemotherapy, alcohol abuse (more than 5 IU/day) that might interfere with general 
nervous system as well as physical functioning. Patients were recruited worldwide at 
26 participating centres with expertise on peripheral neuropathies (fi gure 2). 
Figure 2. Participating centres and list of principal investigators
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Selected outcome measures
Table 2 shows the selected outcome measures and also notes the ones used for the 
studies in this thesis. 
Table 2. Selected outcome measures for the PeriNomS study
Level of outcome Outcome measure Assessment frequency
Cross-sectional
group
Longitudinal group
GBS
CIDP
MGUSP
MMN
Pathology IENF density 1xÍ 2x 2xÍ
Impairment Jamar dynamometer* 3x 5x 3x
Vigorimeter* 3x 5x 3x
MRC sumscore* 3x 5x 3x
NIS motor subset 3x 5x 3x
INCAT sensory sumscore* 3xÍ 5x 3xÍ
NIS sensory subset* 3xÍ 5x 3xÍ
EMG 1x 2x 2x
mD-COMPASS 2xÍ 5x 3xÍ
11-point PI-NRS 2xÍ 5x 3xÍ
VAS-pain 2xÍ 5x 3xÍ
Activity and 
participation
ODSS* 3x 5x 3x
ONLS* 3x 5x 3x
R-ODS/ R-ODS-MMN* 2x 5x 3x
Quality of life Vickrey’s scale 2x 5x 3x
SF-36 2x 5x 3x
EuroQoL-5D 2x 5x 3x
SIP 2x 5x 3x
NHP 2x 5x 3x
WHO-QoL bref 2x 5x 3x
VAS-QoL 2x 5x 3x
Composite levels PPCM - 5x 3x
clinical judgment score* - 5x 3x
Legend to table 2. *= outcome measures used for studies in this thesis. Í = not in patients with MMN. 
IENF= intraepidermal nerve fi bre, MRC= Medical Research Council, NIS= neuropathy impairment 
score, INCAT= Infl ammatory Neuropathy Cause and Treatment group, EMG= electromyography, 
mD-COMPASS= modifi ed Dutch composite autonomic symptom scale, PI-NRS= pain intensity 
numerical scale, VAS= visual analogue scale, ODSS= overall disability sumscore, ONLS= overall 
neuropathy limitations scale, R-ODS= Rash-built overall disability scale, R-ODS MMN= Rash-
built overall disability scale for MMN, Vickrey’s scale is a peripheral neuropathy quality of life 
instrument, SF-36= short form 36-item health survey, EuroQoL-5D= EuroQoL group-5D scale, SIP= 
sickness impact profi le, NHP= Nottingham health profi le, WHO-QoL brief = short form of the 
WHO quality of life scale, QoL= quality of life, PPCM= personal patient-centred measures
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The participating investigators were trained in 2007 at the PNS meeting (Utah, 
USA) aiming to standardise the assessment procedures for all scales as part of 
this study. In addition, participants received a comprehensive research manual 
that integrated a thorough description and pictures illustrating how to assess the 
various outcome measures. In the following, a short description of the selected 
outcome measures:
At the pathology level of outcome:
• Intraepidermal nerve fi bre (IENF) density
IENF density is the number of individual nerve fi bres per unit area crossing the 
dermal-epidermal junction. To determine IENF density according to European 
guidelines, a skin biopsy, a punch biopsy of 3 mm, 10 cm above the right lateral 
malleolus was performed after local anaesthesia with 1% lidocaine.11 Skin biopsy 
is a routine diagnostic procedure in several centres, but determination of IENF 
density is not. Therefore, skin biopsies were only performed in centres with 
suffi cient expertise to determine IENF density (the pathology laboratories in 
Milan and Maastricht). As a result, biopsies were taken once in all cross-sectional 
patients and twice in longitudinal Dutch and Italian patients who gave informed 
consent. No biopsies were taken from MMN patients.
At the impairment level of outcome:
• Vigorimeter and Jamar dynamometer
Both tools are designed to assess grip strength and were assessed at each visit in 
GBS, CIDP, MGUSP and MMN patients.2, 12, 13 The Jamar dynamometer quantifi es 
isometric force in pounds (range 0-200). The Vigorimeter quantifi es grip strength 
on a manometer after squeezing a rubber bulb, and is scored in kilopascal (range 
0-160). All patients were asked to judge both the Vigorimeter and the Jamar 
regarding their comfortability in assessing grip strength when compared to each 
other (1 = great preference for Vigorimeter; 2 = little preference for Vigorimeter; 3 
= no preference for any of the two tools; 4 = little preference for Jamar; 5 = great 
preference for Jamar). 
Jamar dynamometer                Vigorimeter                              Punch biopsy
• Medical Research Council (MRC) sumscore
At each visit the MRC sumscore was assessed, a summation of MRC grades 
given in full numbers (0= no movement, no contraction, 1= visible contraction 
without movement, 2= movement but only with gravity eliminated, 3= movement 
against gravity, 4= movement against resistance, but weaker than normal, 5= 
normal strength) of the arm abductors, elbow fl exors, wrist extensors, hip fl exors, 
knee extensors and foot dorsal fl exors at both sides and thereby, ranging from 0 
(total paralysis) to 60 (normal strength).14 An expanded MRC sumscore ranging 
from 0 (total paralysis) to 140 (normal strength) was used in MMN to cover its 
asymmetrical presentation and its predominantly affected distal arm muscles. 
Based on expert opinion the following fourteen muscle pairs, including the ten 
previously described as the most affected ones, were selected to compose this 
summation: shoulder abductors, elbow extensors and fl exors, wrist extensors and 
fl exors, fi nger extensors and fl exors, thumb abductors, hypothenar abductors, hip 
fl exors, knee extensors and fl exors, ankle dorsifl exors and ankle plantar fl exors.15 
For each muscle group standardised joint/limb positions, point of counterforce 
and some MRC grading scores were defi ned and illustrated in the provided 
research manual.
• Neuropathy impairment score (NIS)
This scale consists of a motor and a sensory subscale.16.17 The NIS motor 
subscale ranges from 0 (no motor defi cit) to 48 (most severe motor defi cit) and 
is composed by grading each of the six assessed muscle groups (arm abductors, 
forearm fl exors, wrist extensors, hip fl exors, knee extensors and foot dorsal fl exors) 
at both sides as follows: 0 = normal, 1 = 25% weak, 2 = 50% weak, 3 = 75% weak, 
3.25 = move against gravity, 3.5 = movement, gravity eliminated, 3.75 = muscle 
fl icker, no movement, 4 = paralysis. An MMN-specifi c motor subscale, ranging 
from 0 (no motor defi cit) to 112 (most severe motor defi cit) was composed by 
the summation of the following fourteen muscle pairs: shoulder abductors, 
elbow extensors and fl exors, wrist extensors and fl exors, fi nger extensors and 
fl exors, thumb abductors, hypothenar abductors, hip fl exors, knee extensors and 
fl exors, ankle dorsifl exors and ankle plantar fl exors using the above mentioned 
NIS grading system. 
The NIS sensory subscale, ranging from 0 (no sensory defi cit) to 32 (most severe 
sensory defi cit), is composed by the summation of the following sensation 
qualities: touch pressure, pinprick, vibration, and joint position sense. Touch 
pressure, pinprick and vibration sensation are tested on the dorsal surface of 
the index fi nger and great toe, at the base of the nail of the terminal phalanx 
at both sides. Touch pressure is assessed with long fi bre cotton wool, pinprick 
is assessed with straight pins and vibration sensation is tested with a 165 Hz 
tuning fork. Joint position is tested by moving the terminal phalanx of the 
index fi nger and great toe at both sides. Each quality is scored according to the 
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following scoring system: 0 = normal, 1 = decreased and 2 = absent sensation. 
For both subscales the examiner scores defi cits by what he (she) considers to 
be normal considering test, anatomical site, age, gender, weight, and physical 
fi tness. Detailed information about the NIS (motor and sensory subscale) is also 
available by video-instruction. Each visit both subscales were assessed, except for 
the sensory subscale in MMN patients.
Table 3. Scoring table for the sensory subset of the NIS - sites of examination 
with corresponding grades. Tick the box that applies.
Scoring sensation
NA= not applicable;     0 = normal;     1 = decreased;     2 = absent
RIGHT LEFT
Sensation – index fi nger NA 0 1 2 NA 0 1 2
Touch pressure Ο Ο Ο Ο Ο Ο Ο Ο
Pinprick Ο Ο Ο Ο Ο Ο Ο Ο
Vibration Ο Ο Ο Ο Ο Ο Ο Ο
Joint position Ο Ο Ο Ο Ο Ο Ο Ο
Sensation – great toe NA 0 1 2 NA 0 1 2
Touch pressure Ο Ο Ο Ο Ο Ο Ο Ο
Pinprick Ο Ο Ο Ο Ο Ο Ο Ο
Vibration Ο Ο Ο Ο Ο Ο Ο Ο
Joint position Ο Ο Ο Ο Ο Ο Ο Ο
• (modifi ed) INCAT sensory sumscore ((m)ISS)
The ISS is composed by the summation of the following sensation qualities: 
pinprick and vibration sense in the arms and legs from distal to proximal recording 
the highest extension of dysfunction, plus two-point discrimination at the index 
fi nger. Joint position and light touch qualities however are not incorporated 
in the original ISS, making this scale less comprehensive and perhaps less 
responsive.6 Furthermore two-point discrimination categories were arbitrarily 
defi ned.18 Therefore, a modifi ed ISS was constructed incorporating light touch 
and joint position sense and grading the collected two-point discrimination 
values. Light touch was examined with a cotton wool stick and pin prick using 
a broken cotton wool stick. Vibration sense was examined using a Rydel Seiffer 
64 Hz graduated tuning fork and graded comparing the fi ndings with published 
normative data.19 Joint position was assessed in a standardised manner based 
on previous recommendations, with predefi ned joint/limb starting positions 
and examiner’s positions to fi xate and initiate movement as illustrated in the 
provided research manual.20, 21 The above mentioned qualities were graded as 
normal (grade 0) or disturbed; at the index fi nger or hallux (grade 1); at the wrist 
or ankle (grade 2), at the elbow or knee (grade 3), at shoulder or hip joint (grade 
4). Two-point discrimination was assessed at the right index fi nger only using a 
sliding aesthesiometer and graded as normal (grade 0) or disturbed (grade 1) 
based on age-dependent normative values now available (see also chapter 2.1).22 
The modifi ed ISS, ranging from 0 (no sensory defi cit) to 33 (most severe sensory 
defi cit), was assessed at each visit in patients with GBS, CIDP, and MGUSP.
Table 4. Modifi ed INCAT sensory sumscore: 
sites of examination with corresponding grades. 
Sensation Normal Abnormal 
Grade 0 1 2 3 4
Pinprick Arms at index 
fi nger
at index 
fi nger
at ulnar 
styloid 
process
at medial 
humerus 
epicondyle
at acromio-
clavicular 
joint
Legs at hallux at hallux at medial 
malleolus
at patella at anterior 
superior iliac 
spine
Light touch Arms at index 
fi nger
at index 
fi nger
at ulnar 
styloid 
process
at medial 
humerus 
epicondyle
at acromio-
clavicular 
joint
Legs at hallux at hallux at medial 
malleolus
at patella at anterior 
superior iliac 
spine
Vibration 
sense
Arms at index 
fi nger
at index 
fi nger
at ulnar 
styloid 
process
at medial 
humerus 
epicondyle
at acromio-
clavicular 
joint
Legs at hallux at hallux at medial 
malleolus
at patella at anterior 
superior iliac 
spine
Joint position Arms DIP joint 
index fi nger
DIP joint 
index fi nger
at wrist at elbow at shoulder 
joint
Legs DIP joint 
hallux
DIP joint 
hallux
at ankle at knee at hip joint
Two-point 
discrimination
Index 
fi nger
at index 
fi nger
at index 
fi nger
Legend to table 4. DIP= distal interphalangeal
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• Electromyography (EMG)
If informed consent was given a routine EMG was performed once in the 
cross-sectional patients and twice, at entry and after one year follow-up, in 
all longitudinally studied patients. A standardised set of electrophysiological 
measurements was performed in the right arm and leg (in the left side if not 
possible due to e.g., injuries or deformities) using conventional techniques with 
surface electrode recordings after limb warming-up procedure.23, 24 Tests included 
assessment of motor nerves: median (two-point stimulation: wrist and distal 
to elbow), ulnar (three-point stimulation: wrist, distal and proximal to elbow), 
peroneal (three-point stimulation: ankle, fi bular head, popliteal fossa), and 
tibial (two-point stimulation: ankle, popliteal fossa) to determine the compound 
muscle action potential following distal and proximal stimulation, terminal 
latencies, conduction velocities, and F-response latencies. Sensory nerves were 
also assessed: the median (II), ulnar (V) and sural nerves were stimulated 
antidromically to determine evoked sensory nerve action potential amplitudes, 
distal latencies and conduction velocities. Needle electromyography of fi rst 
dorsal interosseous, vastus medialis and anterior tibial muscles were carried out 
to evaluate the presence of fi brillation potentials and positive sharp waves. 
• Modifi ed Dutch composite autonomic symptom scale (mD-COMPASS)
COMPASS is an instrument to assess autonomic symptoms. It correlates 
well with the CASS, a composite autonomic scoring scale that encompasses 
several autonomic function tests.25 The English version of the COMPASS was 
translated into Dutch, according to the international guidelines.26 In the modifi ed 
Dutch version, we added questions concerning female sexual dysfunction. The 
assessment of the mD-COMPASS starts the moment patients commence with 
mobilisation, covering at least 6 hours out of their bed or directly at hospital 
admission if patients are not bed bound. Except for MMN patients, all patients 
were asked to fi ll in the mD-COMPASS at each visit. 
• Visual analogue scale for pain (VAS-pain) and 11-point pain intensity numerical scale 
(11 point PI-NRS)
Except for MMN patients, all patients were instructed to complete these pain 
scales at each visit conform the published procedures.27, 28
At the activity limitation level of outcome:
• Overall disability sumscore (ODSS), overall neuropathy limitation scale (ONLS) 
Both the ODSS and the ONLS are composed of a summation of an arm disability 
scale (range: 0-5) and a leg disability scale (range: 0-7). The examiner questions 
and observes the patient in order to determine an arm grade and a leg grade. Each 
visit these activity limitation scales were completed according to the published 
procedures for each.2, 29 
• Rasch-built overall disability scale (R-ODS)
New activity and participation limitation scales were constructed refl ecting the 
specifi c limitations of patients with immune-mediated neuropathies using the 
Rasch method (see also Chapter 3.3 and 3.4).30 This method enables the use of 
sumscores by creating interval scales revealing the real difference in ability levels 
between patients and within patients in time. Both, the R-ODS for patients with 
GBS, CIDP and MGUSP and the R-ODS specifi cally designed for MMN patients 
(R-ODS-MMN), were assessed at each visit. 
At the quality of life level of outcome:
• Vickrey’s scale, short form 36-item health survey (SF-36), EuroQoL-5D, sickness 
impact profi le (SIP), Nottingham health profi le (NHP), and short form of the WHO 
quality of life scale (WHOQoLbref )
The Vickrey’s scale is a health related quality of life measure specifi c for patients 
with peripheral neuropathies.31 The other health-related scales concern generic 
quality of life measures.32-43 At each visit, all patients were asked to complete all 
quality of life questionnaires according to the published procedures by each one 
of them. Furthermore, at each visit patients were asked to tick a box on the quality 
of life visual analogue scale (QoL-VAS).
At the composite level of outcome:
• Clinical judgment score (ClinJSc) 
At each visit, patients were requested to judge whether their clinical condition 
strongly deteriorated (coded 1), slightly deteriorated (coded 2), remained stable 
(coded 3), slightly improved (coded 4), or strongly improved (coded 5) when 
compared with last visit (= defi ned as ‘clinical judgment score’). At study entry, 
patients refl ected their clinical condition against their physical status within the 
two weeks before the start of the study. 
• Personal patient-centred measures (PPCM) 
These are based on the Canadian occupational performance measure (COPM) 
concept of self-reported activities using a semi-structured interview undertaking 
the following steps: the researcher helps the patient to identify problem areas in 
daily activities and social participation. A problem exists when a patient cannot 
do, doesn’t do or isn’t satisfi ed with how he is doing his occupation or a particular 
task. By focusing on the patients’ own roles and environments we tried to identify 
areas that are relevant to them. After identifying problem areas, patients were 
asked to order the selected problems by their priorities (from most important to 
less important). Subsequently, the 5 most important problem areas to the patient 
were selected for follow-up and scored at each visit. These items are scored on 
a 5-point rating scale (1 meaning ‘not able to do’ or ‘not satisfi ed at all’ to 5 
meaning ‘able to do it extremely well’ or ‘extremely satisfi ed’) depending on the 
personal performance and satisfaction by the patient.44, 45 
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Specific PeriNomS study objectives 
within the scope of this thesis
For cross-sectional part
At the impairment level of outcome:
• Reliability and validity studies in patients with GBS, CIDP, and MGUSP:
- Comparison between the hand-held Vigorimeter 
and the Jamar dynamometer. 
- Comparison between (modifi ed) INCAT sensory sumscore 
and NIS sensory subset. 
• Reliability and validity studies in patients with MMN:
- Comparison between the hand-held Vigorimeter 
and the Jamar dynamometer. 
At the activity and participation level of outcome:
• Reliability and validity studies in all patients group: 
- Comparison between the newly devised Rasch-built overall disability scores 
(R-ODS) – one for patients with GBS/CIDP/MGUSP and one for patients 
with MMN – and the ODSS and ONLS separately.  
For longitudinal part
At the impairment level of outcome:
• Responsiveness studies in patients with GBS, CIDP, and MGUSP:
- Comparison between (modifi ed) INCAT sensory sumscore 
and NIS sensory subset 
- Comparison between the hand-held Vigorimeter 
and the Jamar dynamometer  
• Responsiveness studies in patients with MMN:
- Comparison between the hand-held Vigorimeter 
and the Jamar dynamometer. 
At the activity and participation level of outcome:
• Responsiveness studies in all patients group:
- Comparison between the newly devised Rasch-built overall disability scale 
(R-ODS) – one for patients with GBS/CIDP/MGUSP and one for patients 
with MMN – and the ODSS and ONLS separately.   
References
1. van Nes, S.I., C.G. Faber, and I.S. Merkies, Outcome measures in immune-mediated neuropathies: the 
need to standardize their use and to understand the clinimetric essentials. J Peripher Nerv Syst, 2008. 
13(2): p. 136-47.
2. Merkies, I.S.J., Evaluation of scales and measurement instruments in immune-mediated polyneuropathies. 
Thesis, in Neurology. 2001, Erasmus Medical Center: Rotterdam.
3. World Health Organization, International classifi cation of impairments, disabilities, and handicaps. 
2001: Geneva.
4. Aaronson, N.K., Quality of life: what is it? How should it be measured? Oncology (Williston Park), 
1988. 2(5): p. 69-76, 64.
5. Feinstein, A.R., Clinimetrics. 1987, New Haven and London: Yale University Press.
6. Merkies, I.S. and G. Lauria, 131st ENMC International workshop: Selection of Outcome Measures for 
Peripheral Neuropathy Clinical Trials 10-12 December 2004, Naarden, The Netherlands. Neuromuscul 
Disord, 2006. 16(2): p. 149-56.
7. Asbury, A.K. and D.R. Cornblath, Assessment of current diagnostic criteria for Guillain-Barre syndrome. 
Ann Neurol, 1990. 27 Suppl: p. S21-4.
8. Research criteria for diagnosis of chronic infl ammatory demyelinating polyneuropathy (CIDP). Report 
from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology, 
1991. 41(5): p. 617-8.
9. Miescher, G.C. and A.J. Steck, Paraproteinaemic neuropathies. Baillieres Clin Neurol, 1996. 5(1): p. 
219-32.
10. van Schaik, I.N., et al., European Federation of Neurological Societies/Peripheral Nerve Society guideline 
on management of multifocal motor neuropathy. Eur J Neurol, 2006. 13(8): p. 802-8.
11. Lauria, G., et al., EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur 
J Neurol, 2005. 12(10): p. 747-58.
12. Mathiowetz, V., Grip and pinch strength measurements, in Muscle strength testing. Instrumented and 
non-instrumented systems, L.R. Amundsen, Editor. 1990, Churchill Livingstone: New York. p. 163-
177.
13. Desrosiers, J., et al., Comparison of the Jamar dynamometer and the Martin vigorimeter for grip strength 
measurements in a healthy elderly population. Scand J Rehabil Med, 1995. 27(3): p. 137-43.
14. Kleyweg, R.P., F.G. van der Meche, and P.I. Schmitz, Interobserver agreement in the assessment of 
muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve, 1991. 14(11): p. 1103-
9.
15. Van Asseldonk, J.T., et al., Demyelination and axonal loss in multifocal motor neuropathy: distribution 
and relation to weakness. Brain, 2003. 126(Pt 1): p. 186-98.
16.  Dyck, P.J., et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, 
selection bias, and reproducibility of neuropathic tests. Neurology, 1991. 41(6): p. 799-807.
17. Dyck, P.J., et al. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis 
and staged severity. Neurology, 1992. 42(6): p. 1164-70.
18. Dyck, P.J., R.A.C. Hughes, and P.C. O’Brien, Quantitating overall neuropathy symptomes, and 
outcomes, in Peripheral Neuropathy, P.J. Dyck and P.K. Thomas, Editors. 2005, WB Saunders 
Company: Philadelphia.
19. Martina, I.S., et al., Measuring vibration threshold with a graduated tuning fork in normal aging and 
in patients with polyneuropathy. European Infl ammatory Neuropathy Cause and Treatment (INCAT) 
group. J Neurol Neurosurg Psychiatry, 1998. 65(5): p. 743-7.
20. Gilman, S., Joint position sense and vibration sense: anatomical organisation and assessment. J Neurol 
Neurosurg Psychiatry, 2002. 73(5): p. 473-7.
21. Stillman, B., Thesis: an investgation of the clinical assessment of joint position sense, in School of 
physiotherapy. 2000: Victoria, Australia.
22. van Nes, S.I., et al., Revising two-point discrimination assessment in normal aging and in patients with 
polyneuropathies. J Neurol Neurosurg Psychiatry, 2008. 79(7): p. 832-4.
23. Franssen, H. and G.H. Wieneke, Nerve conduction and temperature: necessary warming time. Muscle 
Nerve, 1994. 17(3): p. 336-44.
60 61
Chapter
1.3
PERIPHERAL NEUROPATHY OUTCOME MEASURES STANDARDISATION STUDYCHAPTER 1.3
24. Franssen, H., N.C. Notermans, and G.H. Wieneke, The infl uence of temperature on nerve conduction 
in patients with chronic axonal polyneuropathy. Clin Neurophysiol, 1999. 110(5): p. 933-940.
25. Suarez, G.A., et al., The Autonomic Symptom Profi le: a new instrument to assess autonomic symptoms. 
Neurology, 1999. 52(3): p. 523-8.
26. Streiner, D.L. and G.R. Norman, Health measurement scales. A practical guide to their development 
and use. 1998, New York: Oxford University Press, 2nd ed.
27. Maxwell, C., Sensitivity and accuracy of the visual analogue scale: a psycho-physical classroom experiment. 
Br J Clin Pharmacol, 1978. 6(1): p. 15-24.
28. Farrar, J.T., et al., Clinical importance of changes in chronic pain intensity measured on an 11-point 
numerical pain rating scale. Pain, 2001. 94(2): p. 149-58.
29.  Graham, R.C. and R.A. Hughes. A modifi ed peripheral neuropathy scale: the Overall Neuropathy 
Limitations Scale. J Neurol Neurosurg Psychiatry, 2006. 77(8): p. 973-6.
30. van Nes, S.I., et al., Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral 
neuropathies. Neurology, 2011. 76(4): p. 337-45.
31. Vickrey, B.G., R.D. Hays, and M. Beckstrand, Development of a health-related quality of life measure 
for peripheral neuropathy. Neurorehabil Neural Repair, 2000. 14(2): p. 93-104.
32. Bergner, M., et al., The Sickness Impact Profi le: development and fi nal revision of a health status 
measure. Med Care, 1981. 19(8): p. 787-805.
33. Jacobs, H.M., et al., [The sickness impact profi le; results of an evaluation study of the Dutch version]. 
Ned Tijdschr Geneeskd, 1990. 134(40): p. 1950-4.
34. Aaronson, N.K., et al., Translation, validation, and norming of the Dutch language version of the SF-36 
Health Survey in community and chronic disease populations. J Clin Epidemiol, 1998. 51(11): p. 1055-
68.
35. Erdman, R.A., et al., The Dutch version of the Nottingham Health Profi le: investigations of psychometric 
aspects. Psychol Rep, 1993. 72(3 Pt 1): p. 1027-35.
36. Guyatt, G.H., D.H. Feeny, and D.L. Patrick, Measuring health-related quality of life. Ann Intern Med, 
1993. 118(8): p. 622-9.
37. Hyland, M.E., A brief guide to the selection of quality of life instrument. Health Qual Life Outcomes, 
2003. 1: p. 24.
38. Sprangers, M.A., et al., Assessing meaningful change in quality of life over time: a users’ guide for 
clinicians. Mayo Clin Proc, 2002. 77(6): p. 561-71.
39. Saxena, S., D. Carlson, and R. Billington, The WHO quality of life assessment instrument (WHOQOL-
Bref ): the importance of its items for cross-cultural research. Qual Life Res, 2001. 10(8): p. 711-21.
40. Trompenaars, F.J., et al., Content validity, construct validity, and reliability of the WHOQOL-Bref in a 
population of Dutch adult psychiatric outpatients. Qual Life Res, 2005. 14(1): p. 151-60.
41. EuroQol--a new facility for the measurement of health-related quality of life. The EuroQol Group. Health 
Policy, 1990. 16(3): p. 199-208.
42. Ware Jr, J.E., et al., User’s manual for the SF-36v2 Health survey. Vol. 2nd edition. 2007, Lincoln: 
QualityMetric incorporated.
43. Ware Jr, J.E., et al., SF-36 health survey Manual and interpretation guide. 1993, The Health Institute, 
New England Medical Center: Boston.
44. Law, M., et al., The Canadian occupational performance measure: an outcome measure for occupational 
therapy. Can J Occup Ther, 1990. 57(2): p. 82-7.
45. Law, M., et al., Pilot testing of the Canadian Occupational Performance Measure: clinical and 
measurement issues. Can J Occup Ther, 1994. 61(4): p. 191-7.
Chapter 1.4
Objectives and outline 
of this thesis
64 65
Chapter
1.4
OBJECTIVES AND OUTLINE OF THIS THESISCHAPTER 1.4
Objectives and outline of this thesis 
This thesis focuses on improving and standardising assessment of patients with 
immune-mediated neuropathies by;
1. providing normative values to improve scoring systems 
of existing scales and tools
• revised normative values for the two-point discriminator to defi ne (ab)nor-
mal for this quality in the modifi ed INCAT sensory sumscore (chapter 2.1)
• revised normative values for measuring grip strength with the Jamar dy-
namometer (chapter 2.2)
2. introducing Rasch analyses to improve existing scales 
and to create interval scales
• improving the fatigue severity scale by using Rasch (chapter 3.2)
• creating an activity and participation limitation scale for GBS, CIDP and 
MGUSP (chapter 3.3) and for MMN (chapter 3.4) by using Rasch
3. selecting outcome measures based on comparative validity, 
reliability and responsiveness studies
• comparison of the Jamar dynamometer and the Vigorimeter to assess grip 
strength (chapter 4.1).
• comparison of the sensory subset of the neuropathy impairment score 
(NISs) and the modifi ed INCAT sensory sumscore (mISS) (chapter 4.2)
4. introducing the concept of minimum clinically important 
difference (MCID) to defi ne a responder
• using MCID cut offs to defi ne clinically relevant change (chapter 5.2)
• dynamic MCID based on individual standard errors (chapter 5.3)
OBJECTIVES OF THIS THESIS:
• to construct a neuropathy-specifi c core set of high quality outcome meas-
ures for future immune-mediated neuropathy studies and daily clinical 
practice (aim of the PeriNomS study)
• to contribute to the shift from ordinal outcome measures to measures 
with a linear construct using Rasch analysis
• to demonstrate the challenges of defi ning a responder using the concept 
of MCID
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Abstract
Objectives: To revise the static and dynamic normative values for the two-point 
discrimination test and to examine its applicability and validity in patients with a 
polyneuropathy. 
Methods: Two-point discrimination threshold values were assessed in 427 healthy 
controls and 99 patients mildly affected by a polyneuropathy. The controls were 
divided into seven age groups ranging from 20-29, 30-39,…, up to 80 years 
and older; each group consisting of at least 30 men and 30 women. Two-point 
discrimination examination took place under standardised conditions on the 
index fi nger. Correlation studies were performed between the scores obtained 
and the values derived from the Weinstein enhanced sensory test (WEST) and 
the arm grade of the overall disability sumscore (ODSS) in the patients’ group 
(validity studies). Finally, the sensitivity to detect patients mildly affected by a 
polyneuropathy was evaluated for static and dynamic assessment.
Results: There was a signifi cant age dependent increase in the two-point 
discrimination values. No signifi cant gender difference was found. The dynamic 
threshold values were lower than the static scores. The two-point discrimination 
values obtained correlated signifi cantly with the arm grade of the ODSS (static 
values: r=0.33, p=0.04; dynamic values: r=0.37, p=0.02) and the scores of the 
WEST in patients (static values: r=0.58, p=0.0001; dynamic values: r=0.55, 
p=0.0002). The sensitivity for the static and dynamic threshold values was 28% 
and 33%, respectively. 
Conclusion: This study provides age-related normative two-point discrimination 
values using a two-point discriminator (an aesthesiometer). This easily applicable 
instrument could be used as part of a more extensive neurological sensory 
examination.
Introduction
The assessment of sensory defi cit in clinical practice tends to be less obvious and 
more prone to subjective interpretation than the evaluation of motor dysfunction. 
This may explain the diversity in sensory scales used in polyneuropathy studies. 
To overcome these limitations and to strive for uniformity, the Infl ammatory 
Neuropathy Cause and Treatment (INCAT) group introduced and clinimetrically 
evaluated the INCAT sensory sumscore (ISS).1 The ISS comprises vibration and 
pinprick sense plus a two-point discrimination value using a sliding aesthesiometer. 
On the basis of experts’ opinion, this instrument was assessed in a ‘static’ manner 
at the index fi nger. The scoring system was chosen arbitrarily, because the reference 
values in the available studies turned out to be rather confl icting. In these studies 
different groups were investigated with poor or no information on stratifi cation for 
age and gender using different methodologies.2-6 To date, there is also no consensus 
about the assessment of two-point discrimination quality in a ‘static’ or ‘dynamic’ 
manner. On the basis of these shortcomings and striving for clinically applicable 
reference values, we examined a large cohort of healthy individuals to obtain 
normative values. Moreover, the validity and sensitivity of two-point discrimination 
assessment were investigated in patients mildly affected by a polyneuropathy. 
Participants and methods
Healthy controls
A total of 427 healthy controls were included. They were recruited from hospital 
personnel, relatives and friends of patients, and from homes for the elderly. Healthy 
individuals were stratifi ed for age and gender, forming seven age decade groups 
(20-29, 30-39, ..., up to ≥ 80 years) consisting of at least 30 men and 30 women 
each. Eligibility criteria were: lucid consciousness and no history of mental or 
psychological illness, no history of alcohol misuse, no usage of drugs or history of 
diseases that may cause sensory defi cit or infl uences cooperation, independence 
in activities of daily living, no sensory symptoms in hands or feet (e.g., burning, 
tingling, numbness), absence of any impairment affecting upper limbs (e.g., joint 
problems, deformities, muscle ache), present tendon refl exes and normal sensory 
modalities (pain, touch and vibration sense) at examination. Pain was tested with 
disposable pins, touch with cotton wool sticks and vibration with a Rydel-Seiffer 
tuning fork using the published reference values.7
Patients with a polyneuropathy
Ninety-nine patients were recruited from the university hospital of Maastricht 
outpatients’ databank. They were all able to walk independently. The 
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aetiologies were diabetes mellitus (n=23), chronic infl ammatory demyelinating 
polyradiculoneuropathy (CIDP) (n=23), Guillain-Barré syndrome (n=14), uraemia 
(n=13), drug-induced (n=6), hereditary motor and sensory neuropathy (HMSN) type 
I (n=5), and vitamin B12 defi ciency (n=2). In 13 cases no cause was determined. 
Assessment tools and scale
• A two-point discriminator with adjustable points (an aesthesiometer) was used 
(fi gure 1). The exact measurable distance can be read on one arm of the instrument 
(range 3 mm-10 cm). 
• The Weinstein enhanced sensory test (WEST) delivers calibrated forces to intact 
skin by use of fi ve force-calibrated monofi laments.8 
• The arm grade of the overall disability sumscore (ODSS) was selected, as it captures 
upper limb function through daily activities (e.g., dressing upper part of the body, 
using knife and fork).9 Good clinimetric properties have been demonstrated for 
the WEST and the ODSS. 
Figure 1. Two-point discriminator (aesthesiometer)
Figure 2. Static and dynamic two-point discrimination assessment
Test procedure
All participants gave informed consent before the study. The medical ethics 
committee of the university of Maastricht approved the study. Assessments were 
performed in a random order. For two-point discrimination assessment, the ends 
of the arms of the aesthesiometer were placed simultaneously on the right index 
fi nger. The aesthesiometer was held at its hinge (turning point) while the ends of 
the arms were rested gently on the skin without application of any pressure, only 
the weight of the instrument (30 g, length of arms 12,4 cm). The distance between 
the two ends was varied. The initial distance started at >2 cm (which was enough 
for almost all controls to detect the two points), gradually descending until the 
participant could not differentiate between the two points. First an example of one 
and of two points was given. Subsequently, to obtain a threshold value, a subject had 
to differentiate correctly between two points at a given distance 7 out of 10 times. 
Catch trials were randomly applied to enhance measurements. Participants were 
examined in a standardised position; sitting with the forearm in supination, resting 
comfortably on an armchair or desk, and with eyes closed. Static examination was 
performed by applying the ends of the arms of the aesthesiometer to one point 
at the distal phalanx. For dynamic examination, the ends of the arms were gently 
moved from the proximal to the distal end of the distal phalanx, over a distance 
of approximately 1 cm. Contact with the skin was maintained while the ends were 
moved perpendicular to the gap between the two-points. Three data-collecting 
series were performed for both static and dynamic assessments. In cases of doubt, 
the series were expanded to a maximum of fi ve. The WEST was applied according to 
the instructions given by the manufacturer (Connecticut Bioinstruments, Riverdale, 
New York, USA).8 
Statistical analysis
Static and dynamic reference values were calculated in healthy controls for the two-
point discrimination test (95th centile values, corresponding to a chosen specifi city 
of 95%), depending primarily on age and sex, using quantile regression analyses 
with restricted cubic spline functions on age. The limits obtained were estimated 
and further used to determine the sensitivity for the static and dynamic approach. A 
two-point discrimination score was considered to be abnormal if the corresponding 
value was above the 95th centile limit. 
Construct validity for the aesthesiometer was obtained by correlating the two-
point discrimination values with the values of the WEST and the arm grade of the 
ODSS in patients (Spearman rank test). All analyses were performed using Stata 
7.0 for Windows 2000. A value of p<0.05 was considered statistically signifi cant.
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Results
A total of 427 healthy controls were included (all age groups having 30 men and 
30 women, except age group 20-29 years (31 men and 31 women) and age group 
≥ 80 years (30 men and 35 women). There was an age-dependent increase in the 
acquired static and dynamic two-point discrimination values. The corresponding 
graphics show these increase refl ecting the decline in two-point discrimination 
sense with aging (fi gure 3).
Figure 3. results of static and dynamic measurement with the aesthesiometer
Threshold values obtained from the dynamic assessment turned out to be lower 
than those acquired from static examination (fi gure 3). The 95% centile normative 
static and dynamic scores were independent of gender and were subsequently 
translated for clinical use (table 1). 
Table 1. Normative static and dynamic two-point discrimination values 
Age (years) Static assessment (mm) Dynamic assessment (mm)
20-39
40-49
50-59
60-69
70-79
≥ 80
4.0
4.5
5.0
6.0
7.0
8.5
3.5
4.0
4.0
5.0
6.0
6.5
Legend to table 1. Normative values are 95th centile values per age span. mm=millimetres
A total of 37 women and 62 men with a polyneuropathy were included (mean 
(SD) age 58.9 (13,6), range 26-87 years). No disability in upper limb functioning 
was found in 34.1% of the patients. Minor (ODSS arm grade 1: 9.8%), moderate 
(grade 2: 48.8%) and severe (grade 3: 7.3%) signs were observed in the remaining 
patients. A signifi cant correlation was found between the two-point discrimination 
values obtained and the ODSS arm grade (Spearman rank test: static values versus 
arm grade: r=0.33, p=0.04, dynamic values versus arm grade: r=0.37, p=0.02), and 
the WEST scores in these patients (Spearman rank test: static values versus WEST: 
r=0.58, p=0.0001; dynamic values versus WEST: r=0.55, p=0.0002). The sensitivity 
of the aesthesiometer (ability to detect a patient) was 28% and 33% when assessed 
in a static or dynamic manner, respectively.
Discussion 
This study provides revised static and dynamic normative two-point discrimination 
threshold values. These values increase with age, but are gender independent. This is 
in line with earlier reports, although different devices and assessment methods were 
used.2-5 Various factors may contribute to the increase in two-point discrimination 
values with increasing age: a quantitative change in Meissner corpuscles, a change 
of the mechanical properties of the dermis, degenerative transformations of 
the Pacinian corpuscles, demyelination and fi bre loss in peripheral nerves, and 
degenerative changes in the central nervous system.10 The lower dynamic threshold 
values obtained probably result from measuring the quickly adapting fi bre system 
instead of the slowly adapting fi bres as in static assessment.11, 12 However, in our 
patient group, no method seemed to be superior: the ability to detect a patient was 
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equally low in static and dynamic assessments. A moderate correlation between 
the two-point discrimination values and the arm grade of the ODSS was found 
in the patients who were mildly affected by a polyneuropathy. Apparently, the 
aesthesiometer, measuring an impairment quality, translates its fi ndings to daily 
activity defi cits. Also, the aesthesiometer shows its convergent validity through 
correlation with the WEST. 
Despite the fi ndings in this study, some methodological issues should be 
addressed. Firstly, although most polyneuropathies are known to be length 
dependent, we have chosen to examine two-point discrimination at the index fi nger. 
In a pilot study, we found great variability in threshold values with low inter-rater 
scores when tested at the hallux, whereas a good reliability at the index fi nger has 
been reported.13 Secondly, despite its simplicity, its validity, and its demonstrated 
reliability as part of the ISS, two-point discrimination assessment needs further 
clinimetric evaluation.1 Currently, the reliability and its responsiveness are under 
investigation in patients with infl ammatory polyneuropathies (PeriNomS study). 
Owing to its low sensitivity in mildly affected patients, we suggest using two-
point discrimination assessment as part of a more extensive sensory examination, 
using its revised reference values now available.
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Abstract
The Jamar dynamometer has been widely used in various chronic illnesses and 
has demonstrated its strength as a potential prognostic indicator. Various stratifi ed 
normative values have been published using different methodologies, leading 
to confl icting results. No study used statistical techniques considering the non-
Gaussian distribution of the obtained grip strength values. Jamar grip strength was 
assessed in 720 healthy participants, subdivided into seven age decade groups 
consisting of at least 50 men and 50 women each. Normative values (median and 
5th values) were calculated using quantile regressions with restricted cubic spline 
functions on age. Possible confounding personal factors (hand dominance, height, 
weight, hobby and job categorisation) were examined. Clinically applicable revised 
normative values for the Jamar dynamometer, stratifi ed for age and gender, are 
presented. Hand dominance had no infl uence. Other personal factors only minimally 
infl uenced fi nal values. This study provides revised normative grip strength values 
for the Jamar dynamometer. 
Introduction
Distal weakness generally predominates in patients with polyneuropathy and 
may contribute to defi cits in daily activities and social participation.1, 2 Therefore, 
reliable assessment of grip strength is very important to capture clinical changes 
in interventional studies in these disorders. Assessment of grip strength has also 
demonstrated to be a prognostic indicator of clinical and functional recovery in 
other diseases affecting hand function.3, 4 Two devices are in widespread use, the 
Vigorimeter and the Jamar dynamometer. Normative values for the Vigorimeter 
have been published using new statistical techniques.2 Various stratifi ed normative 
values for the Jamar dynamometer have been published; however, using different 
methodologies leading to confl icting results. No information has been provided 
regarding the statistical analyses for the fi rst report on normative values for the 
Jamar.5 In a descriptive meta-analysis, means and 95% confi dence intervals of 
normative values per age category were listed.6 Unfortunately, the methodology 
among the 12 recruited studies differed substantially, making the proposed 
normative values not suitable. In a recent study, the reported normative values 
were based on means (+SD), while the normative values seemed quite skewed 
showing a curvilinear relationship to age.7 On the basis of these observations, we 
examined a large cohort of healthy individuals from 20 to 96 years of age to obtain 
revised normative values for the Jamar dynamometer using statistical techniques 
that capture the non-Gaussian distribution of the obtained grip strength values. 
Patients and methods
A total of 720 healthy participants (20-96 years) were recruited from university, 
hospital and secondary school personnel, homes for the elderly and sports clubs. 
They volunteered on locally spread pamphlets requesting participation and were 
stratifi ed for age and gender forming seven age decade groups (20-29, 30-39,…,
≥80 years), each consisting of 50 men and 50 women. Inclusion criteria were: 
independence in daily living, absence of any impairment affecting upper limb 
function (e.g., joint deformities), absence of impaired sensory function (e.g., burning, 
tingling, numbness of hands or feet), no concomitant disease or medication possibly 
causing polyneuropathy (e.g., diabetes mellitus, chemotherapy). All participants 
were neurologically examined with emphasis on upper extremity function and signs 
of peripheral nervous system defi cits (e.g., muscle strength (Medical Research 
Council grading), tendon refl exes, light touch, pin-prick, vibration sense (Rydel-
Seiffer tuning fork)).8 Eligibility was obtained if examination was normal. 
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Assessment tools
The portable Jamar hydraulic hand dynamometer (Sammons Preston, Rolyan, 
Bolingbrook, IL, USA) was used, with the second handle position for all subjects. 
The presented scores are expressed in pounds force.
Test procedures 
The local medical ethics committee approved the protocol. All participants gave 
written informed consent. Through interview we collected anthropometric data 
(body height, weight) and hand dominance. Participants were requested to 
categorise their profession and hobby as being physically light (coded: 0), moderate 
(1) or heavy (2), if applicable. 
The Jamar dynamometer was placed in the right or left hand randomly and was 
held loosely around the readout dial by the examiner to prevent dropping.5 In 
alternating order, three maximum voluntary grip strength contractions were taken 
for each hand. The mean value of each hand was used for analysis.9 All participants 
were examined in a standardised position.10
Statistics
After stratifi cation for age and gender, revised normative values (median and 0,05 
quantile values, corresponding to a specifi city of 95%) for the Jamar dynamometer 
were calculated using quantile regression analyses with restricted cubic spline 
functions on age.11 In each gender, multivariate quantile regression analyses were 
performed, with height, weight, categorisation of profession and hobby as the 
independent variables on the calculated 5th quantile normative values (dependent 
variable).2, 11, 12 All analyses were performed using STATA 11.0 for Windows.
 
Results  
Descriptive data of all 720 participants are presented in table 1. Men were generally 
stronger than women. There was a signifi cant curvilinear age-dependent decrease 
of normative values in both genders. Maximum median grip strength was 
reached among women aged 30-39 and among men aged 40-49. Furthermore, no 
signifi cant difference in grip strength between the dominant and non-dominant 
hand was found (overall median difference of 1 pound). Therefore we developed 
one normative values graph for both hands for each gender separately (table 2; 
fi gure 1). 
Multivariate regression analysis did not show any signifi cant impact of height, 
weight, profession or hobby categorisation on the 5th percentile cut-off normative 
values in women. In men, only hobby categorisation was related to the 5th 
percentile cut-off normative values; however, explaining only a small portion of 7% 
(p=0.008).
Table 1. Descriptive data of healthy participants 
Women Men Total
Participants, n 355 365 720
Age
     Mean (SD)
     range (year)
54.7 (21.1)
20-95
55.1 (20.5)
20-96
54.9 (20.8)
20-96
Hand dominance
     Right (%) 90 87 88
     Left (%) 7 10 8
     Ambidextrous (%) 3 4 3
Height
     Mean, in cm (SD) 166 (7.1) 179 (8.3) 173 (10.1)
     Range (cm) 140-184 150-202 140-202
Weight
     Mean, in kg (SD) 68.2 (12.4) 82.1 (12.9) 75.2 (14.4)
     Range (kg) 43-123 45-135 43-135
Profession categorisation
     Light, n (%) 115 (32.4) 136 (37.3) 251 (34.9)
     Moderate, n (%) 95 (26.8) 83 (22.7) 178 (24.7)
     Heavy, n (%) 25 (7.0) 23 (6.3) 48 (6.7)
     Not applicable, n (%) 120 (33.8) 123 (33.7) 243 (33.8)
Hobby categorisation
     Light, n (%) 197 (55.5%) 163 (44.7%) 360 (50.0%)
     Moderate, n (%) 143 (40.3%) 171 (46.9%) 314 (43.6%)
     Heavy, n (%) 15   (4.2%) 31   (8.5%) 46   (6.4%)
Table 2. Normative grip strength values for the Jamar dynamometer for clinical use (in pounds)
Women (n=355) Men (n=365)
Age 
(years)
Number of 
subjects
5th percentile 
Jamar values 
(pounds)
Median 
Jamar values 
(pounds)
Number of 
subjects
5th percentile 
Jamar values 
(pounds)
Median 
Jamar values 
(pounds)
20-29 51 50 62 50 81 100
30-39 50 49 64 51 80 105
40-49 50 48 63 50 78 107
50-59 51 45 61 54 73 104
60-69 49 40 56 58 64 95
70-79 50 32 46 50 51 77
≥ 80 54 22 34 52 34 54
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Figure 1. Revised grip strength values with the Jamar dynamometer for the dominant 
and non-dominant hands combined in healthy women (n= 355, 90.1% right-handed) and 
healthy men (n= 365, 86.6% right-handed).
Legend to fi gure 1. The upper lines in each graph correspond to the calculated median grip strength 
values. The lower lines in each graph represent the 0,05 quantile reference values. These values 
were obtained in each gender separately using quantile regressions with restricted cubic spline 
functions. Note: the y-axis for men and women differ
Discussion
This study provides revised normative values for the Jamar dynamometer in adults. 
We used robust statistical techniques to present the correlation between age and 
grip strength values.11 Normative values for the Jamar dynamometer have been 
provided before.5-7, 13, 14 Unfortunately, all these values were obtained by calculating 
means of sequential age portions, without taking into account the non-Gaussian 
distribution of the obtained grip strength values, as recommended for these kinds 
of continuous data.2, 11, 12 Grip strength showed a curvilinear relationship to age.5, 7, 14
In both genders, a marked decline of grip strength was seen after 60 years of age, 
which is in conformity with earlier reports.5, 7 Our data showed hardly any difference 
in grip strength between the dominant and non-dominant hand, which is in contrast 
with earlier papers reporting up to 33% difference.5, 7 A difference in statistical 
approach could be an explanation for the obtained differences. At a workshop on 
outcome measures in immune-mediated neuropathies, it was argued whether the 
Vigorimeter, with its soft squeezing bulb and particularly used in Europe, would 
have a preference over the Jamar dynamometer, mainly used in the United States.15 
At current stage, there is no consensus regarding which instrument should be used. 
Therefore, a comparison study of these two instruments is warranted, focusing 
primarily on their responsiveness fi ndings and on patients’ preference. These 
efforts are currently being undertaken as part of an international, multi-centre 
collaborative study (Peripheral Neuropathy outcome measures Standardisation 
(PeriNomS) study).
Our calculated 5th percentile normative cut-off grip strength data did not show 
any correlation with parameters like weight, height, occupation, except for hobby 
categorisation in men, which is in contrast with recent literature.7, 16 However, 
the studies by Werle et al. and Angst et al. have used a different approach: they 
have calculated a correlation between the obtained raw grip strength scores and 
other parameters (height, weight, occupation) and have not used a cut-off score 
for these normative values, which may explain the differences with our paper.7, 16 
In conclusion, the current study provides robust clinically applicable normative 5th 
percentile grip strength values for the Jamar dynamometer.
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Introduction
This brief introduction is intended to help clinicians and scientists in neurology 
understand the underlying principles of the Rasch method. Immune-mediated 
neuropathies will be used as an example, however, this writing is essentially 
applicable to all (neurological) illnesses. A review was published in 2008 highlighting 
the use of all types of outcome measures in published randomised controlled trials 
that included patients with various forms of immune-mediated neuropathies (see 
also chapter 1.2).1 This paper (chapter 1.2) also presented the basic clinimetric 
requirements (like validity, reliability, and responsiveness) for any outcome measure 
to be selected for use in a trial.1, 2 Since then, additional randomised trials have 
been published demonstrating the effi cacy of medical interventions in patients with 
chronic infl ammatory demyelinating polyradiculoneuropathy (CIDP) and monoclonal 
gammopathy of undetermined signifi cance related neuropathies (MGUSP) using 
similar ordinal based outcome measures.3-8 All outcome measures used to date in 
immune-mediated neuropathy medical interventional trials are based on the classical 
test theory (CTT).9 DeVellis has summarised various aspects of CTT including its 
disadvantages: outcome measures based on CTT may constitute items that are 
arbitrarily collected with response options generally based on ordinal Likert-type 
choices.9 As an example, physicians often consider a one point response change for 
an item from 0 to 1 equivalent to a one point change from 2 to 3. However, because 
the response options are ordinal based, the true distance between the response 
categories is not known and most probably unequal (fi gure 1). 
Figure 1. Example of an outcome measure based on classical test theory 
with four ordinal Likert response options per item
impossible to 
perform
0
with great 
diffi culty
1
with slight 
diffi culty
2
Easily 
performed
3
washing face
? ?
stand up from a chair
walk 1 fl ight of stairs
take a shower
Legend to fi gure 1. A one point change from 0 to 1 for an item is considered being equivalent to 
a one point change from 2 to 3; however, because the response options are ordinal based, the 
equivalence is highly unlikely.
Also, patients are requested to complete all items, even though some may be 
irrelevant or inappropriate for their level of ability. Often, scores of the items of a 
scale are summed and the obtained data generally treated as if they were linear; 
frequently being exposed to parametric analyses. Creating a sum of the item scores 
CHAPTER 3.1
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also assumes equal relevance (‘weight’) of each item, which is highly unlikely.10 
Based on these shortcomings, CTT-based outcome measures may limit the 
comparison of patients and study results. Ordinal scales lack linearity.
Rasch as a modern clinimetric vehicle
Considering the shortcomings of the CTT, it is clear that a modern scientifi c 
approach is needed for the evaluation and construction of outcome measures to 
improve the fi ndings in interventional trials. Using interval measures with a linear 
construct instead of ordinal scores would give a true refl ection of disease impact, 
of differences between individuals and groups, and treatment effects. One of the 
widely used approaches is the Rasch method, which was introduced by the Danish 
mathematician Georg Rasch.11, 12 
The Rasch method is based on logic assumptions. For example, it is very logical to 
assume that walking a fl ight of stairs will be a much more diffi cult task to accomplish 
compared to washing one’s face. It is also logical to assume that a Guillain-Barré 
syndrome (GBS) patient that is bed-bound due to severe weakness will have more 
problems performing daily activities than a GBS patient walking around with only 
an ankle orthosis. From a more statistical background, the Rasch model states that 
the probability of a patient being able to ‘correctly answer or complete an item or 
task’ is a logistic function of the diffi culty of the task and the ability of the patient 
to accomplish it.11 Rasch analysis transforms obtained ordinal scores into interval 
measures and places both items’ and patients’ parameter estimates on the same 
log-odds unit (logit) scale (fi gure 2). Therefore a less affected patient (a patient 
with a higher ability) will have a greater chance to complete a more diffi cult item 
when compared to a patient that is more disabled. 
Figure 2. Example of a Rasch-built interval activity outcome measure with linearly 
weighted estimates of patient ability and item diffi culty 
Legend to fi gure 2. The Rasch model compares the item response patterns of individuals to the 
entire sample of patients being examined to estimate person ability and item diffi culty and places 
both item and person estimates on the same logit scale. 
This chapter aims to help clinicians and scientists in neurology increase their 
understanding of the various steps of the Rasch methodology.
Ordering item diffi culty estimates and person ability estimates on the same ruler
The statistical calculations and procedures of ordering the diffi culty of the items 
and the ability of patients on the same ruler is based on the so-called Guttman 
scaling.13 As illustrated in fi gure 3A, the Guttman scaling codes items as 0 (‘no/ not 
able’) or 1 (‘yes/ able’). Figures 3B and 3C demonstrate the ordering of the diffi culty 
of items based on Guttman scaling from most easy (coded 01111- sumscore 4) to 
most diffi cult (00001- sumscore 1). Persons are also ordered according to their 
ability level: patient E having a higher sumscore thus a greater ability than patient 
A (fi gure 3D and 3E).
Figure 3A. Guttman scaling 
Legend to fi gure 3A. As an example, item 1 refers to the question ‘are you able to wash your face’.
Person A responded ‘No, I am not able to wash my face’ coded as 0. Person B responded ‘yes, I 
am able to wash my face’ coded as 1.
Figure 3B. Easiest item based on Guttman scaling
Legend to fi gure 3B. Person A responded 0 (‘no, I am not able to…’) to item 1. However, person B-E 
responded 1 (‘yes, I am able to…’) to item 1. Therefore, for this population, item 1 is relatively easy. 
item diffi culty
96 97
EXPLAINING RASCH TO NEUROLOGISTSCHAPTER 3.1
Chapter
3.1
Figure 3C. Most diffi cult item based on Guttman scaling
Legend to fi gure 3C. Person A-D responded 0 (‘no, I am not able to…’) to item 4. Only person E re-
sponded 1 (‘yes, I am able to…’) to item 4. Therefore, for this population, item 4 is rather diffi cult. 
Figure 3D. Guttman scaling reveals the most able patient completing all items
Legend to fi gure 3D. Person E responded 1 (‘yes, I am able to…’) to all items corresponding to be-
ing able to perform all activities captured by item 1-4. Therefore, person E has a high ability level 
compared to other persons in this population. 
Figure 3E. Guttman scaling reveals the least able patient completing none of the items 
Legend to fi gure 3E. Person A responded 0 (‘no, I am not able to…’) to all items corresponding to 
not being able to perform any of the activities captured by item 1-4. Therefore, person A has a low 
ability level compared to other persons in the population examined. 
Figure 4A-J illustrates in a schematic way the statistical steps taken by the Rasch 
model to order items and patients on one ruler. Suppose we are examining n=100 
patients with an immune-mediated neuropathy using a daily activity scale that 
includes 4 items (A, B, C, and D) with ordinal response options ranging from 
0 (‘impossible to perform’), to 1 (‘very diffi cult to perform’), to 2 (‘diffi cult to 
perform’), and to 3 (‘easy to perform’) (fi gure 4A).
Figure 4A. 
Figure 4B. Number of patients per response option after completion of the 4-item daily 
activity scale by 100 patients
Figure 4C. Ordering items according to their diffi culty level: location of the easiest item 
(item A) on the ruler
item diffi culty
patient’s ability
patient’s ability
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As can be seen, item A turns out to be the ‘easiest item’ based on the highest percentage 
(95%) of patients examined choosing response option 3 (‘easy to perform’) for this 
item (fi gure 4C). Conversely, 98 of the 100 patients scored 0 (‘impossible’) on item 
B, making this item the most diffi cult to accomplish (fi gure 4D).
Figure 4D. Ordering items according to their diffi culty level: location of the most diffi cult 
item (item D) on the same ruler
Subsequently, fi gure 4E show a stepwise ordering of all items by the Rasch model 
on the same ruler.
Figure 4E. Ordering the items A, B, C, and D on one ruler according 
to their diffi culty level
Legend to fi gure 4E. Since 50% of the patients had a score of 0 (‘impossible to perform’) on item D 
and only 10% on item C, it is obvious that item D is more diffi cult to accomplish compared to item 
C. The Rasch model estimates their location (‘weight’) as expressed in logits.
Figures 4F through 4J illustrate the stepwise ordering of patients on the same ruler. 
To maintain clarity, we will be comparing the results of 3 patients completing the 
above mentioned daily activities scale as an example. Figure 4F shows the same 
scale, but now the items are listed based on their weights (‘diffi culty to accomplish’). 
As shown, patient I scored 3 (‘easy to perform’) on all four items. 
Figure 4F. Ordering patients according to their ability level, 
starting with patient I (yellow)
The scores for patients II and III are presented in fi gures 4G and 4H. 
Figure 4G. Patient II (green)
Figure 4H. Patient III (blue)
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Based on the obtained results in these three patients it is concluded that patient I 
(yellow) has the highest ability, scoring the maximum on all daily activities scale’s 
items. On the other hand, patient II (green) had the lowest scores when compared 
with the other patients, hence demonstrating having the lowest ability of the three 
patients. Their ordering on the same metric is illustrated in the fi gures 4I and 4J, 
thus obtaining a fi nal model with all items and patients equated on the same metric 
(see also fi gure 2). 
Figure 4I. Starting with the patient with the highest ability: patient I (yellow), because all 
scores of this patient were 3 (‘easy to perform’)
Figure 4J. Final schematic ordering of items’diffi culties and patients’abilities on the 
same metric by the Rasch model
Rasch model expectations
To obtain an interval scale with a linear construct based on the Rasch method, all 
items and persons as part of the model need to fulfi l several model expectations.11,12
These expectations could be seen as check-points in the process of creating a scale. 
Only when all expectations are met, an ideal interval scale can be created. The 
Rasch Unidimensional Measurement Models (RUMM), used for this purpose, 
elegantly integrates the various measurement issues and provides the researcher 
with numerous explanatory graphs.14 The following applications of RUMM are 
used to examine whether the data fi t the model expectations. Items or patients not 
fulfi lling these requirements should be removed or subjected to re-adjustments 
to fi t the model. The statistical background of the RUMM will only be addressed 
briefl y as part of a control panel of the software, which automatically provides the 
results of the analyses performed (fi gure 5).
Fit statistics
The RUMM has three overall fi t statistics that have to be fulfi lled. Two are item-
person interaction statistics transformed to approximate a z-score. Therefore, if 
the items and persons fi t the model, a mean around zero and a standard deviation 
of 1 would be expected (fi gure 5, sections I and II).12 A third fi t statistic score is an 
item-trait interaction statistic reported as a chi-square, refl ecting the property of 
invariance across the trait to be measured. A non-signifi cant chi-square indicates 
that the hierarchical ordering of the items does not vary across the trait, thus 
fulfi lling the required property of invariance (fi gure 5; section III).
Figure 5. Example of summary statistics as provided by RUMM during model creation
Fit residuals
Individual person- and item-fi t statistics are also examined both as residuals (as a 
summation of individual patient and item deviations from expected model scores) 
and as chi-square statistics (see fi gure 5, sections II and III). In the former case, 
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residuals between ±2.5 are considered adequate fi t to the model. In the latter case a 
chi-square statistic is available for each item. Summation of the overall chi-square 
for items gives the item-trait interaction statistic. 
Internal reliability studies
Internal consistency of the scale is determined with the person separation index 
(PSI) or Cronbach’s alpha (the latter is only possible when there are no missing val-
ues) using the logit scores for each person. A value of ≥ 0.7 is considered consist-
ent with the scale being able to differentiate between at least 2 groups of patients 
and is seen as the minimum requirement for measurement.15
Sample size calculations
Professor Linacre, one of the well-known researchers in the fi eld of Rasch analyses, 
has extensively examined the ideal sample size needed to have a stable model 
through modelling. From his publications, a sample size of approximately 250 is 
needed to obtain a 99% confi dence with a stable item calibration within ± 0.5 logits, 
hence providing a stable model.16 
Additional requirements for model fi tting
Threshold examination
The term threshold refers to the point between two adjacent response categories 
where either response is equally probable. That is the point where, for example in 
case of the Rasch-built overall disability scale (R-ODS), the probability of scoring 0
(‘impossible to perform’) and 1 (‘performed with diffi culty’) is 50/50 for an item (fi gure 
6). In this example the individual patient is able to differentiate between the response 
options 0, 1, and 2, since the two threshold locations are ordered (fi gure 6). 
Figure 6. Category probability curves demonstrating the ideal ability of patients to 
discriminate between response options for the item ‘bend forward and pickup an object’
Legend to fi gure 6. The Rasch model translates the response options graphically for each item 
of a scale; in this example, the response options are defi ned as: 0 (‘impossible to perform’) blue 
line, 1(‘performed with diffi culty’) - red line, and 2 (‘easily performed’) - green line. 
Note: Threshold T1 < T2, indicating good ordering of these by the patients.12
One of the most common sources of item misfi t concerns respondents inconsistent 
use of response options. This results in what is known as ‘reversed or disordered 
thresholds’. Disordered thresholds occur when respondents have consistently 
diffi culty discriminating between response options. This can occur when there are 
too many response options, or when the labelling of options is potentially confusing 
or open to misinterpretation (e.g., great - some - little). An example of disordered 
thresholds is given in fi gure 7, demonstrating the inability of patients to properly 
discriminate between the response options for the item ‘fatigue causes frequent 
problems for me’ as part of the fatigue severity scale (see also chapter 3.2).17 
The response options range from: 0 (‘strongly disagree’), 1 (‘mainly disagree’), 
2 (‘partially disagree’), 3 (‘do not agree/disagree’), 4 (‘partially agree’), 5 (‘mainly 
agree’), and 6 (‘strongly agree’). In particular, the response categories 1 to 4 were 
clustered, thus showing a disordered threshold pattern. In order to improve model 
fi t, we subsequently collapsed the response options to obtain ordered thresholds 
(fi gure 7; see also the pattern presented in fi gure 6). In the current example, the 
model suggested rescoring the categories 1 through 5 into 2 response options 
(changing the total response options from 0/1/2/3/4/5/6 to 0/1/2/3).
Figure 7. Example of ‘disordered threshold’ at initial examination and ‘ordered thresh-
olds’ after rescoring of the response categories.
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Local dependency
Residual correlations between items within the same scale are a source of misfi t. 
Local dependency refl ected by residual correlations arises when items are linked 
such that the response on one item may be dependent upon the response to 
another. This fi nding infl ates reliability and the fi nal scale score in a particular 
direction.12 Figure 8 illustrates local dependency by looking at parts of the motor 
question of the SF-36 health survey.18 In cases of local dependency, the researcher 
may consider removing items or creating a subset of correlating items to improve 
model fi t.
Figure 8. Local dependency demonstrated through motor question as part of the SF-36 
health survey
Legend to fi gure 8. If a patient scores 3 (‘no, not limited at all’) on the question ‘does your health 
limit you now in walking more than a mile?’, this automatically has a bearing upon the answer on 
the other two question; in other words: this patient will also be scoring 3 on the questions ‘does 
your health limit you now in walking several hundred yards?’ and ‘does your health limit you now in 
walking one hundred yards?’. Since the results of these 3 questions are linked, the obtained scores 
will infl ate reliability and the fi nal scale’ score in a particular direction. 
Item bias
A scale should always work in the same way irrespective of which personal 
factor (e.g., gender) is being examined.19 For example, if men and women with 
equal ability levels (equal limitations due to their immune-mediated neuropathy) 
respond systematically differently to a daily activity item, then this item would be 
considered to display differential item functioning (DIF) = item bias, and would 
violate the requirement for unidimensionality.12 Figure 9 illustrates DIF on personal 
factor ‘gender’ for the item ‘vacuum cleaning’. As can be seen, females (blue line) 
experienced this activity as more diffi cult to accomplish than males (red line). 
Subsequently, this item was removed from the model. The researcher may consider 
to omit such an item or to split this into two (a vacuum cleaning item specifi cally 
for males and females, separately).
Figure 9. Item characteristic curve for item ‘vacuum cleaning’ related to personal factor 
‘gender’
Legend to fi gure 9. ICC = item characteristic curve. This picture shows how DIF puts the males (red 
line) to the left (easier to perform) side of the Rasch ICC curve, and the females (blue line) to the 
right (more diffi cult to perform) side.
Calibration of the scale – potential drawbacks
Items and persons are selected or discarded based on the above mentioned 
stepwise approach. As a result this determines the fi nal locations of items and 
persons on the ruler (calibration of the scale). Therefore, the study population 
should represent the patients you would like to evaluate in the future. Items should 
be unambiguously constructed to prevent misinterpretation. A questionnaire 
should contain written instructions. Nevertheless, there might be some bias of 
the responses given. Patients may not disclose a proper response without being 
interviewed personally. However, inconsistent responses to certain items will 
probably result in the item being omitted due to misfi t statistics. Once data fi t 
Rasch model expectations, logits of person estimates can be used as an interval 
level variable in parametric statistics. 
In conclusion, modern clinimetric methods such as Rasch need to be adopted 
by neurologists, in order to improve the interpretation of the results of published 
papers and to develop more proper outcome measures for use in future follow-up 
studies and clinical trials.
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Abstract
Fatigue is a major disabling complaint in patients with immune-mediated 
neuropathies. The 9-item fatigue severity scale (FSS) has been used to assess 
fatigue in these conditions, despite having limitations due to its classic ordinal 
construct. The aim was to improve fatigue assessment in patients with immune-
mediated neuropathies through evaluation of the FSS using a modern clinimetric 
approach (Rasch unidimensional measurement models (RUMM2020)). Included 
were 192 stable patients with Guillain-Barré syndrome (GBS) , chronic infl ammatory 
demyelinating polyradiculoneuropathy (CIDP) or polyneuropathy associated with 
monoclonal gammopathy of undetermined signifi cance (MGUSP).
The obtained FSS data were exposed to RUMM2020 model to investigate whether 
this scale would meet its expectations. Also, reliability and validity studies were 
performed. The original FSS did not meet the Rasch model expectations, primarily 
based on two misfi tting items, one of these also showing bias towards the factor 
‘walking independent’. After removing these two items and collapsing the original 
7-point Likert options to 4-point response categories for the remaining items, we 
succeeded in constructing a 7-item Rasch-built scale that fulfi lled all requirements 
of unidimensionality, linearity, and rating scale model. Good reliability and validity 
were also obtained for the modifi ed FSS. In conclusion, a 7-item linearly weighted 
Rasch-built modifi ed FSS is presented for more proper assessment of fatigue in 
future studies in patients with immune-mediated neuropathies. 
Introduction
Fatigue is considered a major disabling symptom in patients with immune-mediated 
neuropathies, such as Guillain-Barré syndrome (GBS), chronic infl ammatory 
demyelinating polyradiculoneuropathy (CIDP), and polyneuropathy associated 
with monoclonal gammopathy of undetermined signifi cance (MGUSP).1 Despite an 
apparent good physical recovery, fatigue may lead to substantial decrement in quality 
of life expectations. The 9-item fatigue severity scale (FSS) has been used to capture 
the consequences of fatigue in patients with immune-mediated polyneuropathies 
and in many other chronic medical conditions. The FSS has demonstrated its 
simplicity, applicability, and various reliability and validity forms.2, 3
Parts of its construct validity were also based on factor analysis and its sumscore 
has been recommended for scale score analyses. However, the use of a scale like the 
FSS has been criticised because it is based on the classical test theory (CTT), which 
recruits items without investigating their relevance for patients at examination.4 
Patients are requested to complete all the items in CTT, even though some may be 
inappropriate for their level of ability. Moreover, the suggested sumscores in CTT 
assume that given differences in these scores have equal meaning. Some caution 
is warranted when changes in sumscores are considered, because the whole score 
may not equal the sum of the parts.5 Also, analysing data using primarily factor 
analysis is prone to misleading results, since observations are non-linear which 
may generate illusory factors.6 
More than 30 multi-item fatigue scales with good clinimetric properties have 
been developed and used for various chronic illnesses in the last decades.7 
However, a linearly weighted fatigue scale is preferred using modern scientifi c 
methods in patients with immune-mediated neuropathies. The Rasch technology 
is increasingly being recognised as a modern test method that could facilitate 
this.8-10 This technology attempts to transform ordinal scores into linear measures 
and is based on a logical assumption: individuals with high ability to perform a 
task should have an increased probability, relative to individuals with low levels, of 
getting a better score on any item.11
The aim of this study is to improve fatigue assessment in patients with immune-
mediated neuropathies. Therefore, we examined whether the original FSS scale 
fulfi ls model expectations using a Rasch measurement model. Deviation from 
model expectation will be examined to determine whether the FSS construct can be 
improved. Finally, reliability and validity aspects will be investigated.
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Patients and methods
Patients
Data obtained from 192 patients (163 with GBS, 21 with CIDP, and 8 with MGUSP) 
were re-examined for the purposes of this study. Patients were recruited from the 
Erasmus Medical Centre Rotterdam databank and the Dutch GBS study group and 
have already contributed to the clinimetric studies of the Infl ammatory Neuropathy 
Cause and Treatment (INCAT) group and a published randomised trial evaluating 
fatigue in GBS.3, 12 The following inclusion criteria were applied: a stable clinical 
condition was mandatory and was defi ned as an unchanged physical or functional 
condition in the last 6 months before the start of the studies as declared by the 
patients to the best of their knowledge. Where possible, fi ndings at physical 
examination at entry were compared with available earlier physical examination 
data to ascertain stability. Patients were excluded from participation if there was 
any concomitant disease or use of medication that might cause chronic fatigue. 
All selected patients declared to have experienced only mild and transient fatigue 
prior to their illness and still had residual symptoms or signs resulting from their 
illness (f-score ≥ 1).13 The patients with GBS and CIDP met the international criteria 
for their illness.14, 15 The diagnosis MGUSP was established after excluding other 
underlying causes for the gammopathy and polyneuropathy.16 
Assessment scales
• The fatigue severity scale (FSS), a brief and simple self-assessed questionnaire, 
has demonstrated its scientifi c soundness in immune-mediated neuropathies.1, 2
The FSS is a 9-item questionnaire with response categories ranging from 1 
(‘strongly disagree’), 2 (‘mainly disagree’), 3 (‘partially disagree’), 4 (‘do not 
agree/disagree’), 5 (‘partially agree’), 6 (‘mainly agree’), to 7 (‘strongly agree’) 
for each inquiry. The sumscore of the nine inquiries ranges from 9 (‘no signs of 
fatigue’) to 63 (‘most disabling fatigue’). 
• The short-form fatigue scale (SFFS), with acceptable validity and reliability, was 
administered in order to evaluate the construct convergent validity of the 
analysed FSS. The score of this scale ranges from 4 (‘no signs of fatigue’) to a 
maximum of 28 points (‘most severe fatigue’).1, 17
• The f-score (GBS disability score) is a 7-point disability scale ranging from 0(‘no 
symptoms’) to 6 (‘death’).18
Test procedure
FSS data were obtained with informed written consent and after approval of the 
medical ethical committee of the Erasmus Medical Centre. Participants were 
lucid and received instructions on how to complete the fatigue forms. These 
questionnaires were answered in random order. Patients were examined at our 
outpatient clinic. Scores were double-checked before departure of the patients. 
The FSS was mailed 2-4 weeks later to all patients (second sample) for a second 
assessment (test-retest). 
General Statistics and Rasch measurement aspects
Descriptive statistics
Personal aspects like age, gender, type of infl ammatory neuropathy, duration 
of illness, and GBS disability level (f-score) were collected. For Rasch analyses 
purposes, these personal factors were arbitrarily categorised as follows: age 
category (1: < 40 years, 2: 40-59 years, 3: ≥ 60 years), gender (0: female, 1: male), 
illness type (1: GBS, 2: CIDP, 3: MGUSP), polyneuropathy form (1: acute = GBS; 2: 
chronic = CIDP and MGUSP patients), duration category (1: < 2 years; 2: 2-5 years, 
3: ≥ 5 years), and walking independent category (0: unable = f-score > 2; 1: able = 
f-score ≤ 2). The rationale for these categories was to investigate their possible 
infl uence on experiencing fatigue.19 
Sample size consideration
For Rasch analyses purposes, a convenient sample size of 150 patients has been 
suggested to estimate item diffi culty, with a confi dence interval of 99% and item 
calibrations within +0.5 logits.20 In the current study, a sample of 192 patients was 
available, thus expecting an acceptable degree of precision of the Rasch analysis. 
Rasch measurement model
The Rasch model is based on the probabilistic Guttman procedure.21 For the 
purposes of the current study, the obtained FSS data and the selected ‘personal 
factors’ were subjected to Rasch analysis using the RUMM2020 software.11, 22, 23 The 
following applications of RUMM2020 were used to examine whether the data fi t 
the model expectations and items or patients not fulfi lling these requirements were 
removed or subjected to readjustments to fi t the model:
• Fit statistics: Three overall fi t statistics are considered. Two are item-person 
interaction statistics transformed to approximate a z-score. Therefore if the items 
and persons fi t the model, a mean around zero and a standard deviation of 1 
would be expected. A third fi t statistic score is an item-trait interaction statistic 
reported as a chi-square, refl ecting the property of invariance across the trait. A 
non-signifi cant chi-square indicates that the hierarchical ordering of the items 
does not vary across the trait, thus fulfi lling the required property of invariance. 
• Internal reliability studies: Internal consistency reliability of the scale was determined 
with the person separation index (PSI) or Cronbach’s alpha (the latter is only 
possible in case of no missing values) using the logit scores for each person. A 
value of ≥ 0.7 was considered consistent with the scale being able to differentiate 
between at least two groups of patients and is seen as the minimum requirement 
for measurement.24
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• Fit residuals: Individual person- and item-fi t statistics were examined, both as 
residuals (deviations of items and persons from expected model scores: residuals 
between ±2.5 are considered adequate fi t) and using a chi-squared statistic 
(signifi cance indicating misfi t). 
• Threshold examination: The term threshold refers to the point between two adjacent 
response categories where either response is equally probable. That is the point 
where, for example in case of the FSS, a threshold would be the point between 
two adjacent response categories for each item (e.g., between 1: strongly disagree 
and 2: mainly disagree; see fi gure 1A). One of the most common sources of item 
misfi t concerns respondents’ inconsistent use of these response options. This 
results in what is known as ‘disordered thresholds’: the failure of respondents 
to use the response categories in a manner consistent with the level of the trait 
being measured. If needed, response options were collapsed in order to improve 
overall fi t to the model.
• Local dependency: Residual correlations between items within the same scale are 
a source of misfi t. This local dependency occurs when a respondent’s answer 
to one item automatically has a bearing upon the answer to another item. Local 
dependency was examined, since it affects the estimation of test information 
and item discrimination parameters, thereby infl ating the fi nal scale score in a 
particular direction.25
• Item bias: A scale should always work in the same way irrespective of which 
personal factor (e.g., gender) is being examined.26 For example, if men and 
women with equal levels of disability for their infl ammatory neuropathy respond 
systematically differently to a fatigue item, then this item would be considered 
to display differential item functioning (DIF), and would violate the requirement 
for unidimensionality. The obtained data were examined for DIF using statistical 
(analyses-of-variance) and graphical methods. 
• Model forms: The unrestricted partial credit Rasch model was used in the current 
study. Finally, the likelihood ratio test was applied to examine whether the fi nal 
obtained model would fulfi l the rating scale model requirements.
• Test for unidimensionality: Unidimensionality is tested by allowing the factor 
loadings on the fi rst residual to determine subsets of items and then testing 
(paired t-test) to see if the person estimate (logit of person ‘ability’ or, in this 
case ‘degree of fatigue’) derived from these subsets signifi cantly differs from that 
obtained from all items. The absence of any meaningful pattern in the residuals 
will support the assumption of local independence and unidimensionality of the 
scale.27
External construct validity and reliability studies
The external construct validity of the fi nal modifi ed FSS was assessed through 
convergent validity with the SFFS (intraclass correlation coeffi cient reported).17 
Also, as part of the fi nal analyses, graphical test-retest validity and reliability studies 
were performed comparing items’ hierarchy and patients’ locations between the 
two samples of patients.28 The obtained correlations were quantifi ed by estimation 
of the intraclass correlation coeffi cient using a one-way random effects analysis-of-
variance model for groups’ comparison.
Software
RUMM2020 Rasch software was used and further statistical and graphical analyses 
were undertaken using Stata 10.0 for Windows XP (Stata Statistical Software: 
Release 10.0, TX: Stata Corporation 2007). A value of p = 0.0055 (0.05/9) was used 
throughout the analyses, based on Bonferroni multiple testing corrections.29 
Results
General description of patients
A total of 192 patients with immune-mediated neuropathies have been included in 
this study. The basic characteristics of all patients are presented in table 1. A total 
of 183 patients returned the second FSS assessment (95.3%). Forty-fi ve patients 
(23.4%) were not able to walk independently (f-score > 2).
Table 1. Basic characteristics of patients with infl ammatory polyneuropathies
fi rst sample
second sample
(for test-retest)
n 192 183
Age, years; mean (SD), range 52.9 (14.3), 17-84 52.3 (14.1), 17-84
Gender; n (%)
females
males
94 (49)
98 (51)
91 (49.7)
92 (50.3)
GBS; n (%)
CIDP; n (%)
MGUSP; n (%)
163 (84.9)
21 (10.9)
8 (4.2)
158 (86.3)
20 (10.9)
5 (2.7)
FSS mean (SD), range 52.1 (10.3), 9-63 50.2 (11.2), 9-63
F-score (GBS disability score); n (%)
1
2
3
4
50 (26.0)
97 (50.5)
34 (17.7)
11 (5.7)
46 (25.1)
95 (51.9)
31 (16.9)
11 (6.0)
Duration of symptoms, years, 
Mean (SD), range 5.5 (5.9), 0-41 5.2 (5.0), 0-28
Legend to table 1. GBS = Guillain-Barré syndrome; CIDP = chronic infl ammatory demyelinating 
polyradiculoneuropathy; MGUSP = monoclonal gammopathy of undetermined signifi cant related 
polyneuropathy; FSS = fatigue severity scale.
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Initial Rasch studies on the FSS
Fit statistic description
The original 9-item FSS scale did not meet the Rasch model expectations. There was 
a substantial items misfi t with a mean fi t residual of -0.253 and a SD of 2.058. The 
patients demonstrated reasonable fi t statistics (mean fi t residual -0.350, SD 1.025). 
There was a signifi cant item-trait chi-square probability (p=0.000006) indicating 
a highly signifi cant deviation from the model. The Cronbach’s alpha was 0.92 and 
the PSI 0.93. Individual item fi t statistics were also investigated and presented in 
table 2. As can be seen, items 1 and 8 demonstrated a misfi t due to fi t residuals 
exceeding ±2.5 (item 1: +4.418 and item 8: -3.185). Item 1 had also a signifi cant low 
chi-square probability. The high negative fi t residual of item 8 demonstrates its 
redundancy to the data set. Item 8 is not adding any information to the data. 
Table 2. Rasch fi t statistics for the initial 9 items FSS data
FSS item Location SE FitResid DF ChiSq DF Prob
1 0.134 0.07 4.418 148.11 26.828 2 0.000001
2 -0.635 0.096 0.363 148.11 5.002 2 0.081988
3 -0.067 0.073 0.382 148.11 0.784 2 0.675829
4 -0.043 0.078 -1.14 148.11 4.032 2 0.133195
5 0.892 0.068 -0.092 148.11 2.736 2 0.254641
6 -0.605 0.085 -0.894 148.11 4.229 2 0.120719
7 -0.128 0.082 -1.329 148.11 3.424 2 0.1805
8 0.085 0.069 -3.185 148.11 8.66 2 0.013165
9 0.367 0.068 -0.796 148.11 1.376 2 0.50254
Legends to table 2. Items 1 and 8 demonstrated a misfi t due to fi t residuals exceeding ±2.5. Item 
1 had also a signifi cant low chi-square probability. The high positive labelled fi t residual and 
signifi cant probability of item 1 suggests that the response to this item differed from the responses 
to the remaining scale items. The high negative fi t residual of item 8 demonstrates its redundancy 
to the data set; in other words, item 8 is not adding any information to the data. 
FSS = fatigue severity scale; SE = standard error; FitResid = Fit residuals; DF = degrees of freedom; 
ChiSq = Chi square; prob = probability.
Threshold examination (category probability curves analyses)
All items demonstrated in the mid response category area (response options 
ranging from 2: ‘mainly disagree’ up to 6: ‘mainly agree’) a general inability of 
the patients to differentiate between these options, with disordered thresholds for 
almost all items. Item 8 (‘Fatigue is among my three most disabling symptoms’) 
demonstrated the strongest disordered threshold pattern (fi gure 1B).
Figure 1. Category probability curves 
A.   Response options 1=strongly disagree to 7=strongly agree 
B.
Item 1 Item 2
Item 4
Item 6
Item 3
Item 5
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Independent t-test
Based on the fi rst principal components analysis, two item subsets were formed 
by grouping the three most positive loading items (item 1: loading 0.685; item 2: 
0.661; item 6: 0.190) vs. the three most negative loading items (item 5: loading 
-0.557; item 9: -0.433; item 7: -0.390). The two subsets were compared through 
independent t-test and demonstrated a proportion of 0.0819, suggesting that the 
data did not show unidimensionality. 
 
Data handling to improve the FSS fi t to the Rasch model 
Rescoring items to improve thresholds and removing items
Based on the fi ndings illustrated in fi gure 1, we decided to systematically (from item 
1 to 9) rescore the items in order to restore reversed thresholds. Items 1, 2, 4, 5, 7, 
8, and 9 were re-scored as follows: original scale scores 1 to 7, initial Rasch scores 
0 - 6; rescoring: 0 = 0, 1 - 3 = 1; 4 – 5 = 2, and 6 = 3. Items 3 and 6 were rescored as 
follows after studying the location of disordered thresholds: 0 = 0, 1 - 2 = 1; 3 – 5 = 2, 
and 6 = 3. After performing these, items 1 and 8 still demonstrated misfi t statistics 
and were subsequently removed from the analyses.
Threshold mapping, fi t statistics and testing for rating scale model expectations
With the help of threshold mapping, we were able to restore the disordered 
thresholds and transformed the response categories in the remaining seven items 
to equivalent 4-point response categories (fi gure 3 and appendix). For the items 
and patients, mean fi t residuals of -0.289 (SD: 1.113) and -0.275 (SD: 1.091) were 
obtained, respectively. The Cronbach’s alpha and PSI remained good (0.89 for 
both) with an overall chi-square probability of 0.22. All individual items had good 
fi t statistics (table 3). Item 2 (‘exercise brings on my fatigue’) turned out to be the 
easiest inquiry to answer while item 5 (‘fatigue causes frequent problems for me’) 
was considered the most diffi cult (table 3). A p-value of 0.10 was obtained for the 
modifi ed 7-item FSS version by means of a likelihood ratio test, implicating that the 
items meet the Rasch rating scale model expectations.
Item 7 Item 8
Item 9
B. Continued
Legend to fi gure 1. 
(A) Graphical respresentation of ideal ability of patients to discriminate between response options 
of fi ctitious items ranging from 1 (‘strongly disagree’) to 7 (‘strongly agree’). FSS question 
number 2 is used as an example. 
(B) Patients with immune-mediated neuropathies demonstrated unanimously inability to 
differentiate between the original response options of the 9-item FSS ranging from 2 (‘mainly 
disagree’) to 6 (‘mainly agree’), leading to many inverted thresholds.
Local dependency (item residual correlations) and item bias analyses 
No signifi cant correlations were seen between the original nine items of the FSS. 
All items were subjected to DIF investigation for the selected personal factors. Only 
for item 8, a uniform DIF was demonstrated (p=0.000562; see fi gure 2). Item 8 
was considered more diffi cult to answer for the 45 patients who could not walk 
independently. The remaining items did not show any item bias.
Figure 2. Item characteristic curve for item 8 related to personal factor ‘ability to walk 
independent’
Legend to fi gure 2. Patients unable to walk independently demonstrated uniform DIF on item 8: this 
item was experienced as more diffi cult to answer compared with those able to walk independently. 
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Figure 3. Rescoring response categories 
Legend to fi gure 3. After deleting misfi tting items and rescoring the response options (from seven 
categories to four categories), we were able to construct a modifi ed 7-item FSS scale fulfi lling all 
Rasch model expectations.
Table 3. Rasch fi t statistics for the fi nal 7-item FSS data
FSS item Location SE FitResid DF ChiSq DF Prob
2 -1.174 0.165 1.95 140.43 0.109 2 0.947176
6 -0.995 0.162 -1.271 140.43 3.082 2 0.2142
3 -0.208 0.153 -0.874 140.43 1.137 2 0.566385
7 0.11 0.15 -1.139 140.43 2.83 2 0.242876
4 0.158 0.15 -0.197 140.43 3.311 2 0.19102
9 0.502 0.148 0.721 140.43 4.186 2 0.12334
5 1.607 0.145 -1.16 140.43 2.991 2 0.224179
Legends to table 3. Items 1 and 8 were removed due to misfi tting the model and the remaining 7 
items met the model requirements. Loading on location indicates item diffi culty in patients with 
immune-mediated neuropathies (most negative = easiest, most positive = most diffi cult item to 
answer) FSS = fatigue severity scale; SE = standard error; FitResid = fi t residuals; DF = degrees of 
freedom; ChiSq= Chi square; prob = probability.
Item bias and test for unidimensionality
The individual items were all free from DIF. Based on the fi rst principal components 
analysis, two item subsets were formed again: positive loading residual items (2, 3, 
and 6) vs. negative items (5, 7, and 9). The independent t-test between these two 
subsets of items demonstrated a proportion of 0.02, which shows unidimensional-
ity. Finally, the raw 7-item FSS sumscore, ranging from 0 (‘no signs of fatigue’) to 
21 (‘most disabling fatigue’) can be transformed to logits for the patients, ranging 
from -6 to +6. Only 1.1% and 9.7% of the patients sample size had a fl oor or ceiling 
effect, respectively. 
External construct validity and reliability studies
The modifi ed FSS demonstrated an acceptable correlation with the SFFS (intraclass 
correlation coeffi cient: 0.71, p<0.0001). Test retest reliability studies were performed 
to investigate whether the items’ hierarchy and patients’ locations were consistent 
over time. As demonstrated in fi gure 4, all seven items were located within the 95% 
confi dence interval lines, indicating ideal invariance. Most patients were also within 
the 95% confi dence interval limits.
Figure 4. Test retest reliability studies between item hierarchy (A) and person location 
(B) for the Rasch-built modifi ed FSS in immune-mediated neuropathies
Legend to fi gure 4. 
(A) Test-retest reliability studies between items’ hierarchy assessed at the fi rst and second FSS 
assessment and the 95% confi dence interval (solid lines) for the ideal invariance. As can be seen, all 
items were ordered in a hierarchal way, thus demonstrating ideal invariance (intraclass correlation 
coeffi cient for the item estimates of 0.95). 
-2 -1 0 1 2
-2
-1
0
1
2
Item hierarchy (logits)
I
t
e
m
 
h
i
e
r
a
r
c
h
y
 
(
l
o
g
i
t
s
)
2
n
d
 
a
s
s
e
s
s
m
e
n
t
1st assessment
ICC 0.95
A
122 123
THE RASCH-BUILT MODIFIED FATIGUE SEVERITY SCALECHAPTER 3.2
Chapter
3.2
Legend to fi gure 4. 
(B) Test-retest reliability studies between persons’ location assessed at the fi rst and second FSS 
assessment and the 95% confi dence interval (solid lines) for the ideal invariance. Acceptable 
reproducibility was obtained between the patients’ locations (intraclass correlation coeffi cient for 
the item estimates of 0.75).
Discussion 
To our knowledge, the current study is the fi rst study examining the modern 
clinimetric aspects of the FSS in patients with immune-mediate neuropathies. The 
original 9-item FSS failed in meeting the requirements addressed by the Rasch 
model.9 However, after systematic evaluation and readjustment of the data, we 
were able to present a linearly weighted 7-item (4 response categories for each item) 
Rasch-built modifi ed FSS, that fulfi lled all clinimetric requirements, including validity 
and reliability (see also appendix).10, 11, 28 The patients’ locations were acceptable, 
although most patients were within the 95% confi dence interval limits and had high 
scores which indicates having a more impaired status due to severe fatigue (see 
fi gure 4B). This is in conformity with earlier fi ndings.1 An elegant and equivalent 
study on FSS has been recently presented, that demonstrated quite similar fi ndings 
in patients with multiple sclerosis (MS).30 In this paper, more items were disordered 
and more DIF was seen in patients at examination. The fi nal modifi ed FSS scale 
in patients with MS turned out to be somewhat different. It is conceivable that the 
obtained differences in experiencing fatigue between patients with MS versus those 
in our study could be related to differences in possible confounding factors such 
as location of illnesses (central versus peripheral nervous system), differences in 
disability, and possible differences in pathophysiological mechanism of fatigue in 
these disorders.
In the current study, the most striking pattern was the patients’ unanimous 
inability to differentiate between the original response categories ranging from 2 
to 6, leading to many inverted thresholds (fi gures 1 and 3). Although the authors 
of the original FSS attempted to improve differentiation between patients, the 
amount of response categories led to confusion in patients with immune-mediated 
neuropathies that could only be visualised using a modern technique like the 
Rasch. This was also in conformity with earlier reports demonstrating diffi culties of 
patients to discriminate among more than three response categories.31
The obtained 7-item Rasch-built modifi ed FSS has the advantages of a modern test 
theory (e.g., linearity, unidimensionality) and its use is believed to improve fatigue 
assessment in immune-mediated neuropathies and will certainly help clinicians 
to focus on ameliorating the enormous disabling impact of fatigue. Therefore, we 
suggest the use of this modifi ed 7-item FSS in future studies targeting fatigue in 
patients with GBS, CIDP, and MGUSP.
B
-8 -4 0 4 8
-8
-4
0
4
8
Patients location (logits)
P
a
t
i
e
n
t
s
 
l
o
c
a
t
i
o
n
 
(
l
o
g
i
t
s
)
1st assessment
2
n
d
 
a
s
s
e
s
s
m
e
n
t
ICC 0.65
124 125
THE RASCH-BUILT MODIFIED FATIGUE SEVERITY SCALECHAPTER 3.2
Chapter
3.2
Appendix
Transforming original 9-item FSS to Rasch-built modifi ed 7-item FSS
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Original fatigue severity scale
1=strongly disagree; 2=mainly disagree; 3=partially disagree; 4=do not agree/disagree; 5=partially agree; 
6=mainly agree 7=strongly agree (circle one answer per question)
1
2
3
4
5
6
7
8
9
My motivation is lower when I am fatigued
Exercise brings on my fatigue
I am easily fatigued
Fatigue interferes with my physical functioning
Fatigue causes frequent problems for me
My fatigue prevents sustained physical functioning
Fatigue interferes with carrying out certain duties and 
responsibilities
Fatigue is among my three most disabling symptoms
Fatigue interferes with my work, family, or social life
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
Ð
Rasch-built modifi ed fatigue severity scale
The higher the score you choose, the more you agree with the question 
(the lower the score the less you agree)
1 Exercise brings on my fatigue 0 1 2 3
2 I am easily fatigued 0 1 2 3
3 Fatigue interferes with my physical functioning 0 1 2 3
4 Fatigue causes frequent problems for me 0 1 2 3
5 My fatigue prevents sustained physical functioning 0 1 2 3
6 Fatigue interferes with carrying out certain duties and responsibilities 0 1 2 3
7 Fatigue interferes with my work, family, or social life 0 1 2 3
Score range of the Rasch-built modifi ed fatigue severity scale: 0 (‘no signs of fatigue’) to 21 
(‘most disabling fatigue’). 
disagree agree
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Abstract
Objective: To develop a patient-based, linearly weighted scale that captures activity 
and social participation limitations in patients with Guillain-Barré syndrome 
(GBS), chronic infl ammatory demyelinating polyradiculoneuropathy (CIDP) and 
monoclonal gammopathy of undetermined signifi cance related polyneuropathy 
(MGUSP). 
Methods: A preliminary Rasch-built overall disability scale (R-ODS) containing 146 
activity and participation items was constructed, based on the WHO international 
classifi cation of Functioning, Disability and Health, literature search, and patient 
interviews. The preliminary R-ODS was assessed twice (interval: 2-4 weeks; test-
retest reliability studies) in 294 patients who experienced GBS in the past (n=174) 
or currently have stable CIDP (n=80) or MGUSP (n=40). Data were analysed 
using the Rasch unidimensional measurement models (RUMM2020).
Results: The preliminary R-ODS did not meet the Rasch model expectations. Based 
on disordered thresholds, misfi t statistics, item bias, and local dependency, items 
were systematically removed to improve the model fi t, regularly controlling the 
class intervals and model statistics. Finally, we succeeded in constructing a 24-
item scale that fulfi lled all Rasch requirements. ‘Reading a newspaper/book’ and 
‘eating’ were the two easiest items, ‘standing for hours’ and ‘running’ were the 
most diffi cult ones. Good validity and reliability were obtained.
Conclusion: The R-ODS is a linearly weighted scale that specifi cally captures activity 
and social participation limitations in patients with GBS, CIDP and MGUSP. 
Compared to the overall disability sumscore (ODSS), the R-ODS represents a 
wider range of item diffi culties thereby better targeting patients with different 
ability levels. If responsive, the R-ODS will be valuable for future clinical trials and 
follow-up studies in these conditions.
Introduction
Disability has been proposed as the preferential level for measuring therapeutic 
response in immune-mediated neuropathies.1 However, most disability scales used 
in these disorders are based on the classical test theory (CTT).2-7 A summary of 
the disadvantages of CTT has been provided.2 Generally, patients are requested to 
complete all items of CTT-based scales, even though some may be irrelevant for 
their level of ability. Furthermore, a sum of item scores is often calculated assuming 
equal relevance and hence weighting of each item which is highly unlikely.2, 8 Given 
these limitations, a modern approach like the Rasch technology is needed to develop 
a scale measuring disability (i.e., activity and social participation limitations) in 
patients with immune-mediated neuropathies.9, 10 Rasch models the probability 
that a person will be able to complete an item, only dependent on the item diffi culty 
and the person’s level of ability.9, 11, 12 It enables scales measuring the same health 
construct to be equated on the same linear ruler optimising comparisons of studies, 
meta-analyses, and systematic reviews.10
The AMC linear disability score (ALDS) item bank and ACTIVLIM are modern 
disability scales.13-15 However, their calibration may not be representative to 
patients with immune-mediated neuropathies since these scales are not disease-
specifi c. Therefore, we developed a linearly weighted scale at the activity and 
participation level, the Rasch-built overall disability scale (R-ODS), specifi cally for 
patients with Guillain-Barré syndrome (GBS), chronic infl ammatory demyelinating 
polyneuropathy (CIDP) and monoclonal gammopathy of undetermined signifi cance 
related polyneuropathy (MGUSP) and evaluated its validity and reliability aspects.
Methods
Participants
A total of 852 members of the Dutch society of neuromuscular disorders (Vereniging 
Spierziekten Nederland [VSN]), registered as having a polyneuropathy were initially 
requested to participate. For this study, we used data from patients who have been 
diagnosed with GBS, CIDP or MGUSP (254 of the 511 members who returned their 
questionnaires). Additionally, 40 patients (11 GBS, 22 CIDP and 7 MGUSP) were 
recruited at the university outpatient clinics of Rotterdam and Maastricht, in the 
Netherlands. All participants were recruited between January 2007 and July 2009. 
Participants aged 18 years and older, with a stable clinical condition, defi ned as an 
unchanged physical and functional condition over 2 months prior to the study as 
declared by the participant, were included.
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Standard protocol approvals, registrations, and patient consents
The local medical ethics committee approved the protocol. Written informed 
consent was obtained from all participants.
Questionnaire development
Step I: International development procedures were applied to construct the 
preliminary R-ODS.12, 16, 17 Since we aimed to develop an outcome measure at the 
activity and participation level, we critically reviewed all potential items listed under 
these headings using the International Classifi cation of Functioning, Disability 
and Health (ICF).18 The chapters learning and applying knowledge, general tasks 
and demands, and communication were excluded. We selected defi ned items 
from this ICF list with probable relevance to polyneuropathy patients based on 
known clinical characteristics. Efforts were made to describe these items in a 
concise, simple and unambiguous way.
Step II: A systematic Medline and Embase search was performed for literature 
published over the last four decades, reviewing all scales at the activity and 
participation levels in patients with any form of (poly)neuropathy. Reports 
published in English were identifi ed with reference tracing using the keywords: 
GBS, CIDP, acquired/idiopathic (poly)(radiculo)neuropathy, polyneuritis, 
gammopathy, dysimmune, paraprotein(a)emia, MGUSP, disability (scale), 
activity limitation, and handicap. Various handbooks of neurological rating 
scales were also evaluated. Additionally, items were selected from an earlier 
semi-structured interview focusing on daily activities addressed by patients with 
infl ammatory polyneuropathies.5 Eventually, we succeeded in constructing the 
preliminary R-ODS containing 146 items with 3 response options: 0 (‘impossible 
to perform’), 1 (‘performed with diffi culty’), and 2 (‘easily performed’). If an item 
was not applicable, the patient was requested to answer this item with the option 
3 (‘not applicable’).
Step III: The selected items were judged by four neuromuscular experts. Based on 
the clinical characteristics of GBS, CIDP and MGUSP, items with insuffi cient face 
and content validity were removed.16
Procedures
Patients received the preliminary R-ODS plus the overall disability sumscore 
(ODSS) with instructions by mail.6 They were requested to answer all questions 
by themselves and to answer ‘impossible to perform’ when unable to complete an 
item or ‘able to perform, but with diffi culty’ when special devices or other forms 
of assistance were needed. After a period of 2-4 weeks, all participants were again 
requested to answer all questions of the preliminary R-ODS (test-retest reliability 
studies).
Rasch analyses
In the model construction, items scored as 3 (‘not applicable’) were interpreted as 
missing data. Items with > 10% missing values and patients with > 10% unanswered 
items were omitted as a quality control procedure. Thereafter, the remaining 
responses of the preliminary R-ODS were analysed using Rasch unidimensional 
measurement models (RUMM2020), which is based on a mathematical model 
proposed by Rasch, a Danish mathematician.19 The fi nally constructed scale should 
be unidimensional, free from item bias, and without disordered thresholds or local 
dependency.10, 20 We checked for possible item bias using the following personal 
factors, categorised arbitrarily as follows: age (<60 years vs. ≥60 years), gender (men 
vs. women), diagnosis (GBS vs. CIDP vs. MGUSP), diagnosis category (acute [GBS] 
vs. chronic [CIDP and MGUSP]), and duration of complaints (<2 years vs. 2-5 years 
vs. ≥5 years). Throughout the analyses, we continuously monitored the distribution 
of persons within the class intervals, the fi t statistics and the independent tests 
for unidimensionality of the scale. Items and persons not fulfi lling Rasch model 
criteria were evaluated and removed one by one if needed.
A sample size of approximately 250 is needed to obtain a 99% confi dence with 
a stable item calibration within ± 0.5 logits, hence providing a stable model.21 We 
expected an acceptable degree of precision of the Rasch analyses, since a sample 
of 294 patients was available.
Validity
Four neuromuscular experts stated that the items of the fi nal R-ODS were ordered 
as expected. The external construct validity was assessed by correlation with the 
ODSS (intraclass correlation coeffi cient after applying quantile regression analysis). 
To compare the diffi culty range of the items of the ODSS and the fi nal R-ODS in 
relation to the ability range of the patients in this population we used the anchor-
based approach in RUMM2020 (targeting validity study). Two identical items in 
the ODSS and the R-ODS (‘turning a key in a lock’ and ‘dressing upper body’) were 
used as anchors to place both measures and all patients on the same linear ruler.
Reliability
Internal reliability was examined by determining the person separation index (PSI). 
In general, a PSI above 0.7 is considered as acceptable, indicating the ability to 
identify at least two groups of patients.22 Moreover, test-retest reliability studies 
were performed to investigate whether hierarchy of item diffi culty and patient 
ability location were consistent over time.23 Reliability was quantifi ed by calculation 
of the intraclass correlation coeffi cient using a one-way random effects analysis of 
variance (ANOVA) model for group comparison.
134 135
THE RASCH-BUILT OVERALL DISABILITY SCALECHAPTER 3.3
Chapter
3.3
Statistics and software
Rasch analyses were performed with the partial credit model as default, using 
RUMM2020 software. Further analyses were undertaken using Stata 10.0 for 
Windows XP. The p-value was adjusted throughout the analyses, based on 
Bonferroni multiple testing corrections.24
Results
General description of patients
A total of 511 of the 852 approached members of the Dutch society of neuromuscular 
disorders returned the fi rst questionnaires (response rate of 60%). For the current 
study, we only used data of patients with a clinically stable form of immune-mediated 
polyneuropathy (174 GBS, 80 CIDP and 40 MGUSP). Most patients (74%) reported 
walking diffi culties, 47% mentioned at least moderate symptoms in their upper 
limbs. A total of 255 patients completed the second preliminary R-ODS assessment 
(87%). The basic characteristics of all participants are presented in table 1.
Table 1. Basic characteristics of study population (fi rst sample, n=294)
Diagnosis; n (%)
 GBS 174 (59)
 CIDP  80 (27)
 MGUSP  40 (14)
Age in years; mean (SD), range  60.2 (13,5), 18-91 
Gender; n (%)
 Women 132 (45)
 Men 162 (55)
Duration of symptoms, years; mean (SD), range  8.2 (7.8), 0.5 - 40
ODSS arm grade; n (%)*
 ≤ 1 (normal or minor symptoms, not affecting any) 123 (53.3)
    2 (moderate symptoms, not preventing any)   87 (37.7)
    3 (severe symptoms, preventing at least one not all)  20 (8.7)
 ≥ 4 (severe symptoms, preventing all or no purposeful    
                 movements)
    1 (0.4)
ODSS leg grade; n (%)*
     0 (normal)   59 (25.5)
  1-2 (walking affected, with or without gait disturbance) 103 (44.6)
     3 (unilateral support)  40 (17.3)
     4 (bilateral support)   10 (4.3)
  ≥ 5 (wheelchair)   19 (8.2)
* Corresponding ODSS grades were only collected in 231 of the 294 patients
Legend to table 1. GBS = Guillain-Barré syndrome (GBS), chronic infl ammatory demyelinating 
polyradiculoneuropathy (CIDP) and monoclonal gammopathy of undetermined signifi cance 
related polyneuropathy (MGUSP). 
Data quality control (Step 0)
Based on experts’ opinion, n=12 items with insuffi cient face and content validity 
were removed (questionnaire development - step III). Also, another n=36 items 
with >10% missing values and n=14 patients with >10% unanswered items were 
omitted as a quality control procedure.
Initial Rasch analysis on the preliminary R-ODS
The fi rst Rasch analysis was performed on the remaining 98 items. The mean items’ 
fi t residual showed reasonable model fi t (mean -0.188, SD 1.119). However, the mean 
persons fi t residual was -0.363 with a standard deviation exceeding the expected 
value of 1 (SD 1.428). The signifi cant Chi-square probability implied no invariance 
of items. Initially, a proportion of 0.20 (95% confi dence interval: 0.18-0.23) of the 
t-tests performed fell outside the ±1.96 range, indicating multidimensionality.
Stepwise approach to fi t data to the Rasch model
Step 1. Disordered thresholds were seen in two items (‘driving a car’ and ‘riding 
a bike’). Apparently, the response categories were confl icting for the patients. 
These two items were removed.
Step 2. Individual item and person fi t statistics were inspected. Individual item fi t 
statistics of 19 items demonstrated misfi t to the model (fi t residuals exceeding ± 
2.5 or a signifi cant chi-square probability or both). These 19 items were removed 
one by one, starting with the item with the highest deviation. In addition, two 
patients showed misfi t (fi t residuals exceeding ± 2.5) and were also removed.
Step 3. In six items (e.g., ‘standing up from squat position’, ‘shaving/epilating’, 
and ‘vacuum cleaning’) men and women with equal ability levels responded in a 
signifi cant different manner (demonstrating uniform differential item functioning 
(DIF) on gender). Another three items demonstrated item bias on personal 
factor diagnosis (category) (two items had uniform DIF, one item non-uniform 
DIF). Finally, one item demonstrated item bias (uniform DIF) on the duration of 
complaints. All these items were removed one by one.
Step 4. A systematic evaluation of the correlation matrix fi ndings (starting with the 
highest correlations ≥0.7, then ≥0.6, through to ≥0.28) was performed to identify 
local dependency (e.g., a person answering positively to the item ‘able to walk 1 
km’ will most likely also respond positively on the item ‘able to walk 100 m’). Item 
characteristic curves of each correlating item set were subsequently inspected to 
select the items that best fi t the expected model curve. The item showing the 
most over- or under-discrimination was then removed. Eventually, a total of 43 
items were stepwise removed.
Final R-ODS
After completing these procedures, we succeeded in constructing a 24-tem scale 
which met the Rasch model expectations, the fi nal R-ODS. Mean fi t residuals for 
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items were -0.238 (SD 0.853) and for persons 0.352 (SD 0.839). The chi-square 
probability was p=0.29, thereby supporting the presence of invariance of item 
diffi culty across the scale. Based on the fi rst principal components analysis, two 
subsets of items were formed, with the six most positively loaded vs. the six most 
negatively loaded items. The independent t-tests between these two subsets were 
signifi cant at the 5% level in 14 of the 261 patients (0.053%, confi dence interval 
0.027-0.080%) which indicates acceptable unidimensionality.
In the fi nal R-ODS scale, the item ‘reading a newspaper/book’ was the easiest 
to perform while ‘running’ turned out to be the most diffi cult task (fi gure 1). Item 
diffi culty ranges from -3.15 to 5.60 logits and patient ability level from -6.95 to 8.11 
logits. Table 2 provides a nomogram allowing the translation of raw sumscores of 
the fi nal R-ODS (range 0 to 48) to logits, placing patients’ estimates on the same 
log-odds units (logit) scale. Since logits are diffi cult to interpret instinctively, we 
have converted the person locations into a centile metric score with values ranging 
from 0 (most severe activity and social participation limitations) to 100 (no activity 
and social participation limitations).
Figure 1. Threshold map and overall item diffi culty locations for each item of the fi nal 
Rasch-built overall disability scale (R-ODS)
Legend to fi gure 1. Black sections (0) = ‘impossible to perform’, dark grey sections (1) = ‘with 
diffi culty performed’, and light grey sections (2) = ‘easily performed’. The length of the coloured 
sections at the left panel respresent the number of patients giving a certain response. A gradual 
shift is seen: the black section of the item ‘reading a newspaper/book’ is much shorter than the 
black section of the item ‘running’. Patients considered ‘reading a newspaper/book’ the easiest 
item and ‘running’ the most diffi cult item. The right panel presents the overall item diffi culty 
locations and     corresponding standard errors for each item.
Table 2. Nomogram
R-ODS summed 
raw score
Rasch person location
(logits)
centile metric
0 -6.95 0
1 -6.03 6
2 -5.36 11
3 -4.87 14
4 -4.48 16
5 -4.14 19
6 -3.84 21
7 -3.57 22
8 -3.32 24
9 -3.09 26
10 -2.87 27
11 -2.66 28
12 -2.46 30
13 -2.26 31
14 -2.07 32
15 -1.88 34
16 -1.70 35
17 -1.52 36
18 -1.33 37
19 -1.15 39
20 -0.97 40
21 -0.79 41
22 -0.61 42
23 -0.42 43
24 -0.24 45
25 -0.05 46
26 0.14 47
27 0.34 48
28 0.53 50
29 0.73 51
30 0.94 52
31 1.15 54
32 1.36 55
33 1.58 57
34 1.81 58
35 2.04 60
36 2.28 61
37 2.54 63
38 2.80 65
39 3.09 67
40 3.40 69
41 3.74 71
42 4.11 73
43 4.54 76
44 5.03 80
45 5.59 83
46 6.25 88
47 7.07 93
48 8.11 100
Legend to table 2. This nomogram allows the translation of raw sumscores of the fi nal R-ODS 
(range 0 to 48) to logits or to a centile metric score with values ranging from 0 (most severe activity 
and social participation restrictions) to 100 (no activity and social participation limitations). The 
corresponding logits in relation to the raw summed scores are provided by the RUMM software. 
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Validity 
The intraclass correlation coeffi cient between the fi nal R-ODS and the ODSS was 
0.85, indicating good external construct validity. Furthermore, the population of 
patients examined demonstrated a ceiling effect of 5.8% on the fi nal R-ODS vs. 
19.4% ceiling effect on the ordinal ODSS (Student t-test p<0.0001). As shown in 
fi gure 2 item diffi culties of the ODSS ranged from -1.869 to 1.336 logits (span of 
3.205 logits). By contrast, the fi nal R-ODS demonstrated a wider range of item 
diffi culties (span of 8.750 logits).
Legend to fi gure 2. The numbers 8 to -6 under ‘location (logits)’ represent corresponding logits on 
a linear ruler. The open dots under ‘persons’ respresent the number of patients having a person 
location (ability level) at this point on the ruler. Each open dot corresponds to the location of 1 
patient on the ruler. At the right side of the ruler, item locations (item diffi culty) of the overall 
disability sumscore (ODSS) and the fi nal Rasch-built overall disability scale (R-ODS) are presented 
enabling comparison through targeting (e.g., item diffi culty range in relation to the different levels 
of ability in the sample). 
 
Persons ODSS items R-ODS items
ooooooooooooooo
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oooooooooo 7
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oooo 5 stand for hours
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ooooooooo
ooooooooooooooooo 4 dance
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oo carry and put down a heavy object
ooooooooooooo
oooooooooooo 3
ooooooooooooo
o
ooooooooo
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ooooooooooo 2 walk outdoor < 1 km
oooooooooo
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oooooooo 10 meters walk travel by public transport
oooooo 1
ooooooooooooo
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oooooo walk 1 fl ight of stairs
ooooooo handle buttons/ zippers bend and pick up an object
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ooooo
ooooooo
oooooo wheelchair use do the dishes
oo -1 wash and brush hair take a shower
ooooo turn a key in a lock go to general practitioner/turn a key in a lock/move a chair
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oooo use knife/ fork (spoon)
ooo -2 dress upper body dress upper body / make a sandwich
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o sit on a toilet
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o
o -4
oo
o -5
o
-6
Location
(logits)
Figure 2. Person locations vs. item locations
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Reliability 
Internal reliability remained good indicated by a PSI of 0.97 for the fi nal R-ODS. 
Also, test-retest reliability was good: item hierarchy and patients’ locations were 
located within the 95% CI lines, refl ecting good invariance (fi gure 3A and 3B).
Figure 3. Test-retest reliability of the fi nal Rasch-built overall disability scale
Legend to fi gure 3. (A) Item diffi culty hierarchy of the fi nal R-ODS in the fi rst vs. the second as-
sessment. All items (dots) were located within the 95% confi dence interval (solid lines) refl ecting 
ideal reliability. (B) Patient’s location in the fi rst assessment vs. the second assessment. Almost 
all persons (dots) were located within the 95% confi dence interval (solid lines). ICC= intraclass 
correlation coeffi cient
Discussion
We developed the R-ODS, a linearly weighted outcome measure that specifi cally 
captures activity and social participation limitations in patients with GBS, CIDP and 
MGUSP. This questionnaire was constructed using patient’s perception of their 
ability to perform daily and social activities. All 24 items of the fi nal R-ODS met the 
Rasch model expectations. Although the clinical characteristics of clinically stable 
GBS, CIDP and MGUSP patients are slightly different, their response pattern was 
quite similar in this study. Only three items of the preliminary scale were removed 
due to item bias for the personal factor diagnosis.
Since calibration of the R-ODS is based on the characteristics of our study 
population, we also questioned whether this population represents patients included 
in clinical trials. The baseline characteristics of patients in trials often report a 
sumscore of the ordinal ODSS of around 4. Moreover, inclusion criteria sometimes 
include minimum sumscores of the ODSS (e.g., at least two in the randomised 
methotrexate CIDP (RMC) trial, evaluating the effi cacy of methotrexate in CIDP 
patients requiring immunoglobulin or corticosteroids) or a minimum ODSS arm or 
leg grade (e.g., at least arm grade 2 or leg grade 1 in a trial evaluating the effi cacy of 
intravenous immunoglobulin in MGUSP).25-27 The basic characteristics of our sample 
show arm grades ≥2 in 47% and leg grades ≥1 in 74% of the patients. This implies 
suffi cient disability in the sample to calibrate the R-ODS for future use in CIDP and 
MGUSP trials. Only 30% of our sample was unable to walk independently (table 1, 
ODSS leg grade ≥ 3), corresponding to a GBS disability score of ≥ 3 which is often 
used as criterion to enrol patients in GBS trials.28, 29 Clearly, patients with GBS in the 
acute phase may often have more severe symptoms, signs, and functional defi cit 
than our clinically stable patients who experienced GBS in the past. It is therefore 
conceivable that the weights of the items might have been different if more severely 
affected patients were included. However, since the person separation index of the 
R-ODS turned out to be extremely high (0.97) it is reasonable to assume that this 
scale will also be able to differentiate between the various functional phase changes 
in patients with GBS.22
The AMC linear disability score (ALDS) item bank and ACTIVLIM are both linearly 
weighted scales quantifying functional status. The ALDS focuses on chronic 
conditions and ACTIVLIM on various neuromuscular disorders. We compared the 
item locations of the R-ODS with the locations of similar items of the ALDS and the 
ACTIVLIM.13, 15 Not only do the person locations (logits) differ considerably between 
these scales and the R-ODS, but also the item diffi culty ordering differs noticeably. 
This strengthens the idea that disease-specifi c scales should be constructed. In our 
view, although activity and social participation limitations are considered not being 
disease-specifi c, the signifi cance and weight of corresponding items may appear 
A
B
-2 -1 0 1 2
-2
-1
0
1
2
I tem hierarchy (logits)
I
t
e
m
 
h
i
e
r
a
r
c
h
y
 
(
l
o
g
i
t
s
)
2
n
d
 
a
s
s
e
s
s
m
e
n
t
1st assessment
I C C  0.95
-8 -4 0 4 8
-8
-4
0
4
8
Patients location (logits)
P
a
t
i
e
n
t
s
 
l
o
c
a
t
i
o
n
 
(
l
o
g
i
t
s
)
1st assessment
2
n
d
 
a
s
s
e
s
s
m
e
n
t
I C C  0.65
142 143
THE RASCH-BUILT OVERALL DISABILITY SCALECHAPTER 3.3
Chapter
3.3
specifi c for the various illnesses. Support for this implication is also obtained when 
looking at the responses of patients having multifocal motor neuropathy (MMN).30 
Our primary aim was to construct an outcome measure suitable for use in future trials 
evaluating therapeutic effi cacy in a wide range of immune-mediated neuropathies. 
Therefore, at fi rst not only the current patient population (GBS, CIDP and MGUSP), 
but also patients with stable MMN were included. However, the primary analyses 
showed the MMN patients behaving strongly differently. Fine motor upper limb 
items like ‘turn a key in a lock’ and ‘make a sandwich’ were considered much more 
diffi cult to accomplish by the MMN group (thus showing signifi cant uniform DIF 
on personal factor ‘diagnosis’). Their responses to the above items resembled the 
diffi culty levels of items like ‘walking uphill’ and ‘standing for hours’ in our patients 
with GBS, CIDP and MGUSP. We decided to not split the deviating items for the 
various illnesses. Instead, we are currently constructing a MMN-specifi c activity 
and participation scale to bypass these limitations (see also chapter 3.4).
Both item response theory (IRT) and Rasch measurement estimate the probability 
that a person with a given ability level will be able to complete an item/task.9, 11, 31 
The ALDS is based on IRT, which aims to fi nd the best model that explains the 
data whereas data based on Rasch have to satisfy the model expectations.32-34 As 
a result, in IRT often a model with generally fewer restrictions is chosen to explain 
all data. We developed the R-ODS using the Rasch model since it is considered a 
strong model with many restrictions aiming to satisfy mathematical requirements 
necessary to achieve fundamental measurement.35
There are some limitations that should be addressed. Most participants (86%) were 
members of a patient organisation, the Dutch society of neuromuscular disorders 
(Vereniging Spierziekten Nederland [VSN]). We could not verify their diagnosis, 
but the board of the VSN has ascertained us that all patients came from centres 
with great expertise in neuromuscular disorders, ensuring the right diagnosis. 
Written instructions were given how to respond when assistance or special devices 
were needed. Nevertheless, there might be some bias of the responses given, 
depending on the daily and social situation of patients and adaptations made. 
Furthermore, due to cultural and geographic differences items may be applicable 
to the Netherlands but not necessarily elsewhere. The ability of the R-ODS to 
detect relevant clinical changes over time (responsiveness) also needs further 
evaluation. Its responsiveness and international applicability is currently being 
investigated in patients with newly diagnosed immune-mediated neuropathies as 
part of the international multi-centre Peripheral Neuropathy outcome measures 
Standardisation (PeriNomS) study.
Nevertheless, the R-ODS seems to be a valid and reliable outcome measure 
capturing activity and social participation limitations in patients with GBS, CIDP 
and MGUSP. Compared to the ODSS, the R-ODS represents a wider range of item 
diffi culties, thereby showing a better targeting of the different ability levels of these 
patients. If its responsiveness can be demonstrated, we expect that the R-ODS will 
be valuable for future clinical trials and follow-up studies in patients with these 
disorders.
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Abstract
Background: Disability outcome measures that have been used in studies of patients 
with multifocal motor neuropathy (MMN) are ordinal based and may not be 
ideally suited to accurately capture functional changes after treatment. Currently, 
there is no MMN-specifi c scale with a linear construct as an alternative.
Objective: To construct an interval outcome measure suitable to capture the 
limitations in daily and social activities of patients with MMN using the Rasch 
model. 
Methods: 146 preliminary activity and participation items were assessed twice 
(interval: 2-4 weeks; test-retest reliability studies) in 107 MMN patients and 
subjected to Rasch analyses. The ordinal based overall disability sumscore (ODSS) 
was also assessed for validity purposes. The fi nal Rasch-built overall disability 
scale for MMN (R-ODS-MMN) was longitudinally applied (period: 1 year) in 7 
patients with newly diagnosed MMN receiving intravenous immunoglobulin to 
capture its responsiveness.
Results: 121 items were removed step by step due to insuffi cient face and content 
validity, disordered thresholds, misfi t statistics, item bias, and local dependency. 
The 25 remaining items were ordered on a linearly weighted scale and 
demonstrated good validity, reliability, and responsiveness.
Conclusion: The 25 item-R-ODS-MMN is a disease-specifi c, interval measure 
suitable to detect activity and social participation limitations in patients with 
MMN, overcoming the shortcomings of previous scales. Its use is recommended 
for future clinical trials in patients with MMN. 
Introduction
Multifocal motor neuropathy (MMN) is an uncommon immune-mediated 
demyelinating disorder characterised by slowly progressive, predominantly distal, 
asymmetrical limb weakness with involvement of motor nerves. The diagnosis is 
mainly based on clinical and electrophysiological fi ndings.1 Patients with MMN 
benefi t from intravenous immunoglobulin (IVIg) therapy based upon randomised 
cross-over trials using the Medical Research Council grading system as the primary 
impairment outcome measure.1-7 From a review of these trials, no signifi cant difference 
was seen at the disability level.8 Most studies in MMN have used the (modifi ed) 
Rankin scale to assess disability.3, 4, 6, 7, 9, 10 The Guy’s neurological disability scale, the 
nine-hole pegboard test, a self-evaluation scale, and the Norris scale are examples 
of other disability scales or composite scales containing disability items that have 
been used in MMN.3, 4, 11-19 Despite having defi ciencies from modern clinimetric 
perspective, these disability outcome measures have been generally used in MMN 
in the absence of linearly constructed ability and participation measures.20, 21 Also, 
these measures may be less sensitive to capture relevant clinical changes over 
time and therefore may have contributed to the non-signifi cant difference between 
patients receiving IVIg compared to placebo.8 
The aim of this paper is to present the construction of the Rasch-built overall 
disability scale specifi cally designed to capture the limitations in daily and social 
activities of patients with MMN (R-ODS-MMN).
Methods
Patients
Cross-sectional group
A total of 107 patients, aged 18 years and older with a stable clinical condition 
(of which 68 have been receiving maintenance interval therapy with IVIg) were 
recruited between July 2009 and May 2010. All patients met the clinical and 
electrophysiological diagnostic criteria for MMN.22 A clinically stable condition 
was defi ned as unchanged activities in daily living as declared by the patient, or 
no objective changes at neurological examination when compared with previous 
clinical fi ndings ≥ two months before the start of the study. Eighty-three patients 
were recruited from the neuromuscular research group at the Rudolf Magnus 
institute of neuroscience, University Medical Centre Utrecht, the Netherlands, and 
24 were recruited from other centres with expertise in MMN: 10 from Italy, 9 from 
France, 4 from the USA, and 1 from Belgium. 
Longitudinal group
Seven newly diagnosed patients with MMN were enrolled to investigate the 
responsiveness of the newly constructed disability scale. These patients were all 
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treated with IVIg. 
For both the cross-sectional and the longitudinal group, patients could not 
be included if concomitant diseases (e.g., diabetes, renal insuffi ciency, (prior) 
chemotherapy, alcohol abuse (> 5 IU/day)) could interfere with general nervous 
system as well as physical functioning.
Standard protocol approvals, registrations, and patient consents
The local medical ethics committee in each participating centre approved the 
protocol. Written informed consent was obtained from all participants.
Questionnaire development
Accepted standardised scale development procedures were applied to create 
the MMN-specifi c activity and participation scale, similar to the construction of 
the Rasch-built overall disability scale (R-ODS) for patients with Guillain-Barré 
syndrome (GBS), chronic infl ammatory demyelinating polyneuropathy (CIDP), 
and polyneuropathy associated with monoclonal gammopathy of undetermined 
signifi cance (MGUSP).23-25 In brief, we critically reviewed potential items at the activity 
and participation level using the WHO International Classifi cation of Functioning, 
Disability and Health (ICF), systematic literature review with reference tracing, and 
interviews with a focus group of 12 MMN patients.26 Information elicited from this 
group was subsequently combined with earlier selected items to form a large item 
pool, the so-called preliminary MMN-specifi c Rasch-built overall disability scale 
(preliminary R-ODS-MMN), containing 146 items. Patients were asked to rate their 
perceived diffi culty to perform the selected items on a three-level scale: 0 (‘unable 
to perform’), 1 (‘able to perform, but with diffi culty’), and 2 (‘easily performed, 
without diffi culty’). An item was scored 3 if it was not applicable to the patient. 
Additional outcome measure 
The overall disability sumscore (ODSS) is a previously validated scale in patients 
with GBS and CIDP that comprises a functional description of the arms and legs 
and ranges from 0 (‘no signs of disability’) to 12 (‘most severe disability score’; arm 
grade: 0–5, leg grade 0-7).27 The ODSS was applied in the cross-sectional group of 
patients to examine construct validity of the fi nal R-ODS-MMN.
Procedures
After presenting standardised instructions, the cross-sectional group was requested 
to complete the preliminary R-ODS-MMN questionnaire twice (test-retest study; 
interval 2-4 weeks; 1st assessment: n=107 patients, 2nd assessment: n=77 patients 
returned the questionnaire). The ODSS was assessed once in the cross-sectional 
group (validity study). The longitudinal group completed the fi nal R-ODS-MMN at 
entry, 3, and 12 months of follow-up.
Rasch analyses and statistical aspects
The preliminary R-ODS-MMN was subjected to Rasch analysis to determine 
whether model expectations were met. This methodology has been described 
thoroughly elsewhere, also specifi cally for neurologists (see also chapter 3.1).25, 28-30 
In brief, this statistical technique transforms ordinal obtained scores (which are 
scale dependent and of limited accuracy), into interval measures that are scale 
independent and suitably accurate for individual patient assessment. This method 
is based on the logical assumption that individuals with greater ability to perform 
a particular task should have an increased probability, relative to individuals with 
lower ability levels, of achieving a higher score on the item in question.28, 30 Analyses 
were performed to obtain a fi nal R-ODS-MMN meeting all Rasch expectations, such 
as proper fi t statistical parameters, lack of item bias, no disordered thresholds or 
local dependency, and fulfi lment of unidimensionality.25, 28, 30 
Descriptive statistics and sample size
Personal factors like age, gender, duration of symptoms, and country of assessment 
were collected. For the purposes of the current study, these person factors were 
categorised as follows: age (<40 years vs. 40-49 years vs. 50-59 years vs. ≥60 
years), gender (female vs. male), duration of complaints (<5 years vs. 5-9 years vs. 
10-20 years vs. ≥20 years), and country (Holland/Belgium vs. France vs. Italy vs. 
USA). Age and duration factors were categorised striving for equivalent distribution 
of participants per subgroup. According to sample size rules, at least 150 records 
were needed for acceptable model stability.32 To fulfi l this requirement, the data of 
the fi rst and second assessments were stacked, controlling for ‘time factor’ as a 
possible confounding factor.33 These procedures led to a sample size of 184 patient 
records (1st and 2nd assessment) for examination.
Reliability and validity
Internal reliability was examined by determining the person separation index (PSI). 
A PSI above 0.7 is considered acceptable, indicating the ability to identify at least two 
groups of patients.31 Test-retest reliability studies (patients’ ability locations) were 
also performed to determine the consistency of the fi nal scale created.34 Reliability 
was quantifi ed by calculation of the intraclass correlation coeffi cient using a one-
way random effects analysis-of-variance (ANOVA) model for group’ comparisons. 
The external construct validity of the fi nal scale was assessed by correlation with 
the ODSS.
Responsiveness
Traditional responsiveness at the longitudinal group level was calculated using 
the effect size (ES) indicator at 3 and 12 months of follow-up. The ES is equal 
to the mean change in score divided by the standard deviation of the scores at 
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entry (ES=μi-μo/SD
entry
); μi = mean fi nal R-ODS-MMN score of the longitudinally 
examined group at month = i; μo = mean fi nal R-ODS-MMN score at entry).35 
Responsiveness at the individual person level was also calculated. Modern 
clinimetric approaches have demonstrated that the standard error (SE) around an 
individual patient location may vary across the theoretical range of an outcome 
measure, and with this also the clinical importance of changes within a patient 
over time.36, 37 Minimal clinically important difference-standard error (MCID-SE), 
as a score for individual responsiveness, was calculated based on the previously 
described signifi cant change (SigChange).38 In brief, MCID-SE was calculated by 
computing for each of the seven serially examined patients separately: a) their own 
change (person location at i month minus person location at entry; where i = 3 
or 12 months of follow-up), b) the corresponding SE of difference related to their 
individual change (SE
diff 
= square-root(SE
entry
2+SE
i month
2), and c) the fi nal MCID-
SE calculations by dividing the individual change scores by corresponding SE
diff
 
(MCID-SE = (person location at i month minus person location at entry)/SE
diff
). 
Since MMN is considered an indolent illness, we arbitrarily defi ned the minimum 
clinically important difference cut-off using ≥ 1 standard error (corresponding to 
68% certainty that the ability estimate is no measurement error). As a result, the 
following subgroups were defi ned: 
• subgroup 1 (clinically important improvement): MCID-SE ≥ 1 
• subgroup 2 (clinically unimportant improvement): 0 < MCID-SE < 1 
•  subgroup 3 (no change): MCID-SE = 0
• subgroup 4 (clinically unimportant worsening): -1 < MCID-SE < 0
• subgroup 5 (clinically important worsening): MCID-SE ≤ -1.
 
Software
Rasch analyses were performed using Rasch Unidimensional Measurement Models 
(RUMM2030), with the partial credit model as default. Further analyses were 
undertaken using Stata 11.0 for Windows XP. The p-value was adjusted (Bonferroni) 
throughout the analyses correcting for multiple testing.39
Results
Study population and data quality control
The study population demographics are presented in table 1. Most patients were 
men. Based on the clinical characteristics of patients with MMN, a total of 19 
items had insuffi cient face and content validity and were removed. In the model 
construction, items scored as 3 (‘not applicable’) were interpreted as missing data. 
In addition, a total of 16 items with > 10% missing values were omitted as part of 
the quality control procedure. A total of 111 items were kept and subjected to Rasch 
analyses.
Table 1. General characteristics of patients with multifocal motor neuropathy
Cross-sectional group
(for R-ODS-MMN scale 
construction including 
validity and reliability 
studies)
Longitudinal 
group
(for R-ODS-MMN 
responsiveness 
studies)
Number of patients 107 7
Age (years); mean (SD), range 52.58 (11.4), 29 – 86 49.4 (9.3), 35 - 61
Gender; n (%)
female
male
25 (23.4)
82 (76.6)
1 (14.3)
6 (85.7)
Duration of symptoms (years); mean 
(SD), range
12.8 (7.8), 0.2 – 46 8 (3.7), 3 - 12
Country of assessment; n (%)
Holland
Italy
France
USA
Belgium
83 (77.6)
10 (9.4)
9 (8.4)
4 (3.7)
1 (0.9)
2 (28.6)
1 (14.3)
4 (57.1)
ODSS arm grade; (%) 
≤ 1 (normal or minor symptoms, not 
affecting any)
2 (moderate symptoms, affecting but 
not preventing any)
3 (severe symptoms, preventing at 
least one but not all)
≥ 4 (severe symptoms, preventing all 
or no purposeful movements)
19.1%
56.2%
22.5%
2.2%
ODSS leg grade; (%)
0 – 1 (normal or affected walking, but 
looks normal)
2 – 4 (walking looks abnormal; 
unilateral/bilateral support)
5 – 7 (wheelchair or bedbound)
40.5%
56.2%
3.3%
-
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Initial Rasch analyses on the preliminary R-ODS-MMN
The remaining 111 items of the preliminary R-ODS-MMN showed overall misfi t. 
The items fi t residuals showed acceptable fi t statistics (mean: -0.435; SD: 1.196), 
whereas the obtained scores for the person fi t residuals deviated from model 
expectations (mean: -0.455, SD: 1.523). The signifi cant chi-square probability 
(p<0.00001) demonstrated no invariance of items and a proportion of 0.25 of the 
t-tests performed fell outside the ± 1.96 range, indicating multidimensionality. 
Data handling to fi t the Rasch model
Throughout the analyses, we continuously monitored the distribution of persons 
within the class intervals. In order to improve the model, items and persons not 
fulfi lling the Rasch model requirements were step by step evaluated and removed 
one by one if needed.
Step 1: Two items (‘get in a car’ and ‘drive a car’) demonstrated disordered 
thresholds and were removed. 
Step 2: The individual item fi t statistics of 10 items demonstrated misfi t to the model 
(having a signifi cant chi-square probability or having fi t residuals exceeding ± 2.5) 
and were removed. 
Step 3: Seven items demonstrated item bias: 5 items had differential item 
functioning (DIF) on personal factor ‘country’ (2 uniform, 2 non-uniform, 1 both), 
and 2 items demonstrated DIF (1 uniform, 1 non-uniform) on personal factor 
‘duration’. We systematically removed these 7 items. Also, 4 cross-sectional 
patients demonstrated DIF (using the 95th confi dence intervals) on time factor 
and were removed as well.
Step 4: Numerous local dependency fi ndings were found between many items. All 
item sets with correlations above 0.28 were evaluated starting with the highest 
correlations (>0.7, subsequently >0.6, etc., to >0.28). Of each item set, the 
item showing less clinical relevance (face and content validity according to two 
experts having consensus on their judgment) and with most over- or under-
discrimination on its category probability curve was removed. A total of 67 items 
were stepwise removed.
After completing these procedures, we succeeded in constructing a 25-item interval 
measure (R-ODS-MMN) that met all Rasch model expectations (item fi t residuals: 
mean -0.352, SD 0.997; person fi t residuals: mean -0.333, SD 0.982; item-trait chi-
square: p-value=0.10, DF=50). Based on the fi rst principal components analysis 
two subsets of items were formed (6 most positively loading vs. 6 most negatively 
loading items). The independent t-tests between these two subsets suggested 
acceptable unidimensionality (0.052 (95% confi dence interval (CI): 0.019-0.084). 
In the fi nal R-ODS-MMN scale, the item ‘read a newspaper’ was the easiest to 
perform while ‘serve coffee/tea on a tray’ turned out to be the most diffi cult task 
(table 2). Item diffi culty ranged from -2.877 to 2.806 logits. A total of 18 patients 
demonstrated a maximum score (9.8%). The raw scores were translated to an 
interval measure with logits as unit. These less intuitive logits may be translated 
to a more understandable centile metric ranging from 0 (most severe activity 
and participation restrictions) to 100 (no activity limitations and participation 
restrictions) (nomogram available on request). 
Table 2. Final 25-item Rasch-built overall disability scale for multifocal motor neuropathy 
(R-ODS-MMN)
Are you able to: 
unable to 
perform
able to perform,
but with diffi culty
able to perform
without diffi culty
0 1 2
1 Read a newspaper? 
2 Eat? 
3 Make a telephone call? 
4 Open or close a door? 
5 Brush your teeth? 
6 Drink out of a glass? 
7 Turn a key in a lock? 
8 Use knife and fork (spoon)? 
9 Wash upper body? 
10 Wash lower body? 
11 Dress upper body? 
12 Shave/epilate? 
13 Clean after toilet visit? 
14 Zip trousers? 
15 Fill in a form? 
16 Get money from a cash point? 
17 Work on a computer? 
18 Vacuum cleaning? 
19 Dress lower body? 
20 Catch an object (e.g., ball)? 
21 Slice vegetables? 
22 Handle small objects (e.g., coin)? 
23 Tie laces? 
24 Clip nails? 
25 Serve coffee/tea on a tray? 
Legend to table 2. The easiest item turned out to be ‘read a newspaper’, the most diffi cult item 
‘serve coffee/tea on a tray’. The raw scores can be translated to the less intuitive logits, and from 
here to a more understandable centile metric ranging from 0 (most severe activity and participation 
restrictions) to 100 (no activity limitations and participation restrictions).
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Validity and reliability studies
The fi nal 25-item R-ODS-MMN scores demonstrated acceptable construct validity 
when correlated with the ODSS scores (fi gure 1). 
Figure 1. Construct validity demonstrated for the 25-item R-ODS-MMN when compared 
to the scores of the overall disability sumscore (ODSS)
Legend to fi gure 1. A high patient location on the R-ODS-MMN refers to minor activity and 
participation limitations. Low scores on the ODSS also refer to less disability. This fi gure visualises 
the correlations between R-ODS-MMN patient locations and ODSS scores, refl ecting acceptable 
construct validity. 
Internal reliability remained robust as indicated by a person separation index 
of 0.87. Also, the test-retest reliability for personal location was good: patients’ 
locations were almost always located within the 95% CI lines, refl ecting ideal 
invariance (R2=0.87).
Responsiveness studies
At 3 months, only 1 patient had an improvement in R-ODS-MMN score; 3 patients 
did not show any changes, while 3 others demonstrated some deterioration. At 
12 months, 6 patients had higher scores for the R-ODS-MMN and 1 patient had 
unchanged values. The effect size values were poor (at 3 and 12 months 0.1 and 
0.4, respectively). However, responsiveness at the individual person level, taking the 
changing standard errors into account, demonstrated a different dynamic (table 
3 and fi gure 2): at 3 months, 1 patient (#4) demonstrated a clinically important 
deterioration compared to entry (subgroup 5), while 2 others (#1 and #6) 
deteriorated although not clinically important (subgroup 4), 3 patients (#2,#3 and 
#7) remained unchanged (subgroup 3), and 1 (#5) showed improvement although 
clinically not important (table 3). At 12 months, 2 patients (#1 and #3) demonstrated 
a clinically important improvement compared to entry (subgroup 1), 4 others (#2, 
#4-6) improved clinically not important (subgroup 2; having MCID-SE scores: 0.71-
0.89), and 1 patient (#7) remained unchanged (table 3).
Table 3. Categorising MCID-SE scores of each longitudinally examined patient (n=7)
Patient
#
MCID-SE at 3 
months
MCID-SE at 12 
months
subgroup 
classifi cation at 3 
months compared 
to entry
subgroup 
classifi cation at 12 
months compared 
to entry
1 -0.47 1.04 4 1
2 0 0.89 3 2
3 0 1.73 3 1
4 -1.2 0.71 5 2
5 0.79 0.79 2 2
6 -0.34 0.71 4 2
7 0 0 3 3
Legend to table 3. MCID-SE scores were determined by dividing the individual change scores by 
corresponding SE
diff
 (MCID-SE = (person location at i month minus person location at entry)/SE
diff 
; where i = 3 or 12 months of follow-up and SE
diff 
= square-root(SE
entry
2+SE
i month
2)). 
Subgroup classifi cation: 1 (clinically important improvement: MCID-SE ≥ 1), 2 (clinically unimportant 
improvement: 0 < MCID-SE < 1), 3 (no change: MCID-SE = 0), 4 (clinically unimportant worsening: 
-1 < MCID-SE < 0), 5 (clinically important worsening: MCID-SE ≤ -1).
Figure 2. Patient location on the R-ODS-MMN with corresponding standard error 
Legend to fi gure 2. An ‘U’-shape pattern is shown indicating that the standard error changes with 
the changing location of a patient on the theoretical range of the R-ODS-MMN. As an example: the 
black dots correspond with the location of patient 1 at entry (I), at 3 months (II), and 12 months 
(III) of follow-up. Note the changing corresponding standard error with each time point. See also 
table 3 for the categorisation of changes seen in these patients.
158 159
THE RASCH-BUILT OVERALL DISABILITY SCALE FOR MMNCHAPTER 3.4
Chapter
3.4
Discussion
The R-ODS-MMN scale is a linearly weighted outcome measure constructed 
specifi cally to capture activity and participation limitations in patients with MMN. 
This scale was developed noting the limitations seen in most disability ordinal 
based outcome measures used thus far in MMN.20 The R-ODS-MMN fulfi lled all 
Rasch model expectations and demonstrated acceptable validity, reliability, and 
responsiveness. These fi ndings contribute to the paradigm shift needed to improve 
monitoring of treatment and follow-up of patients with chronic conditions like 
MMN. 
The clinical presentation of a disease determines which items or tasks will be 
completed easily or with more effort. For example, based on differences in the clinical 
features, it is logical to expect that patients with MMN will experience more diffi culty 
with fi ne motor upper limb items compared to patients with GBS. We previously 
created a R-ODS scale for patients with GBS, CIDP and MGUSP.25 Comparing the 
R-ODS for GBS/CIDP/MGUSP vs. the R-ODS-MMN, for similar and beforehand 
non-disease specifi c items used for their construction, the locations (weights or 
diffi culties) of items included in the fi nal scales are certainly disease specifi c and 
varied considerably. For example, for patients with MMN, the item ‘serve coffee/tea 
on a tray’ (location: 2.806 logits) was the most diffi cult to accomplish, whereas in 
GBS/CIDP/MGUSP patients the ‘ability to run’ (location: 5.604 logits) turned out 
to be the most diffi cult to perform. For GBS/CIDP/MGUSP patients the item ‘wash 
upper body’ was relatively easy to accomplish (location: -2,5716), but for patients with 
MMN this item was considerably more diffi cult to accomplish (location -0,320).25 
Other outcome measures with a linear construct capturing disability in 
neuromuscular disorders are the ACTIVLIM and the AMC linear disability score 
(ALDS).40, 41 However, these scales should be considered as generic based measures 
for chronic illnesses with the ACTIVLIM focusing on numerous neuromuscular 
disorders. Furthermore, little common ground was found in the diffi culty of the 
items between these scales and the R-ODS-MMN since only 3 items demonstrated 
the same content. In MMN distal arm muscles are mainly affected, it is therefore 
not surprising that most items address distal muscle functioning. However, the 
ACTIVLIM focuses on neuromuscular disorders in general and this is refl ected by 
the content of the selected items. 
The effect sizes of the longitudinally examined patients were poor at 3 and 12 months 
of follow-up. However, using traditional responsiveness indicators like the effect 
size does not always provide information on the personal magnitude and direction 
(improvement, stable, or deterioration) of changes for each individual patient as 
is the case when using modern tools like the Rasch method. Hence, traditional 
methods tend to be misleading and do not take the changing measurement errors 
observed in individual patients into consideration (fi gure 2).28-30, 36, 37 The clinical 
dynamics were clearly captured by the Rasch method, showing improvement at 
12 months in 6 of the 7 patients, although this was only clinically important in 2 
patients (table 3).
Some methodological limitations in this study need to be addressed. In the ideal 
situation, a sample size of 150, but preferably approximately 250 patients is needed to 
provide accurate model stability.32 The minimal requirement could only be achieved 
after stacking the data to a total sample size of 184 records. However, for an orphan 
disease like MMN this is a large series of patients. Further efforts are needed in 
collaboration with neuromuscular centres worldwide to provide a more stable scale 
for this rare disease. Second, there was a ceiling effect in 9.8%, which could hamper 
the applicability of the scale. Efforts have been made to extend the fi nal R-ODS-MMN 
to ~30 items, but the ceiling effect remained unchanged. A proportion of patients 
in the cross-sectional group hardly experienced any disability related to their illness. 
Finally, more longitudinally examined patients with MMN are needed to assess the 
responsiveness of the R-ODS-MMN at the individual person level. Efforts for this 
are currently underway as part of the Peripheral Neuropathy outcome measures 
standardisation (PeriNomS) study, an international multi-centre study to improve 
the clinical assessment in patients with infl ammatory neuropathies. Despite these 
limitations, the R-ODS-MMN fulfi ls all Rasch model requirements and therefore 
substantially increases our ability to accurately measure activity and participation 
limitations to capture clinically important changes in patients with MMN.
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Abstract
Background: The Jamar dynamometer and Vigorimeter have often been used to 
assess grip strength in immune-mediated neuropathies, but there have been no 
comparison studies to determine which device is superior. 
Objectives: To perform a prospective clinimetric comparison (assessing validity, 
reliability, and responsiveness) between the Jamar dynamometer and Vigorimeter 
in patients with immune-mediated neuropathies, and to determine patients’ 
preference.
Methods: Jamar and Vigorimeter grip strength values, Medical Research Council 
(MRC) sumscores and overall disability sumscore (ODSS) arm grades were 
collected in 102 cross-sectional (stable condition) and 89 longitudinal (newly 
diagnosed or relapse) patients with Guillain-Barré syndrome (GBS), chronic 
infl ammatory demyelinating polyneuropathy (CIDP), monoclonal gammopathy of 
undetermined signifi cance related polyneuropathy (MGUSP) or multifocal motor 
neuropathy (MMN). Cross-sectional patients were assessed twice for validity and 
reliability studies (interval 2-4 weeks). Longitudinal patients were assessed 3 to 5 
times during one year, each time rating their clinical condition compared to the 
last visit (responsiveness studies). All patients were asked whether they preferred 
the Jamar or the Vigorimeter using a 5-point Likert scale.
Results: The obtained values of both devices correlated moderately with the ODSS 
arm grades and the MRC sumscores (Jamar: r
s
 =-0.58 to 0.59, Vigorimeter: 
r
s
 =-0.55 to 0.58). Similar intraclass correlation coeffi cients (Jamar: ICC 0.996/0.956; 
Vigorimeter: ICC 0.946/0.977) were found. The Guyatt responsiveness ratio was 
0.64 for the Jamar and 0.56 for the Vigorimeter. More patients preferred the 
Vigorimeter (Vigorimeter vs. Jamar; 47% vs. 27%). 
Conclusion: Validity, reliability and responsiveness aspects were comparable for 
the Jamar dynamometer and Vigorimeter. However, more patients preferred 
the Vigorimeter. Therefore, we recommend using the Vigorimeter as the 
standard device to assess grip strength in future studies in immune-mediated 
neuropathies.
Introduction
Weakness and sensory defi cits in patients with immune-mediated neuropathies can 
have a major impact on activities of daily living, social functioning and quality of life.1 
Since distal weakness is pre-dominant in these conditions, it seems logical to use grip 
strength to assess outcome. Grip strength has been used as a prognostic indicator 
of recovery and to evaluate treatment effects in patients with diseases affecting hand 
function.2-5 The Jamar dynamometer and the Vigorimeter have been used most 
often to assess grip strength in immune-mediated neuropathy trials.6-9 Separately, 
both devices have demonstrated good scientifi c properties.4, 10-20 As there is no 
‘gold standard’, a clinimetric comparison between the Jamar dynamometer and the 
Vigorimeter has been suggested but has never been performed in immune-mediated 
neuropathies.21 If one of these devices is a superior measure of grip strength, it could 
be used as a standard for future studies thus increasing precision, reliability and 
responsiveness analyses. Furthermore, choosing one standard grip strength device 
would enhance the comparability of future therapeutic trial results.
Therefore, the purpose of this study was to compare the validity, reliability and 
responsiveness of both devices and select the superior device as the standard 
grip strength measure for future studies in patients with immune-mediated 
neuropathies. 
Methods
Patients
Cross-sectional patients
Between April 2007 and January 2010, a total of 102 patients with clinically stable 
immune-mediated neuropathies participated in this study: 30 patients with Guillain-
Barré syndrome (GBS), 30 with chronic infl ammatory demyelinating polyneuropathy 
(CIDP), 20 with monoclonal gammopathy of undetermined signifi cance related 
polyneuropathy (MGUSP) and 22 with multifocal motor neuropathy (MMN). 
Longitudinal patients
Between August 2007 and December 2010, 89 immune-mediated neuropathy 
patients with new or relapsing symptoms and signs participated in this study. 
These 36 GBS, 34 CIDP, 9 MGUSP and 10 MMN patients are participants in the 
on-going international multi-centre Peripheral Neuropathy outcome measures 
Standardisation (PeriNomS) study.22
Eligibility
All patients were 18 years or older and met the international criteria for their 
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illness.23-26 Only MGUSP patients with serologically proven IgM anti-MAG positive 
antibodies were included. Patients were excluded if they had any other potential 
cause for polyneuropathy, family history of neuropathy, exposure to neurotoxic 
medication or alcohol abuse. All cross-sectional patients had residual symptoms 
and signs and a stable neurological and functional status within 2 months prior 
to enrolment (with or without interval treatment), which was confi rmed by patient 
interview and record review. All longitudinal patients were newly diagnosed or had a 
relapse after at least 2 months without any treatment. 
Recruitment location
Cross-sectional patients were recruited at university outpatient clinics in the 
Netherlands (Rotterdam, Utrecht and Maastricht). Longitudinal patients were 
recruited during hospital admission or at outpatient clinics in the USA (Boston 
and Detroit), Canada (Ontario), Brazil (Ribeirão Preto), United Kingdom (London), 
Italy (Milan and Venice), France (Paris), Spain (Barcelona), Belgium (Brussels) and 
the Netherlands (Maastricht and Rotterdam).
Outcome measures
• Grip strength was assessed using the Jamar hydraulic hand dynamometer 
(Sammons Preston Rolyan, Bolingbrook, IL, USA) and the Vigorimeter (Martin, 
Tuttlingen, Germany) (fi gure 1). The Jamar dynamometer quantifi es isometric 
force in pounds (range 0-200). The Vigorimeter quantifi es grip strength on a 
manometer after squeezing a rubber bulb, and is scored in kilopascal (range 
0-160). All devices were newly purchased and provided to all investigators before 
study onset. For each patient the same set of devices was used each visit. Position 
two of the adjustable handle of the Jamar dynamometer was used. The middle 
size bulb (diameter 4.8 cm) of the Vigorimeter was used. Patients were examined 
sitting on a straight-backed chair, arm unsupported, feet fl at on the fl oor and 
positioned according to the recommendations by the American Society of Hand 
Therapists; shoulder adducted and neutrally rotated, elbow fl exed at 90°, forearm 
in neutral position, and wrist between 0°-30° dorsifl exion and between 0°-15° of 
ulnar deviation.27 Three maximum voluntary contractions were recorded for each 
hand in alternating order (resting period: ~30 seconds), and for each trial patients 
were encouraged to use maximum force. The mean of the six values obtained 
from both hands was used for analyses. At each visit patients were asked if they 
had a preference for the Jamar dynamometer or the Vigorimeter using a 5-point 
Likert scale; ‘great preference to the Jamar’, ‘slight preference for the Jamar’, ‘no 
preference for either device’, ‘slight preference for the Vigorimeter’, and ‘great 
preference for the Vigorimeter’.
Figure 1: Images of the Jamar dynamometer (A) and the Vigorimeter (B)
     A. Jamar dynamometer  B. Vigorimeter
• The Medical Research Council (MRC) sumscore is a summation of MRC grades given 
in full numbers: 0 (‘no movement, no contraction’), 1 (‘visible contraction without 
movement’), 2 (‘movement but only with gravity eliminated’), 3 (‘movement 
against gravity’), 4 (‘movement against resistance, but weaker than normal’), and 
5 (‘normal strength’) of the arm abductors, elbow fl exors, wrist extensors, hip 
fl exors, knee extensors and foot dorsal fl exors on both sides, and thereby ranging 
from 0 (total paralysis) to 60 (normal strength).28 An expanded MRC sumscore 
ranging from 0 (total paralysis) to 140 (normal strength) was used in MMN to 
cover its asymmetrical presentation and its often predominating weakness in 
distal arm and hand muscles. Based on expert opinion, the following fourteen 
muscle pairs, including the ten previously described as the most affected ones, 
were selected to compose this summation: shoulder abductors, elbow extensors 
and fl exors, wrist extensors and fl exors, fi nger extensors and fl exors, thumb 
abductors, hypothenar abductors, hip fl exors, knee extensors and fl exors, ankle 
dorsifl exors and ankle plantar fl exors.29
• The arm grade of the overall disability sumscore (ODSS) ranges from 0 (normal) to 5 
(severe symptoms and signs in both arms preventing all purposeful movements) 
and can be derived from the answers to a fi ve-question arm disability checklist 
(‘dressing upper part of the body’, ‘washing/brushing hair’, ‘turning a key in a 
lock’, ‘using knife and fork’, and ‘doing/undoing buttons and zips’).30
• The clinical judgment score (ClinJSc) is the score given by patients refl ecting their 
condition. Therefore, at each visit patients were asked to answer the following 
question, “How would you describe your physical status now, compared to what 
it was on the last time you were examined?”, with one of the following 5 response 
options: ‘much worse’, ‘slightly worse’, ‘the same’, ‘better’, and ‘much better’ 
compared to the last visit.
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Study design
We standardised data collection by formally training all investigators in how 
to perform and record all outcome measures in a standardised manner. Also, a 
picture enriched training manual, demonstrating the appropriate methods of data 
collection, was provided to every institute participating in the PeriNomS study.
Cross-sectional patients (validity and reliability studies)
Each patient was subjected to a total of three assessments during two visits 
(interval 2-4 weeks). At one of two visits, two trained investigators in a blinded 
fashion assessed independently and consecutively grip strength using both the 
Jamar dynamometer and the Vigorimeter, the MRC sumscore and the arm grade of 
the ODSS. During the other visit one of the two investigators reassessed the same 
set of outcome measures without having access to the previous assessed results. 
Longitudinal patients (responsiveness studies)
All patients were scheduled for examination at entry, 3 and 12 months. In patients 
with GBS and CIDP additional examinations at 1 and 6 months were collected to 
capture quicker changes in clinical status. Each visit the following assessments were 
performed by a trained investigator: grip strength using the Jamar dynamometer and 
the Vigorimeter, the MRC sumscore, the arm grade of the ODSS and the ClinJSc.
The local medical ethics committee from each participating institution approved 
the study protocol and all patients gave informed consent before participating.
Statistical analysis
Validity and reliability
Correlations with the ODSS arm grades and the MRC sumscores were calculated 
for both devices (construct validity study; Spearman’s rank correlation coeffi cients). 
Our a priori hypothesis was that these correlations should be at least moderate 
to fulfi l the requirements of convergent validity for each device. Furthermore, 
the intra- and inter-observer reliability scores of both devices were compared by 
estimating the intraclass correlation coeffi cients using a one-way random-effects 
analysis of variance (ANOVA) model. To visualise potential intra- and inter-observer 
measurement errors we used Bland-Altman plots.31 The smallest detectable 
difference (SDD) in grip strength was computed from these plots using the formula 
1.96*SD of differences. Differences in consecutive grip strength assessments 
greater than the SDD can be interpreted with 95% certainty as a true change (no 
measurement error).
Responsiveness
To determine differences in responsiveness, we correlated the difference in 
grip strength between all consecutive visits with the clinical judgment scores 
(Spearman’s rank correlation coeffi cients). Furthermore, for both devices the 
Guyatt responsiveness ratio was calculated.32 This signal/noise ratio relates the 
minimum clinically important difference (MCID) to the variability in patients rating 
themselves as stable: MCID /standard deviation of change (SD
change
). The MCID 
was defi ned as the mean difference in grip strength between consecutive visits of 
patients who rated their clinical condition as ‘being better compared to the last 
visit’ (on the ClinJSc). SD
change
 was obtained by calculating the SD of this difference 
in grip strength of patients rating their clinical condition as ‘being stable compared 
to the last visit’ (on the ClinJSc).
All analyses were performed using Stata 11.0 for Windows XP. A p-value 
(Bonferroni adjusted) of <0.05 was considered signifi cant.33
Results
Descriptive statistics
Cross-sectional patients
Patient characteristics at entry are presented in table 1. Most individuals were right-
handed (82%). Some patients (n=45) remained clinically stable with maintenance 
interval treatment. Twenty three patients with CIDP, 17 with MMN and 1 with MGUSP 
were being treated with periodic infusions of intravenous immunoglobulins (IVIg). Two 
CIDP patients were receiving plasma exchange, one CIDP patient was being treated 
with corticosteroids and one MGUSP patient was being treated with rituximab.
Table 1. Characteristics of the cross-sectional, clinically stable, study population (n=102) 
at visit one
GBS (30) CIDP (30) MGUSP (20) MMN (22)
Gender; male:female, n:n 13:17 21:9 17:3 17:5
Age in years; median (range) 62 (47-76) 61 (26-74) 68 (54-81) 52 (29-75)
Years since diagnosis; median (range) 11 (2-29) 6 (1-23) 9 (2-24) 12 (4-43)
Grip strength (mean both hands)
Jamar (pounds); median (range)
Vigorimeter (kPa); median (range)
63 (1-123)
73 (17-122)
61 (17-120)
76 (18-140)
81 (24-118)
75 (23-139)
22 (0-118)
43 (0-120)
ODSS arm grade; n (%)
0 
1 
2 
3
9 (30%)
5 (17%)
13 (43%)
3 (10%)
2 (7%)
4 (14%)
17 (58%)
6 (21%)
3 (15%)
2 (10%)
10 (50%)
5 (25%)
1 (5%)
1 (5%)
11 (50%)
9 (41%)
MRC sumscore; median (range) 59 (48-60) 55 (46-60) 57(42-60) 109 (96-124)
Legend to table 1. kPa= kilopascal, ODSS=overall disability sumscore, MRC= Medical Research Council
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Longitudinal patients
The characteristics of these 89 patients are presented in table 2. Eighty-six percent 
were right-handed. All patients with GBS had been treated; 23 received IVIg, 6 had 
plasma exchange, 5 had IVIg combined with corticosteroids and 2 received IVIg after 
plasma exchange. All but one of the CIDP patients were treated during follow-up, 
most received IVIg (18), the others received corticosteroids (6), plasma exchange 
(1), immunosuppressive drugs (2) or a combination of IVIg with corticosteroids 
and/or plasma exchange (6). Of the 9 MGUSP patients, 5 were treated: 2 with 
IVIg and 3 with rituximab. All MMN patients were treated with IVIg, and 1 had IVIg 
combined with cyclophosphamide.
Table 2. Characteristics of the longitudinal patients at entry and at 12 months
GBS CIDP MGUSP MMN
Baseline
n=36
12 months
n=11
Baseline
n=34
12 months
n=17
Baseline
n=9
12 months
n=3
Baseline
n=10
12 months
n=8
Newly diagnosed: relapse; n:n 36 :0 19:15 6:3 5:5
Gender; male:female, n:n 25:11 8:3 25:9 11:6 6:3 2:1 8:2 6:2
Age in years; median (range) 57 (19-90) 60 (39-91) 58 (18-74) 59 (32-75) 62 (45-85) 63 (47-86) 47 (32-60) 49 (35-61)
Grip strength (mean both hands)
Jamar (pounds); median (range)
Vigorimeter (kPa); median (range)
16 (0-99)
32 (0-98)
63 (21-135)
74 (32-142)
41 (0-116)
55 (0-108)
38 (5-99)
61 (0-100)
53 (31-109)
74 (38-107)
34 (5-61)
59 (0-80)
61 (14-103)
77 (10-121)
60 (19-75)
68 (7-120)
ODSS arm grade; n (%)
0 
1 
2 
3 
4 
5
unknown
1 (3%)
2 (6%)
11 (31%)
9 (25%)
9 (25%)
4 (11%)
9 (82%)
1 (9%)
1 (9%)
7 (21%)
3 (9%)
12 (35%)
10 (29%)
2 (6%)
6 (35%)
2 (12%)
3 (18%)
5 (29%)
1 (6%)
5 (56%)
4 (44%) 2 (67%)
1 (33%)
2 (20%)
1 (10%)
4 (40%)
3 (30%)
1 (13%)
1 (13%)
6 (75%)
MRC sumscore; median (range) 48 (0-60) 60 (50-60) 52 (8-60) 58 (37-60) 57 (52-60) 58 (39-59) 131 (99-139)131 (109-139)
Floor and ceiling effects
Of the cross-sectional group 5 MMN patients reached a fl oor effect using the Jamar 
dynamometer and 3 when using the Vigorimeter. In the longitudinal group a fl oor 
effect was seen in 17 patients (13 GBS and 4 CIDP) using the Jamar dynamometer 
and in 18 patients (12 GBS and 6 CIDP) using the Vigorimeter. No ceiling effects 
were observed.
Validity and reliability
A strong correlation was found between the two grip strength devices (r
s
= 0.86, 
p<0.0001). Correlation between both devices and the ODSS arm grade and the MRC 
sumscore were moderate and comparable (table 3). Similar intraclass correlation 
coeffi cients were found for both devices (table 3). Differences in grip strength values 
in a single investigator and between two investigators were approximately evenly 
distributed around the almost zero mean difference line of all Bland-Altman plots 
(fi gure 2). The SDD values derived from the intra-observer plots (20.5 pounds for 
the Jamar dynamometer and 22.0 kPa for the Vigorimeter) were higher than those 
derived from the inter-observer plots (15.0 pounds for the Jamar and 18.3 kPa for 
the Vigorimeter).
Figure 2: Bland-Altman plots refl ecting inter-and intra-observer agreement for the Jamar 
(fi gure 2A+2C) and the Vigorimeter (fi gure 2B+2D). SDD= smallest detectable difference
Responsiveness
Correlations between the clinical judgment scores and the difference in grip 
strength values between visits and the calculated Guyatt responsiveness ratios for 
both devices are presented in table 3. During follow-up patients rated their clinical 
condition 64 times ‘better compared to the last visit’ and 39 times ‘stable compared 
to the last visit’ on the ClinJSc.
SDD SDD
SDD
SDD
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Figure 3: Patients’ preference for grip strength device
Legend to fi gure 3. Per condition the preference of the cross-sectional and longitudinal patients 
summed. 
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Table 3: Comparative validity, reliability and responsiveness of the Jamar and the Vigo-
rimeter
Jamar Vigorimeter
Validity
Spearman’s rank correlation coeffi cient 
-  correlation with the ODSS arm grades
-  correlation with the MRC sumscores
-0.58
 0.59
-0.55
 0.58
Reliability
Intraclass correlation coeffi cient (ICC) - intra-observer
Intraclass correlation coeffi cient (ICC) - inter-observer
Bland-Altman plot - systematic intra-observer difference
Bland Altman plot - systematic inter-observer difference
0.996
0.956
0.6 pound
0.7 pound
0.946
0.977
1.0 kPa
1.1 kPa
Responsiveness
Spearman’s rank correlation coeffi cient
-  correlation with Clinical judgment scores
Guyatt responsiveness ratio
0.23
0.64
0.43
0.56
Patients’ preference
Cross-sectional patients consistently preferred the Vigorimeter above the Jamar 
dynamometer (Vigorimeter vs. Jamar; 49% vs. 26% at visit one, 55% vs. 29% 
at visit two). Also, 36 of the 59 longitudinal patients having a preference chose 
the Vigorimeter at the initial visit. The overall preference and the preference per 
condition are presented in fi gure 3. Patients’ preference was not related to their 
grip strength values. 
Cross-sectional and longitudinal patients at visit 1
GBS
MGUSP MMN
CIDP
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Discussion
In conformity with earlier reports grip strength assessment with the Jamar 
dynamometer as well as the Vigorimeter demonstrated good validity and 
reliability.4, 10-20 Our comparative validity analyses showed similar correlations 
between the obtained grip strength values of both devices with the ODSS arm 
grades and the MRC sumscores. Only one other study, in healthy children, directly 
compared reliability aspects of the Vigorimeter and a Jamar-like device (Lode 
dynamometer) and showing signifi cantly lower intraclass correlation coeffi cients for 
the Vigorimeter.34 In contrast, we observed high intraclass correlation coeffi cients 
and low systematic measurement errors (Bland-Altman plots) for both devices. 
These fi ndings suggest that both devices are equally valid and reliable in immune-
mediated neuropathies.
The ability to detect change in relation to an external anchor (clinical judgment 
score) was examined calculating Guyatt responsiveness ratios for both devices. A 
ratio greater than 1.96 is indicative of being a highly responsive device. However, 
both devices demonstrated similar low ratios suggesting limited responsiveness. 
In contrast, previous comparative responsiveness analyses in immune-mediated 
neuropathies ranked the Vigorimeter among the impairment and disability scales 
with the highest responsiveness capacity.35 Another approach to select the device 
with the best chance of detecting true change is to consider the smallest detectable 
differences (SDDs) derived from the Bland-Altman plots. Differences greater than 
the SDD are necessary to detect a true change with 95% certainty for two consecutive 
grip strength assessments. Therefore, SDDs have been used to calculate the 
minimum clinically important difference (MCID), the smallest difference in score 
in the domain of interest which patients perceive as benefi cial.36 The calculated 
intra-observer SDDs (20.5 pounds for the Jamar dynamometer and 22 kPa for the 
Vigorimeter) were rather high compared to those in other populations.10, 12, 34, 37 The 
difference in grip strength between baseline and 12 months was only in patients 
with GBS large enough to reach the SDDs of both devices. Further evaluation of 
MCID cut-off values will be necessary to ensure the clinical applicability of both grip 
strength devices in all immune-mediated neuropathies.
Our study demonstrated patients’ preference for the Vigorimeter over the Jamar 
dynamometer. Reasons often mentioned for preferring the Vigorimeter include: 
‘less heavy’, ‘easier’, ‘more comfortable’, ‘less painful to squeeze a bulb’ and 
‘squeezing makes you feel the force you are giving’. Those who preferred the Jamar 
dynamometer listed reasons like ‘more robust’, ‘more suitable for big hands’ and 
‘less chance of using it incorrectly’. Although normative values are available for 
both devices, the values calculated for the Jamar dynamometer do not consider 
the non-Gaussian distribution of grip strength values.4, 17, 38 Therefore, we have 
collected Jamar grip strength values in healthy subjects to overcome this limitation 
(see also chapter 2.2).39 Based on our observations indicating equivalent validity, 
reliability and responsiveness for both devices, it seems that the Vigorimeter 
should be selected as the standard device for future studies based upon patients’ 
preference.
Our study has some methodological limitations. Construct validity was calculated 
correlating linear grip strength scores with sumscores of ordinal outcome measures. 
Accordingly, the obtained ordinal sumscores were treated as if these were linear 
with all the components having equal relevance, which is highly unlikely.40, 41 To 
calculate the Guyatt responsiveness ratio we used the clinical judgment score 
as an anchor. However, the correlation between this score and the difference in 
grip strength was only moderate for the Vigorimeter and even low for the Jamar 
dynamometer. If another anchor having higher correlations with difference in 
grip strength would be available, this could improve the responsiveness analyses. 
Furthermore, our sample size might be too small to draw a robust conclusion 
concerning responsiveness. Different disease courses of certain immune-mediated 
neuropathies may necessitate subgroup analyses to detect potential differences in 
responsiveness attributable to the underlying condition. The international multi-
centre longitudinal part of the PeriNomS study will further evaluate these issues.
In conclusion, this study demonstrated that the Jamar dynamometer and the 
Vigorimeter show similar validity and reliablity to assess grip strength in immune-
mediated neuropathies. Although responsiveness scores were rather low, this 
applied for both devices. Therefore, based on patients’ preference, we recommend 
that the Vigorimeter should be used as the standard to assess grip strength for 
future studies in these conditions. 
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Abstract
Background: Although the sensory subset of the neuropathy impairment 
score (NISs) and the INCAT sensory sumscore (ISS) both fulfi l all clinimetric 
requirements in patients with immune-mediated neuropathies, it is unknown 
which scale is superior.
Objective: Comparison of the NISs and the modifi ed ISS (mISS) to select one 
sensory scale as the standard for future follow-up studies and clinical trials in 
patients with Guillain-Barré syndrome (GBS), chronic infl ammatory demyelinating 
polyradiculoneuropathy (CIDP), and monoclonal gammopathy of undetermined 
signifi cance related polyneuropathy (MGUSP).
Methods: 
Step 1. NISs and mISS data were subjected to Rasch analyses to transform these 
ordinal sensory scales to interval scales (1st visit data of 82 newly diagnosed 
patients plus 1st and 2nd visit data of 80 clinically stable patients). 
Step 2. Comparing clinimetric properties of the (Rasch-built) NISs and mISS. 
Construct validity and explanatory validity (correlation with disability) were 
calculated for both scales. To determine reliability both scales were assessed 
twice (interval 2-4 weeks) in the clinically stable patients (30 GBS, 30 CIDP, 20 
MGUSP). Finally, traditional group-level responsiveness (effect size (ES)) and 
individual-person-level responsiveness (MCID-SE: individual change/standard 
error of difference (SE
diff
)) were estimated for each scale in 74 newly diagnosed 
patients (32 GBS; 33 CIDP, 9 MGUSP).
Results: A Rasch-built interval scale could be constructed for both sensory 
measures demonstrating good fi t statistics, with the Rasch-built mISS (R-mISS) 
demonstrating a broader span than the Rasch-built NISs (R-NISs); R-mISS: 5.01 
logits vs. R-NISs: 3.85 logits. Construct validity (R2=0.72; p<0.0001) was good. 
However, explanatory validity was poor (mISS: 22% and NISs 18% of disability 
explained). Reliability aspects were good and comparable. Responsiveness values 
(ES and MCID-SE) were constantly higher for the (R-)mISS compared to the (R-)
NISs. 
Conclusion: The mISS and NISs were successfully transformed to interval scales 
with a linear construct using the Rasch model. Both scales demonstrated similar 
satisfactory clinimetric fi ndings. However, the R-mISS had a larger targeting 
range, less fl oor effect and seemed to have slightly better responsiveness scores 
than the R-NISs. Therefore, the use of the R-mISS is suggested for future studies 
in immune-mediated neuropathies.
Introduction 
Sensory defi cit may contribute to limitations in activity and participation in patients with 
immune-mediated neuropathies. The sensory subset of the neuropathy impairment 
score (NISs) and the Infl ammatory Neuropathy Cause and Treatment (INCAT) 
sensory sumscore (ISS) have been widely used to assess sensory defi cit in these 
conditions. Both scales have demonstrated good traditional scientifi c soundness, 
including responsiveness.1-4 However, it is unknown which scale is superior. 
At a workshop on outcome measures, both scales were criticised due to their 
apparent defi ciencies.5 The NISs embraces touch pressure, pinprick, joint position 
and vibration sense, but sensory defi cit is being assessed only distally at the index 
fi nger and great toe, hereby omitting proximal sensory disturbances.2, 3, 5 In addition, 
vibration sense is being assessed using a non-graduated 165 Hz tuning fork, hence not 
taking into account the possible graduation of this quality at bedside.6 Furthermore, 
assessment of two-point discrimination at the index fi nger is not incorporated in the 
NISs. 
The original ISS measures pinprick and vibration sense in the arms and legs 
from distal to proximal recording the highest extension of dysfunction, plus two-
point discrimination at the index fi nger.1 Joint position and light touch modalities 
however are not incorporated, making this scale less comprehensive and perhaps 
less responsive.5 Additionally the two-point discrimination categories were arbitrarily 
taken.7 Therefore, we created the modifi ed ISS (mISS) combining the apparent 
advantages of both scales. The modalities touch pressure and joint position were 
incorporated and proximal assessment was preserved. In addition, static two-point 
discrimination values were collected and graded as normal or abnormal based on 
age-related reference values now available (see also chapter 2.1).8 Still, the biggest 
disadvantage of both the NISs and the (m)ISS is that both scales are ordinal 
composite measures. The obtained scores are treated as if these were linear with 
all modalities having equal relevance, which is highly unlikely.9, 10 Therefore, we 
investigated whether the NISs and the mISS could be translated to interval scales 
showing the exact distance between patients’ ability levels and items’ diffi culty levels 
on a linear ruler using the Rasch method.11, 12 In addition, from the constructed interval 
measures, we compared clinimetric qualities with emphasis on responsiveness in 
order to determine whether one scale is superior to the other.4, 13
Methods
Patients
Cross-sectional group (for Rasch modelling, validity, and reliability studies)
Eighty patients (30 patients with Guillain-Barré syndrome (GBS), 30 with chronic 
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infl ammatory demyelinating polyradiculoneuropathy (CIDP), and 20 patients with 
monoclonal gammopathy of undetermined signifi cance related polyneuropathy 
(MGUSP), aged 18 years and older with a stable clinical condition were recruited 
for the purposes of the current study (recruitment period: July 2008 to November 
2010). A stable clinical condition was defi ned as an unchanged clinical functionality 
as declared by the patient to the best of his knowledge, plus (if applicable) no 
objective changes at neurological examination when compared with previous 
clinical fi ndings over two months before the start of the study. All patients were 
recruited from three university outpatient clinics in the Netherlands (Erasmus 
University Medical Centre of Rotterdam, University Medical Centre Utrecht and 
Maastricht University Medical Centre).
Longitudinal group (for Rasch modelling and responsiveness studies)
Eighty-two patients with newly diagnosed GBS (36), CIDP (35), or MGUSP (11) were 
enrolled. These patients are participants in the on-going international multi-centre 
longitudinal part of the Peripheral Neuropathy outcome measures Standardisation 
(PeriNomS) study in immune-mediated neuropathies (37 from the Netherlands, 18 
from the USA, 11 from Italy, 5 from Belgium, 4 from Canada, 2 from France, 2 from 
the United Kingdom, 1 from Spain, and 2 from Brazil). All patients with GBS, all but 
one of the patients with CIDP and fi ve of the 11 patients with MGUSP were treated 
according to standard regimens (e.g., with intravenous immunoglobulin, plasma 
exchange, corticosteroids, rituximab)
All patients with GBS and CIDP met the international criteria for their illness.14, 15 All 
patients with MGUSP had IgM anti-MAG antibodies, with demyelinating features in 
nerve conduction studies. The diagnosis of MGUSP was established after excluding 
all other possible causes for gammopathy and polyneuropathy.16
Outcome measures
• Neuropathy impairment score – sensory subset (NISs): The NISs was applied 
according to the published procedures and comprises touch pressure, pinprick, 
vibration sense and joint position.2, 3 In brief, touch pressure was assessed with 
long fi bre cotton wool, pinprick with straight pins and vibration sense with a 
non-graduated 165 Hz tuning fork on the dorsal surface of the terminal phalanx 
of the index fi nger and great toe on both sides. Joint position was assessed by 
moving the terminal phalanx of the index fi nger and great toe on both sides.2, 3 
Each modality was scored as being normal (0), decreased (1), or absent (2). The 
NISs ranges from 0 (no sensory defi cit) to 32 (most severe sensory defi cit).
• Modifi ed INCAT sensory sumscore (mISS): Based on recommendations given at 
a workshop on outcome measures in infl ammatory neuropathies, we modifi ed 
the original ISS.5 The mISS embraces light touch, pinprick, vibration sense, joint 
position and two-point discrimination assessment. Light touch and pinprick 
modalities were assessed using disposable cotton wools and pins. Vibration 
sense was assessed using a graduated 64 Hz Rydel Seiffer tuning fork and 
graded based on published normative values.6 Joint position was assessed in a 
standardised manner according to previous recommendations.17, 18 In addition, a 
static two-point discrimination value was collected using a sliding aesthesiometer. 
Two-point discrimination was assessed only at the right index fi nger, all other 
modalities were assessed from distal to proximal in the arms and legs, with only 
the most affected side being recorded.1 Modalities were graded as normal (grade 
0) or disturbed; at the index fi nger or hallux (grade 1); at the wrist or ankle (grade 
2), at the elbow or knee (grade 3), at shoulder or hip joint (grade 4). Two-point 
discrimination was graded as normal (grade 0) or disturbed (grade 1) based on 
age-dependent normative values.8 The mISS ranges from 0 (no sensory defi cit) 
to 33 (most severe sensory defi cit).
• Rasch-built overall disability scale (R-ODS): This scale is a 24-item interval measure 
specifi cally designed to capture activity limitations and participation restrictions 
in patients with GBS, CIDP, and MGUSP.19 The R-ODS summed raw scores range 
from 0 (most severe activity and social participation restriction) to 48 (no activity 
and social participation restrictions). Without missing data these raw scores 
can be translated to logits demonstrating the exact distance between patients’ 
ability levels on a linear scale, ranging from -6.95 (most severe activity and social 
participation restriction) to 8.11 (no activity and social participation restrictions) 
logits.
Study design
Medical ethics, patient consent and training
The local medical ethics committee of all participating centres approved the 
protocol. Written informed consent was obtained from each participant. All 
investigators participating in the international PeriNomS study (n=26) were trained 
in 2007 (by IM and SvN) at the Peripheral Nerve Society meeting (Utah, USA) 
aiming to standardise the assessment procedures for all scales as part of this study. 
In addition, participants received a comprehensive research manual that included 
a thorough description and pictures illustrating how to assess the various sensory 
modalities for the mISS. For the NISs, a video showing in practice how to measure 
the various entities was provided.
Examination schedule
All 80 cross-sectional patients were examined twice by the same investigator with 
an interval of 2-4 weeks, both times assessing the NISs, the mISS and the R-ODS. 
During one of those two visits a second investigator also assessed the NISs and 
the mISS for inter-rater reliability studies. For responsiveness analyses follow-up 
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records of 74 longitudinally studied patients (32 GBS, 33 CIDP and 9 MGUSP) 
were available. Patients with GBS and CIDP were investigated at entry, 1, 3, 6, and 
12 months of follow-up. Patients with MGUSP were examined at entry, 3, and 12 
months (see fi gure 1 for the study algorithm).
Figure 1. Study algorithm
Legend to fi gure 1. NISs = neuropathy impairment score - sensory subset. mISS = modifi ed INCAT 
sensory sumscore. First visit data of the cross-sectional and the longitudinal group (n=162) and 
the assessment fi ndings of the second visit of the cross-sectional sample (n=80) were stacked (162 
+ 80 = 242) to strengthen the Rasch model.
Statistical analyses - step 1: From ordinal to interval measures using Rasch
The NISs and mISS were subjected to Rasch analyses to determine whether model 
expectations would be met. The Rasch method including its expectations (e.g., 
proper fi t statistics, unidimensionality, no item bias or local dependency) has been 
described thoroughly elsewhere, also specifi cally for neurologists (see also chapter 
3.1).11, 12, 19 In brief, this statistical technique attempts to transform ordinal obtained 
scores that are scale dependent and of limited accuracy, into interval measures 
that are scale independent and suitably accurate for individual patient assessment. 
In essence, this method is based on a logical assumption: individuals that are 
clinically less affected should have an increased probability, relative to clinically 
more affected individuals, of getting a better score.11, 12, 19 First visit NISs and mISS 
data of the cross-sectional and the longitudinal group (n=162) and second visit data 
of the cross-sectional sample (n=80) were stacked (162 + 80 = 242) to strengthen 
the Rasch model, hereby controlling for ‘time factor’ as possible confounder and 
fulfi lling the minimum requirement for scale stability.20, 21 Personal factors like age, 
gender, illness, and country were collected. For the purposes of the current study, 
these factors were categorised as follows: age (<50 years vs. 50-59 years vs. 60-69 
years vs. ≥70 years), gender (female vs. male), illness (GBS vs. CIDP vs. MGUSP), 
and country (the Netherlands vs. others). Age was categorised as such striving for 
an equivalent distribution of participants per subgroup. Analyses were performed 
to obtain an interval scale for both sensory measures separately. Attempts were 
made to maintain the structures of the NISs and mISS while meeting the Rasch 
model expectations.
Statistical analyses - step 2: Clinimetric comparison of the NISs and the mISS
Validity and reliability studies
Construct convergent validity was obtained by correlating the scores of the 
obtained interval measures, the Rasch-built NISs (R-NISs) and the Rasch-built 
mISS (R-mISS), using quantile regression with restricted cubic spline function to 
overcome possible non-Gaussian distribution of the data.22, 23 Explanatory validity 
(sensory defi cit explaining disability) was determined by correlating both the R-NISs 
and the R-mISS scores with the fi rst visit R-ODS scores in both patient groups. 
Internal reliability was examined by determining the Person Separation Index 
(PSI) for each of the interval sensory scales, separately. In general, a PSI above 
0.7 is considered acceptable, indicating the ability to identify at least two groups 
of patients.24 In addition, reliability studies were performed comparing the fi rst 
and second assessment data of the cross-sectional sample to investigate whether 
hierarchy of patients’ ability locations were consistent over time.25 Validity and 
reliability were quantifi ed by calculation of the intra-class correlation coeffi cient 
using a one-way random effects analysis of variance (ANOVA) model. 
Responsiveness studies
Traditional responsiveness at group level was calculated using the effect size (ES) 
indicator at 1, 3, 6 and 12 months of follow-up using the traditional sumscore values 
for both sensory scales. The ES is equal to the mean change in score divided by 
the standard deviation of the scores at entry (ES=μi-μo/SD
entry
; μi = mean NISs 
or mISS sumscore of the longitudinally studied group at month = i; μo = mean 
NISs or mISS sumscore at entry).26 According to Cohen’s rule of thumb, an effect 
size value between 0.5 and 0.8 is considered moderate, and ≥ 0.8 represents 
high responsiveness.27 The Rasch method demonstrates that the error around an 
individual personal score (standard error (SE)) may vary across the theoretical 
range of an outcome measure, and with this also the signifi cance of individual 
changes (see also fi gure 2).28 Therefore, responsiveness at the individual-person-level 
was calculated and referred to as minimum clinically important difference-standard 
error (MCID-SE) score based on the previously described signifi cant change 
NIS s  vers us  mIS S  s tudy
For:
Rasch modelling,
validity & reliability studies
For: 
Responsiveness studies
Mixed population (n=162):
GBS 66, CIDP 65, MGUSP 31
Longitudinal group (n=74):
GBS 32, CIDP 33, MGUSP 9
Cross-sectional group 
1st researcher
n=80 assessed twice
Cross-sectional group
2nd researcher
n=80
Longitudinal 
group
n=82
For: Rasch
modelling
and validity studies
For: 95th confidence 
interval reliability 
studies
Effect size
Traditional responsiveness 
calculations 
MCID-SE
Individual-person-level 
responsiveness calculations
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(SigChange) score.29 In brief, MCID-SE scores were calculated by computing for 
each of the 74 longitudinally studied patients separately: a) their individual change 
(person location at i month minus person location at entry; where i = 1, 3, 6, or 
12 months of follow-up for patients with GBS and CIDP and i = 3 or 12 months 
for patients with MGUSP), and, b) the corresponding SE of difference related to 
their locations at entry and at i months (SE
diff 
= square-root (SE
entry
2+SE
i month
2), 
and c) the fi nal MCID-SE calculations by dividing the individual change scores by 
corresponding SE
diff
 (MCID-SE = individual change/SE
diff 
).29 Since the changes in 
sensory defi cits tend to be small in these disorders, we have arbitrarily defi ned the 
minimum clinically important difference (MCID) cut-off using a change of at least 1 
SE (69%CI).30-32 Accordingly, the obtained MCID-SE scores were classifi ed into the 
following subgroups: 
• subgroup 1 (clinically important deterioration): MCID-SE ≥ 1; 
• subgroup 2 (clinically unimportant deterioration): 0 < MCID-SE < 1; 
• subgroup 3 (no change): MCID-SE = 0; 
• subgroup 4 (clinically unimportant improvement): -1 < MCID-SE < 0; 
• subgroup 5 (clinically important improvement): MCID-SE ≤ -1 
The distribution of MCID-SE subgroups among the longitudinally studied patients 
for both sensory measures was compared using chi square statistics. 
Figure 2. Graph showing the changing standard error with changing patients’ ability 
locations on the sensory metrics 
Legend to fi gure 2. A ‘U’-shape pattern is shown indicating that the standard error changes with 
the changing patients’ ability locations on the theoretical range of the R- mISS or the R-NISs. 
R- mISS = Rasch-built modifi ed INCAT sensory sumscore, R-NISs = Rasch-built sensory subset of 
the neuropathy impairment score.
Statistics and software
Rasch analyses were performed with the partial credit model as default (RUMM2030). 
Further statistical analyses were undertaken using Stata 11.0 for Windows XP. The 
p-value was adjusted throughout the analyses, based on Bonferroni multiple test-
ing corrections.33
Results
General aspects
The general characteristics of participants are presented in table 1. 
Table 1. General characteristics of participants
Cross-sectional group
(for Rasch modelling, validity 
and reliability studies)
Longitudinal group 
(for Rasch modelling and 
responsiveness studies)
Number of patients 80 82
Age (years); mean (SD), range 62 (10), 26-81 55 (16), 18-90
Gender; n (%)
female
male
29 (36)
51 (64)
25 (31)
57 (70)
Diagnosis; n (%)
GBS
CIDP
MGUSP
30 (38)
30 (38)
20 (25)
36 (44)
35 (43)
11(13)
R-ODS (logits); mean (SD), range 3.04 (2.13), -2.79-6.55 -.61 (3.47), -6.95-5.71
Country of assessment; n (%)
the Netherlands
USA
Italy
Belgium
Canada
France
UK
Spain
80 (100) 34 (46)
17 (23)
10 (14)
5 (7)
4 (5)
2 (3)
1 (1)
1 (1)
Step 1: From ordinal to interval measures using Rasch
Initial Rasch analyses on the sensory measures
Misfi t to the Rasch model was demonstrated for both sensory measures (table 2, 
Initial analysis). The person fi t residuals showed acceptable fi t statistics, whereas 
the obtained scores (particularly the SD) for the item fi t residuals deviated from the 
expected value of 1 (mISS: SD 1.697, NISs: 1.501). The signifi cant chi square probability 
for both measures demonstrated no invariance of items. A substantial proportion 
of the t-tests performed fell outside the ± 1.96 range, indicating multidimensionality 
(table 2).
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Data handling to fi t the Rasch model
Throughout the analyses, we continuously monitored the distribution of persons 
within the class intervals, the overall fi t statistics and the independent tests for 
unidimensionality. The aim was to modify the data of each scale to fulfi l model 
requirements maintaining the structure of the original scale. The ‘time factor’ 
introduced because of stacking the data was not a confounding factor for both 
sensory measures.
• NISs: All eight sensory modality pairs (e.g., vibration sense on the left and the 
right great toe, joint position on the left and right index fi nger) demonstrated a 
strong local dependency (ρ>0.696-0.924). Subsequently, eight subsets of items 
were created combining left and right scores of each modality. Touch pressure 
and pinprick still demonstrated local dependency for the fi ngers as well as the 
toes. Based on these fi ndings and the anatomical distribution of the sensory 
modalities, a second round of subsets was created combining touch pressure 
with pinprick and vibration sense with joint position creating 4 subsets (vital 
sense fi nger, proprioceptive sense fi nger, vital sense toe, proprioceptive sense 
toe). After this, model expectations were met, refl ected by good fi t statistics, no 
local dependency and unidimensionality (table 2, fi nal analysis). There was one 
uniform item bias (on personal factor age category for vital sense in the legs), 
which was accepted in order to maintain the internal structure of the NISs. A 
total of 9.9% of the patients (24/242) demonstrated a fl oor effect and 0.8% had 
a ceiling effect (2/242). The R-NISs ranged from -1.76 to 2.09 (3.85) logits. 
• mISS: Similar to the NISs, correlations were seen between the vital modalities 
in the arms and legs, separately. Therefore, similar subsets were created also 
incorporating two-point discrimination into the subset proprioceptive sense arms. 
After this, the R-mISS fulfi lled the Rasch model requirements and was free of item 
bias and local dependency, and demonstrated good unidimensionality (table 2, 
fi nal analyses). A total of 8.7% (21/242) of the patients demonstrated a fl oor effect. 
No ceiling effect was seen. The R-mISS ranged from -2.43 to 2.58 (5.01) logits.
Step 2 - Clinimetric comparison of the NISs and mISS
Validity and reliability studies
The R-NISs and R-mISS demonstrated good correlation with each other (construct 
validity: R2=0.72; p<0.0001). However, explanatory validity (sensory defi cits 
explaining disability as measured with the R-ODS through variance studies) was 
poor: the NISs explained 18% of the disability fi ndings; for the mISS this was 
slightly higher (22%). Good person separation indices (PSI) were obtained for 
both sensory measures (table 2, fi nal analyses). The test-retest reliability of items’ 
diffi culty locations was good (NISs: R2=0.9; mISS: R2=0.94). Also, patients’ ability 
locations were almost always within the 95% confi dence interval lines, refl ecting 
acceptable test-retest reliability (fi gure 3).
Table 2. Summary statistics of Rasch analyses, for (A) the mISS and (B) the NISs
A. modifi ed INCAT sensory sumscore
Rasch 
analyses
Item Fit 
Residuals
Person Fit 
Residuals
Item-trait 
Chi-square 
interaction
PSI Unidimensionality
indep. t-test 
(95%-CI)
Mean SD Mean SD DF p-value
Initial 0.209 1.697 -0.318 1.037 27 0.00001 0.87 0.10 (0.07-0.12)
Final 0.209 0.671 -0.393 0.940 12 0.383 0.80 0.03 (0.003-0.06)
B. Neuropathy impairment score – sensory subset
Rasch 
analyses
Item Fit 
Residuals
Person Fit 
Residuals
Item-trait 
Chi-square 
interaction
PSI Unidimensionality
Indep. t-test 
(95%-CI)
Mean SD Mean SD DF p-value
Initial -0.456 1.501 -0.361 0.949 48 0.000006 0.94 0.20 (0.18-0.23)
Final 0.113 1.175 -0.237 0.795 12 0.053 0.84 0.03 (0.003-0.06)
Legend to table 2. CI = confi dence interval, DF = degrees of freedom, PSI = person separation 
index, SD = standard deviation. 
Figure 3. Test-retest reliability of patients’ ability locations for the Rasch-built NISs and 
Rasch-built mISS
       Rasch-built modifi ed INCAT sensory sumscore     Rasch-built neuropathy impairment sensory score 
                  (R-mISS)                  (R-NISs)
Legend to fi gure 3. Patients’ ability locations in the fi rst visit versus the second visit. Almost all 
persons (dots) were located within the 95% confi dence interval (solid lines). 
-4 -2 0 2 4
-4
-2
0
2
4
P atients ' location (logits )
P
a
t
i
e
n
t
s
'
 
l
o
c
a
t
i
o
n
 
(
l
o
g
i
t
s
)
2
n
d
 
a
s
s
e
s
s
m
e
n
t
1s t as s es s ment
-4 -2 0 2 4
-4
-2
0
2
4
P atients ' location (logits )
P
a
t
i
e
n
t
s
'
 
l
o
c
a
t
i
o
n
 
(
l
o
g
i
t
s
)
2
n
d
 
a
s
s
e
s
s
m
e
n
t
1s t as s es s ment
R2=0.74 R2=0.70
192 193
SENSORY SUBSET OF THE NEUROPATHY IMPAIRMENT SCORE VERSUS THE MODIFIED INCAT SENSORY SUMSCORECHAPTER 4.2
Chapter
4.2
Responsiveness studies
Traditional responsiveness scores using the effect size (ES) varied from poor to 
moderate for both scales. Slightly better responsiveness scores were seen for the 
mISS (fi gure 4A). The responsiveness calculation at the individual-person-level, 
taking the changing standard errors into account (see also fi gure 2), demonstrated 
higher percentages of patients with clinically important improvement on the Rasch-
built mISS, especially during the fi rst months of follow-up (fi gure 4B). Compared 
to the Rasch-built NISs also more patients with clinically important deterioration 
were seen on the Rasch-transformed mISS during the fi rst month (table 3). The 
differences were however not signifi cant.
Figure 4. Responsiveness fi ndings (fi gure 4A. effect size and fi gure 4B. MCID-SE) in 
longitudinally studied patients with GBS, CIDP and MGUSP
Legend to fi gure 4. (B) *patients with MCID-SE<=1 correspond to subgroup 5 (clinically important 
improvement) 
Table 3. Percentages of longitudinally studied patients per subgroup for the R-NISs and 
the R-mISS, categorised based on their MCID-SE cut-off values during follow-up 
Rasch-built NISs Rasch-built mISS
Subgroup classifi cation
% of longitudinal studied 
patients 
during follow-up (months)
% of longitudinal studied 
patients 
during follow-up (months)
1 3 6 12 1 3 6 12 
1 = clinically important 
deterioration
(MCID-SE ≥1)
8.1% 6.7% 3.9% 6.3% 8.1% 1.6% 2.0% 3.1%
2 = clinically unimportant 
deterioration
(0 < MCID-SE < 1)
14.5% 8.3% 11.8% 3.1% 14.5% 21.7% 7.8% 0.0
3 = no change
(MCID-SE = 0)
21.0% 11.7% 9.8% 12.5% 16.1% 10.0% 13.7% 15.7
4 = clinically unimportant 
improvement
(-1 < MCID-SE < 0)
37.1% 48.3% 39.2% 46.9% 37.1% 31.7% 39.2% 50.0
5 = clinically important 
improvement
(MCID-SE ≤ -1)
19.3% 25.0% 35.3% 31.2% 24.2% 35.0% 37.3% 31.2
Legend to table 3. MCID-SE = minimum clinically important difference-standard error. The MCID-
SE refers to individual-person level responsiveness calculated by individual change divided by their 
corresponding SE of difference (related to their locations at entry and at i months where i = 1, 3, 
6, or 12 months of follow-up for patients with GBS and CIDP and i = 3 or 12 months for patients 
with MGUSP). 
Note: A negative MCID-SE score corresponds to an improvement, since the original sensory 
scales range from 0 (no defi cit) to 32 and 33 (maximum sensory defi cit), for the NISs and mISS 
respectively.
Discussion
This study compared two widely used composite sensory scales in patients with 
immune-mediated neuropathies, the NISs and the mISS.1-3 First, both scales were 
subjected to Rasch analyses which demonstrated that the whole may not equal the 
sum of the parts for the NISs and mISS as ordinal composite measures.10 Both scales 
did not meet the Rasch model expectations showing in particular local dependency 
between the various sensory modalities. After creating subsets acceptable model 
fulfi lment was obtained for the mISS and the NISs, hereby constructing two sensory 
interval measures.
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Secondly, both scales were compared regarding their clinimetric properties. At 
fi rst glance, the two constructed sensory interval measures demonstrated similar 
clinimetric properties, despite the differences regarding location of assessment 
(NISs measuring only at the index fi nger and great toe; in contrast, mISS capturing 
sensory defi cit up to the shoulders and hips). However, targeting of the R-mISS was 
better, with a larger span (5.01 logits) when compared to the span of the R-NISs 
(3.85 logits). This probably explains the lower fl oor effect and no ceiling effect for the 
R-mISS. In addition, the responsiveness calculations, both effect size and MCID-
SE, were in favour of the (R-)mISS. Its responsiveness scores were generally higher 
throughout the follow-up period and captured clinically important improvement 
and clinically important deterioration faster (fi gure 4 and table 3). Apparently, the 
(R-)mISS had a higher ability to capture clinically important changes in patients 
with GBS, CIDP, and MGUSP. Based on these observations, a preference may be 
given to the use of the Rasch-built mISS. 
The Rasch method demonstrated the varying standard errors across the theoretical 
range of the interval sensory measures, and with this also the signifi cance and 
direction of clinically important changes in patients with different ability levels 
(Table 3).28, 29 These fi ndings are in contrast with traditional methods, stating that 
the measurement error around a patient is a constant value.29 The Rasch method 
enabled the use of individual standard errors based on patient ability levels. However, 
we arbitrarily defi ned a change of 1xSE a minimum clinically important difference 
(MCID), thereby accepting that some change due to measurement error might 
be attributed to clinically important change. A higher cut-off value, like 1.96xSE, 
reduces the percentage of patients categorised as being a responder, but more 
importantly defi nes small changes as clinically unimportant which is arguable.
In conclusion, we succeeded in constructing interval measures for the NISs 
and the mISS in patients with GBS, CIDP and MGUSP by subjecting both ordinal 
sensory scales to Rasch analyses. Despite the apparent similarity, the clinimetric 
comparative studies were in favour of the R-mISS. This scale demonstrated a larger 
targeting range, less fl oor effect, and seems to have better responsiveness scores. 
Therefore, the use of the Rasch-built mISS is suggested, as part of the fi nal aim of 
the PeriNomS study, to standardise outcome measures applied in future clinical 
trials and observational studies in patients with GBS, CIDP, and MGUSP. 
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The concept of minimum clinically 
important difference (MCID): general aspects
One of the most important aspects of evaluating treatment effect is to defi ne 
whether a change in clinical condition is relevant or not. Trial results are often 
based on statistical signifi cant differences between the change scores of a treatment 
group and a control group. A difference may be statistically signifi cant, in other 
words not based on chance or error alone, however whether this implies a clinically 
relevant change is questionable. Relevant change is captured in the terminology 
‘minimum clinically important difference (MCID)’.1-3 The concept of MCID was 
defi ned by Jaeschke as being the smallest difference in score in the domain of 
interest which patients perceive as benefi cial and which would mandate, in the 
absence of troublesome side effects and excessive cost, a change in the patient’s 
management.2
Although several parties will recognise the need and share an interest in determining 
MCID thresholds it is not a simple concept, nor simple to calculate. No fi xed 
method to establish MCIDs is available.4 In general, the available methods can be 
categorised as distribution-based or anchor-based. Distribution-based approaches 
are built upon measures of variablity of the obtained scores, like the standard 
deviation (SD), the standard error of measurement (SEM), the smallest detectable 
change (SDD) of effect size (ES). In contrast, anchor-based approaches compare 
the obtained scores with an external criterion, like a global assessment rating in 
which patient rate themselves as better, stable or worse. 
The concept of MCID has hardly been addressed in immune-mediated neuropathy 
studies. In chapter 5.2 data of the ICE trial (placebo versus IVIg in CIDP) were 
used to illustrate various MCID methods to determine a responder, thereby shifting 
from statistical signifi cant differences to clinically relevant differences. Chapter 5.3 
highlights the use of variable individual standard errors as derived from Rasch-built 
interval outcome measures as possible MCID method for effi cacy and maintenance 
trials in immune-mediated neuropathies.
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Abstract
Background: The ICE trial demonstrated the effi cacy of immune globulin intravenous 
(IGIV-C: Gamunex®) over placebo in chronic infl ammatory demyelinating 
polyradiculoneuropathy (CIDP). However, improving the interpretability of the 
results by analysing the minimum clinically important difference (MCID) had not 
been considered.
Objectives: To identify MCID thresholds of various outcome measures using 
different methods and to test treatment differences (IGIV-C vs. placebo) using 
these thresholds. 
Methods: One anchor-based (Short Form-36 question 2) and three distribution-
based (1/2 standard deviation, 1 standard error of measurement, and effect size) 
techniques were employed to identify MCID cut-offs for various impairments 
(electromyographic parameters, Medical Research Council [MRC] sumscore, 
grip strength, Infl ammatory Neuropathy Cause and Treatment [INCAT] sensory 
sumscore), disability (INCAT disability scale score, Rotterdam handicap scale 
[RHS] score), and quality of life (SF-36). IGIV-C or placebo was administered 
every 3 weeks for up to 24 weeks to 117 CIDP patients. Patients who did not 
improve by ≥1 point on the INCAT disability scale received alternate treatment. 
The proportion of patients with results exceeding identifi ed MCID thresholds 
was compared. 
Results: MCID cut-offs for outcomes were determined using each method. For 
the INCAT disability scale (primary ICE-trial outcome), all MCID methods 
identifi ed signifi cantly more responders with IGIV-C than placebo. Signifi cant 
differences favouring IGIV-C were also demonstrated for various nerve 
conduction parameters, MRC sumscore, grip strength, RHS score, and SF-36 
physical component summary score.
Conclusion: In addition to being statistically signifi cant, all MCID analyses showed 
that CIDP improvements with IGIV-C are clinically meaningful. Consideration 
of MCID is recommended in future therapeutic trials.
Introduction
Chronic infl ammatory demyelinating polyradiculoneuropathy (CIDP) is characterised 
by a clinical course that may show either a continuous or stepwise progression or 
may have a more fl uctuating pattern over months to years.1, 2 Patients with CIDP 
often have a predominantly symmetrical distal weakness and sensory defi cits that 
may lead to considerable long-term disability with decrement in health-related 
quality of life expectations.1-4 
Recently, the IGIV-C CIDP effi cacy trial (ICE trial), the largest randomised clinical 
trial of any agent for the treatment of CIDP ever performed, demonstrated the 
effi cacy and safety of immune globulin intravenous, 10% caprylate/chromatography 
purifi ed (IGIV-C).4 Signifi cant statistical differences in favour of IGIV-C were 
observed when comparing the results obtained with the Infl ammatory Neuropathy 
Cause and Treatment (INCAT) disability scale as well as other outcome measures. 
However, despite these robust fi ndings, no clinical trial in CIDP had ever examined 
whether the statistically signifi cant results refl ect clinically relevant changes for 
patients. Minimum clinically important difference (MCID) has been advanced as 
a concept that could enhance the interpretability of results of clinical studies and 
overcome the shortcomings of the ‘statistically signifi cant difference’.5, 6 Jaeschke 
and associates fi rst defi ned MCID as being ‘the smallest difference in score in the 
domain of interest which patients perceive as benefi cial and which would mandate, 
in the absence of troublesome side effects and excessive cost, a change in the 
patient’s management’.7 Despite this seemingly clear defi nition, the MCID concept 
has been criticised because of diffi culties with its calculation and because different 
methods produce different MCID values.8 A number of techniques have been used 
to address these issues.5, 6, 8 
The current study systematically addresses, for the fi rst time in any neurological 
condition, the concept of MCID in a wide variety of outcome measures that capture 
disease progression in CIDP. Data were analysed from the ICE trial data to discover 
whether MCID techniques capture the effi cacy of IGIV-C compared with placebo 
during up to 24 weeks of therapy.
Methods
Patients and study design
Complete details of the patient population and the randomised, double-blind, placebo-
controlled, response-conditional study design and methodology are described in 
the publication of the primary effi cacy analysis.4 Eligible patients developed CIDP, 
progressive or relapsing motor and sensory dysfunction resulting from neuropathy 
over at least 2 months before study entry, and clinical disability as defi ned by an 
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overall INCAT disability score of 2-9.9 Eligible patients were randomised to receive 
either IGIV-C (Gamunex®, Talecris Biotherapeutics, Inc, Research Triangle Park, 
North Carolina, USA) or placebo (0.1% albumin). Patients received a baseline loading 
dose of 2 g/kg and then a maintenance infusion of 1 g/kg every 3 weeks for up to 
24 weeks. The selected outcome measures applied in the ICE study were based 
on various consensus meetings addressing standardisation of outcome measures 
in immune-mediated neuropathies; the WHO’s International Classifi cation of 
Functioning, Disability, and Health (ICF); and the quality of life concept.10-13 All 
selected measures had demonstrated acceptable interpretability, good validity, 
reliability, and responsive values in patients with CIDP, and scales used in the ICE 
study were applied in a standardised fashion.14 For the purpose of the current study, 
analyses were performed using the fi rst-period data (up to 24 weeks) based on the 
intention-to-treat principle.
MCID determination
Because there is no global consensus on which technique is optimal for calculating 
MCID, this study employed four methods for quantitatively determining MCID, 
using either patient perception or mathematical modelling to calculate an MCID 
threshold value.6, 8 One of the methods included in this study, an anchor-based 
method, compares changes in scale scores with those of another measurement or 
phenomenon that has known clinical relevance (e.g., patient perception of a clinical 
change after therapy). Three other techniques for calculating MCID, distribution-
based methods, are determined from the statistical characteristics of the scores 
obtained (e.g., effect size).5, 6, 8 The various threshold MCID values were then applied 
to assess the clinical importance of changes in outcome data from the fi rst period 
of the ICE study. A goal of the study was to determine whether the selected MCID 
techniques would consistently rank all the scales used in favour of the IGIV-C group 
compared with the placebo group.
Anchor-based method
The global change of health assessment used the answers to Short Form-36 
(Medical Outcomes Trust, Boston, MA, USA) question number 2 in which patients 
were asked to compare their global health rating at entry and at the end of the fi rst 
period (week 24 receiving IGIV-C or placebo in a blinded fashion) versus 1 year 
ago.15 This question is not used in scoring the domains and summary measure of 
the SF-36. This question asked patients to compare their current health to their 
health 1 year ago. Patient response options were ‘much better’, ’somewhat better’, 
‘about the same’, ‘somewhat worse’, or ‘much better’ now compared with 1 year 
ago. Various MCID techniques have been applied using the response options of 
the SF-36 question number 2.16, 17 The MCID for the current study was based on a 
widely used approach and was determined as the mean score difference between 
the response options ‘somewhat better now than 1 year ago’ and ‘about the same as 
1 year ago’.17, 18 Separately for both the IGIV-C and placebo groups, the patients were 
classifi ed into two subgroups depending on whether their change in health score 
from baseline visit to week 24 was 1 (corresponding to relevant improvement) or 0 
(corresponding to no improvement).
Distribution-based methods
The one-half standard deviation (1/2 SD) benchmark of an outcome measure has 
been proposed as the ‘unifying theory’ for assessing the MCID and has gained 
support in the literature.6, 19-21 The SD for all outcome measures is based on their 
theoretical range. For example, the theoretical range for the grip strength, using 
the Vigorimeter (Martin, Tuttlingen, Germany), was based on available normative 
data.22 
The standard error of measurement (SEM) was used to evaluate the intraindividual 
changes in selected outcome measures in both patient groups.23 The SEM is 
equivalent to the SD of a scale multiplied by the square root of 1 minus its reliability 
coeffi cient (Cronbach’s α). A change of 1 SEM has empirically been found to 
correspond with the original MCID criterion of an outcome measure.23, 24 For each 
scale, the Cronbach α was calculated using only the placebo group with the repeat 
measurements at the baseline and at week 24 or the last measurement of the fi rst 
period.
The effect size is the mean change in scores divided by the SD of the baseline 
scores. In the current study for the fi rst period, the equation was: effect size = 
(μ
24
 - μ
0
)/SDμ
0
, where μ
24
 = mean scale value at week 24 or the last visit of the 
fi rst period and μ
0
 = mean scale value at baseline.25 The effect size was calculated 
for both the IGIV-C and placebo groups. An effect size of 0.5 was considered an 
appropriate defi nition of MCID and was used in the current study.6, 26
Applying calculated MCID values
The MCID cut-off values were determined for each outcome measure applied 
in the ICE study based on all four MCID techniques. A patient was defi ned as a 
responder for a particular scale if the clinical condition of the patient improved 
enough to reach the MCID threshold for that scale. The percentage of patients in 
each treatment group was then calculated for those who reached the predefi ned 
MCID thresholds at the end of the fi rst period, and the percentages were compared 
between the groups (Fisher exact two-tailed test). A p-value <0.05 was considered 
statistically signifi cant. SAS version 8.2 was used for all statistical analyses (SAS 
institute, Cary, North Carolina, USA).
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Results
During the fi rst period of the ICE study, 117 individuals were randomised; 59 
patients received IGIV-C and 58 patients received placebo.4 Baseline values for 
the impairment measures (electromyographic parameters, Medical Research 
Council [MRC] sumscore, grip strength, and Infl ammatory Neuropathy Cause 
and Treatment [INCAT] sensory sumscore), activity and participation scale scores 
(INCAT disability scale score and Rotterdam handicap scale [RHS] score), and 
quality of life component measures (SF-36 physical component score [PCS] and 
SF-36 mental component score [MCS]) were similar between the two treatment 
groups.3, 4, 27
MCID calculations
Determination of MCID was calculated using four methods, an anchor-based 
approach (SF-36, question 2) and three distribution-based approaches (1/2 SD, 
1 SEM, and effect size). The calculated MCID cut-off scores of all measures for 
the anchor-based, 1/2-SD, and 1 SEM methods are shown in table 1. To strive for 
uniformity, the mean MCID for the grip strength of dominant and non-dominant 
hands was calculated and applied to both hands. As indicated in the methods, the 
fourth technique of identifying an effect size of 0.5 as a cut-off value for MCID was 
also applied. 
Applying MCID calculations to the ICE study
Anchor-based MCID method
All outcome measures except the MCS scores demonstrated higher percentages 
of improved values for the IGIV-C–treated patients compared with the placebo 
group when using the SF-36 question number 2 as the anchor (table 2). The INCAT 
disability score (the primary endpoint of the ICE study) showed a statistically 
signifi cant difference in the percentage of patients reaching the MCID cut-off 
values in favour of the IGIV-C group. Signifi cant differences in favour of IGIV-C 
were also observed for changes in average amplitude for all motor nerves, average 
conduction velocity for all motor nerves, percentage changes in conduction block, 
grip strength (non-dominant hand), MRC sumscore, and RHS score (table 2). A 
consistent trend in favour of IGIV-C was also observed for all outcome measures 
using the MCID cut-off values determined by 1/2 SD and 1 SEM methods (table 2). 
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Table 2. Responder analyses defi ned by the MCID cut-off values for anchor-based, 
1/2-SD, and 1 SEM techniques for the IGIV-C and placebo groups of patients with CIDP 
(fi rst period of the ICE study)
Parameter MCID
MCID 
cut-off
Responders IGIV-C: 
placebo,*
n (%)
Percentage of 
responders, IGIV-C 
minus placebo 
(95% CI)
p-value†
CMAP of most severely 
affected motor nerve, mV 
   Anchor based
   1/2 SD
   1 SEM
0.42
0.86
0.83
23 (39.0): 21 (36.2)
19 (32.2): 13 (22.4)
19 (32.2): 13 (22.4)
2.8 (-16.5, 22.0)
9.8 (-0.8, 27.5)
9.8 (-0.8, 27.5)
0.849
0.301
0.301
Average CMAP for all 
motor nerves, mV 
   Anchor based
   1/2 SD
   1 SEM
0.92
1.15
0.73
21 (35.6): 9 (15.5)
17 (28.8): 7 (12.1)
  26 (44.1): 12 (20.7)
20.1 (3.0, 37.2)
16.7 (0.8. 32.7)
23.4 (5.3, 41.5)
0.019
0.038
0.010
Average velocity for all 
motor nerves, m/s
   Anchor based
   1/2 SD
   1 SEM
2.21
5.58
2.23
24 (40.7): 8 (13.8)
    17 (28.8): 4 (6.9)
    24 (40.7): 8 (13.8)
26.9 (9.8, 44.0)
21.9 (6.9, 36.9)
26.9 (9.8, 44.0)
0.002
0.003
0.002
Conduction block, %
   Anchor based
   1/2 SD
   1 SEM
3.07
10.76
6.46
     30 (50.8): 17 (29.3)
17 (28.8): 5 (8.6)
     23 (39.0): 14 (24.1)
21.5 (2.5, 40.6)
20.2 (4.9, 35.5)
14.8 (-3.5, 33.2)
0.024
0.008
0.112
MRC sumscore 
   Anchor based
   1/2 SD
   1 SEM
3.6
3.53
2
25 (42.4): 6 (10.3)
25 (42.4): 6 (10.3)
  35 (59.3): 14 (24.1)
32.0 (15.5, 48.6)
32.0 (15.5, 48.6)
35.2 (16.8, 53.6)
<0.001
<0.001
<0.001
Grip strength-dominant 
hand, kPa‡
   Anchor based
   1/2 SD
   1 SEM
14
8
7.78
21 (36.2): 12 (20.7)
29 (50.0): 15 (25.9)
29 (50.0): 15 (25.9)
15.5 (-2.4, 33.4)
24.1 (5.3, 43.0)
24.1 (5.3, 43.0)
0.100
0.012
0.012
Grip strength-non-
dominant hand, kPa‡
   Anchor based
   1/2 SD
   1 SEM
14
8
6.78
23 (39.7): 11 (19.0)
30 (51.7): 20 (34.5)
31 (53.4): 22 (37.9)
20.7 (2.8, 38.5)
17.2 (-2.2, 36.7)
15.5 (-4.1, 35.2)
0.025
0.091
0.136
INCAT sensory sumscore 
   Anchor based
   1/2 SD
   1 SEM
0.9
2.43
2.12
26 (44.1): 20 (34.5)
18 (30.5): 9 (15.5)
18 (30.5): 9 (15.5)
9.6 (-9.7, 28.9)
15.0 (-1.7, 31.7)
15.0 (-1.7, 31.7)
0.345
0.078
0.078
Parameter MCID
MCID 
cut-off
Responders IGIV-C: 
placebo,*
n (%)
Percentage of 
responders, IGIV-C 
minus placebo 
(95% CI)
p-value†
INCAT disability score
   Anchor based
   1/2 SD
   1 SEM
0.6
0.72
0.64
31 (52.5): 13 (22.4)
31 (52.5): 13 (22.4)
31 (52.5): 13 (22.4)
30.1 (11.8, 48.5)
30.1 (11.8, 48.5)
30.1 (11.8, 48.5)
0.001
0.001
0.001
Rotterdam handicap 
scale score 
   Anchor based
   1/2 SD
   1 SEM
3.4
3.41
2.89
21 (35.6): 8 (13.8)
21 (35.6): 8 (13.8)
27 (45.8): 11 (19.0)
21.8 (5.0, 38.6)
21.8 (5.0, 38.6)
26.8 (8.9, 44.7)
0.010
0.010
0.003
SF-36 mental component 
score
   Anchor based
   1/2 SD
   1 SEM
4.13
5.91
6.69
18 (30.5): 19 (32.8)
16 (27.1): 17 (29.3)
16 (27.1): 13 (22.4)
-2.3 (-20.8, 16.3)
-2.2 (-20.2, 15.8)
4.7 (-12.6, 22.0)
0.844
0.839
0.669
SF-36 physical 
component score 
   Anchor based
   1/2 SD
   1 SEM
8.87
4.14
5.1
18 (30.5): 11 (19.0)
22 (37.3): 15 (25.9)
21 (35.6): 14 (24.1)
11.5 (-5.7, 28.7)
11.4 (-7.0, 29.8)
11.5 (-6.7, 29.6)
0.199
0.234
0.226
Legend to table 2. *59 and 58 patients received IGIV-C and placebo, respectively. †Difference in 
percentage of patients in both groups (IGIV-C and placebo) reaching the MCID cut-off values were 
examined using Fisher exact test. ‡Mean values for both hands were taken for uniformity. Values 
that are signifi cantly different versus placebo are shown in bold text. CI = confi dence interval; 
CIDP = chronic infl ammatory demyelinating polyradiculoneuropathy; CMAP = compound muscle 
action potential; ICE = IGIV-C CIDP effi cacy trial; IGIV-C = immune globulin intravenous, 10% 
caprylate/chromatography purifi ed; INCAT = Infl ammatory Neuropathy Cause and Treatment; 
MCID = minimum clinically important difference; MRC = Medical Research Council; SD = standard 
deviation; SEM = standard error of measurement, SF-36 = Short form-36 health survey.
Distribution-based MCID methods
In the 1/2 SD method, signifi cant differences were obtained in favour of the IGIV-C 
group for the nerve conduction parameters, improvement in the average CMAP 
amplitude for all motor nerves, average conduction velocity for all motor nerves, and 
reduction in percentage of conduction block (table 2). More patients in the IGIV-C 
group reached the MCID cut-off values for the MRC sumscore and dominant hand 
grip strength (p≤0.012). Applying the MCID cut-off value obtained for the INCAT 
disability scale using the 1/2 SD method demonstrated that a substantially higher 
percentage of patients in the IGIV-C group reached the MCID threshold (52.2% vs. 
Table 2. Continued
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22.4% in IGIV-C and placebo groups, respectively; p=0.001). A signifi cant difference 
in favour of the IGIV-C group was also seen for the MCID fi ndings for RHS score.
An almost similar pattern was seen using the 1 SEM method to determine 
the MCID thresholds for the applied outcome measures (table 2). A substantial 
signifi cant difference in favour of the IGIV-C group was observed for improvement 
in average amplitude for all motor nerves, improvement in average conduction 
velocity for all motor nerves, MRC sumscore, grip strength (dominant hand), INCAT 
disability score, and RHS score. For the INCAT sensory score and the component 
quality of life measures, the differences were not statistically signifi cant.
For the fourth technique, using effect size to determine MCID, the effect size 
values were consistently higher in the IGIV-C group than with the scores in the 
placebo group (table 3). None of the applied outcome measures in the placebo 
group reached the MCID cut-off value of 0.5. In the IGIV-C group, the MCID cut-off 
value was obtained for INCAT disability score, grip strength, and PCS. The INCAT 
disability score had the highest effect size. The effect size for MRC sumscore, RHS 
score, and changes in amplitude for most severely affected motor nerve nearly 
reached the cut-off score of 0.5. 
Table 3. Responder analyses comparing effect size scores in the IGIV-C and placebo 
groups of patients with CIDP (fi rst period of the ICE study)
Parameter
Effect size*
IGIV-C group
n=59
Placebo group
n=58
CMAP of most severely affected motor nerve, mV 0.493 0.235
Averaged CMAP from all motor nerves, mV 0.343 0.065
Averaged velocity from all motor nerves, m/s 0.245 0.041
Conduction block, % 0.236 0.064
MRC sumscore 0.474 0.026
Grip strength-dominant hand, kPa 0.557 0.066
Grip strength-non-dominant hand, kPa 0.532 0.187
INCAT sensory sumscore 0.237 0.050
INCAT disability score 0.754 0.226
Rotterdam handicap scale score 0.458 0.071
SF-36 mental component score 0.111 0.215
SF-36 physical component score 0.719 0.170
Legend to table 3. *Effect size was defi ned as: (μ
24
 - μ
0
)/SDμ
0
; μ
24
 = mean scale value of the 
longitudinally examined group at week 24; μ
0
 = mean scale value at week = 0 [entry].25 An effect size 
of 0.5 was defi ned as the MCID.6Values that were signifi cantly (p<0.05) different versus placebo 
are shown in bold text. CIDP = chronic infl ammatory demyelinating polyradiculoneuropathy; 
CMAP = compound muscle action potential; ICE = IGIV-C CIDP effi cacy trial; IGIV-C = immune 
globulin intravenous, 10% caprylate/chromatography purifi ed; INCAT = Infl ammatory Neuropathy 
Cause and Treatment; MCID = minimum clinically important difference; MRC = Medical Research 
Council; SF-36 = Short Form-36 health survey.
Discussion
The current study is the fi rst in the fi eld of peripheral nerve treatment trials to 
use MCID methods to evaluate treatment response. It considered measures of 
impairment, activity and participation, and quality of life and used both anchor-
based and distribution-based methods on the data of the ICE trial.4 The four 
methods evaluated resulted in varied MCID cut-off values, an observation that has 
been reported in other studies.5, 6, 8, 28 However, in the current study, the threshold 
variation among the four MCID methods was smaller for the INCAT disability score 
and RHS score than for other outcome measures. Thus, for these scales, the MCID 
threshold is likely to be well defi ned and corroborated by all four methods used. 
The INCAT disability score consistently demonstrated a higher percentage of 
responders reaching the calculated MCID threshold in the IGIV-C group compared 
with the placebo group. The differences for the INCAT disability score were always 
statistically signifi cant regardless of the MCID method used, thereby neutralising 
any debate about the optimal method for the MCID calculation in this study. Using 
the 1/2 SD as the unifi ed theory MCID technique, a total of 52.2% of the IGIV-C 
group reached the MCID threshold for the INCAT disability score compared with 
22.4% in the placebo arm in the fi rst period of treatment, which is almost identical 
to the calculation of the number improving by ≥1 point, the primary outcome in the 
trial.4 Similar percentage scores were found when applying the 1 SEM distribution 
and SF-36 question number 2 as methods for assessing MCID. Using the effect size 
method, the INCAT disability scale demonstrated the highest value in the IGIV-C 
group and can therefore be considered the most sensitive to capture responsiveness 
when compared with other outcome measures applied. 
A systematic trend in favour of the IGIV-C group was also seen when evaluating 
the proportion of responders demonstrating changes greater than the MCID 
thresholds for the other outcome measures. These differences were robust in both 
the anchor-based and distribution-based techniques, with signifi cant changes seen 
for various nerve conduction study parameters, MRC sumscore, grip strength, RHS 
score, and effect size for the quality of life PCS.
The anchor-based method using the SF-36 question number 2 to identify changes 
in global health has been criticised because patient answers may be infl uenced 
by health issues unrelated to the illness examined. The retrospective rating using 
SF-36 question number 2 with an extended period of time of 1 year is probably 
susceptible to a number of known recall biases.29 In light of these biases, global 
ratings may not give an accurate picture of an individual’s ‘true’ change. Also, 
global ratings may only explain parts of the health-related quality of life fi ndings.18 
However, despite these reported shortcomings, the results in the current study with 
the SF-36 question number 2 as the anchor were comparable to the results seen 
in the various distribution-based methods, despite the differences in their cut-off 
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values for the various outcome measures. Similar comparable clinically meaningful 
changes were also reported in patients with lung cancer using anchor-based and 
distribution-based MCID methods.30
Another important issue is whether the baseline level of functioning, disability, 
or health status affects MCID thresholds. Do more severely affected patients with 
CIDP require a greater change from baseline to be considered clinically meaningful 
than patients less severely affected?[28, 31 In a study of patients with low back pain, 
a greater MCID change was required in patients with initial higher pain intensity 
than those with less pain.32 According to modern clinimetric approaches, clinically 
meaningful changes may vary across the theoretical range of an outcome measure.33 
Another important issue is whether to use a combination of an anchor-based and a 
distribution-based method to ascertain improvement in patients with CIDP.30, 34 To 
compensate for the differences seen in cut-off values for some outcome measures 
in the current paper and in the light of lack of consensus on this topic, we propose 
for future trials that patients with CIDP should be considered improved only when 
they meet 1 anchor-based plus 1 distribution-based MCID technique for change 
(the so-called ‘combined MCID robustness approach’) as has been addressed by 
others.30, 34, 35 The combination of SF-36 question number 2 (anchor-based form) 
plus the unifi ed distribution-based method of 1/2 SD is suggested in the absence of 
any current consensus. 
There are some methodological limitations to the current study that should be 
addressed. One overall limitation of using MCID techniques is the applicability to 
nonlinear scales. Most of the outcome measures evaluated in the current study 
were nonlinear, except for grip strength and neurophysiologic data. Therefore, the 
analyses in the current study should be interpreted with some caution because it 
is conceivable that a calculated MCID may vary over the range of a nonlinear scale. 
Also, the MCID approach in the current study should not be simply extrapolated to 
other illnesses. The current MCID results could, however, be useful in trials with a 
similar patient population. The results also serve as a fi rst step and framework for 
defi ning appropriate MCIDs in other chronic neurologic conditions. Importantly, 
the Peripheral Neuropathy outcome measures Standardisation (PeriNomS) study 
group has developed a linearly weighted overall disability scale for immune-mediated 
peripheral neuropathies, aiming to bypass the above postulated shortcomings and 
to increase the future applicability of MCID techniques in these conditions.36
Rheumatologists have used consensus meetings to determine the optimal 
outcome measures and methods of analysis, and neurologists have begun to follow 
a similar approach.10, 11, 31, 37-39 Additional consensus meetings should be organised 
to help researchers in the fi eld to determine whether MCID should be based on the 
patients’ or the clinicians’ points of view, whether more emphasis should be put on 
objective measures rather than subjective measures, whether future studies should 
be based on a desirable amount of change rather than a minimal measurable 
change, and whether inferences about MCID are made with respect to individuals 
or groups of patients.5-7, 18, 28, 31, 37-39
In conclusion, the current paper shows how MCID techniques for a variety 
of outcome measures can be used to compare disease progression in a CIDP 
treatment trial. The MCID approach adds a dimension of clinical relevance to 
statistical signifi cance and to the conclusions about the effi cacy of IGIV-C. The 
concept of MCID is an important contribution to the interpretation of clinical trials 
and deserves further consideration in this and other fi elds of neurology.
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Abstract
Background: Often, studies report as the primary outcome whether a statistically 
signifi cant difference between a placebo and intervention group was present, 
without taking the concept of a minimum clinically important difference (MCID) 
into account. When the MCID is considered to defi ne a responder, usually a fi xed 
cut-off value, like a fi xed estimate of the standard error (SE), is used. However, 
Rasch analysis has demonstrated that the individual SE varies, with higher SE 
at the extremes than at the centre of the scale of an interval outcome measure. 
Therefore, defi ning a responder using the concept of the MCID based on the 
individual SE should also have a dynamic pattern 
Objective: To examine the dynamic pattern of being a responder through the 
concept of minimum clinically important difference using changing SE values 
(MCID-SE) in patients with Guillain-Barré syndrome (GBS), chronic infl ammatory 
demyelinating polyradiculoneuropathy (CIDP), monoclonal gammopathy of 
undetermined signifi cance related polyneuropathy (MGUSP), and multifocal 
motor neuropathy (MMN).
Methods: Ninety-two newly diagnosed patients (GBS: 36, CIDP: 35, MGUSP: 11, 
MMN: 10) were serially examined during 1 year of follow-up. MCID-SE was 
determined in each patient for each outcome measure (GBS/CIDP/MGUSP: 
Rasch-built MRC sumscore, Rasch-built modifi ed INCAT sensory scale, Rasch-
built overall disability scale (R-ODS); MMN: Rasch-built modifi ed MRC sumscore, 
R-ODS for MMN). Since GBS and CIDP are characterised by an acute or subacute 
onset, as opposed to the more indolent course of MGUSP and MMN, and since 
there is no consensus on the magnitude of MCID-SE, different cut-off values 
were examined (1x and 1.96x SE). 
Results: In all four diseases, the changing SE values throughout all outcome 
measures captured the direction of changes (improvement, stable, deterioration). 
The number of patients being a responder varied depending on the cut-offs and 
type of illness, and were high for the R-ODS.
Conclusion: The concept of MCID-SE using variable SE values for several interval 
outcome measures demonstrated a dynamic pattern of defi ning a responder in 
patients with immune-mediated neuropathies. Future intervention studies in 
these conditions should thus consider using the concept of MCID-SE to capture 
the dynamics of defi ning a responder.
Introduction 
Clinical interventional trials performed in patients with immune-mediated 
neuropathies like Guillain-Barré syndrome (GBS), chronic infl ammatory 
demyelinating polyradiculoneuropathy (CIDP), monoclonal gammopathy of 
undetermined signifi cance related polyneuropathy (MGUSP) and multifocal 
motor neuropathy (MMN) have generally used traditional ordinal based outcome 
measures in the absence of alternative linearly constructed measures.1-6 These 
studies have generally used a fi xed cut-off score to determine responders among 
patients receiving a particular intervention. The approach of a ‘fi xed cut-off’ to defi ne 
a responder also implied a fi xed estimate of the standard error (SE) across the 
whole range (continuum) of the scales used.7 Based on the methodology of a fi xed 
standard error, the effi cacy of intravenous immunoglobulin (IVIg) over placebo was 
demonstrated in patients with CIDP through the concept of minimum clinically 
important difference (MCID) (see also chapter 5.2).8 A comparable approach has 
also been described by others.9-11 However, modern methods like Rasch analysis 
have shown variable SE values related to different patient locations on the metric 
applied, thus suggesting a dynamic changing pattern of defi ning a responder as 
opposed to the traditional approach for assessing outcome.12-15
No interventional study in patients with GBS, CIDP, MGUSP or MMN has 
examined the varying SE along the continuum of outcome measures applied. 
The purpose of the current paper is to illustrate the variable SE across various 
impairment and disability measures applied in these conditions, after converting 
these to interval measures with a linear construct using the Rasch method.11, 12 
The dynamics of defi ning a responder are demonstrated through the concept of 
minimum clinically important difference using the variable SE values (MCID-SE) in 
serially examined patients receiving interventional therapy.
Methods
Patients and examination schedule
Patients were recruited between July 2008 and November 2010 as part of the 
on-going large, international, multi-centre collaborative study, the Peripheral 
Neuropathy outcome measures Standardisation (PeriNomS) study that aims 
to improve and standardise the clinical assessment of patients with immune-
mediated neuropathies through a comprehensive clinimetric approach. A total of 
92 newly diagnosed patients with GBS (36), CIDP (35), MGUSP (11), and MMN 
(10) were recruited. Patients with GBS and CIDP were examined at entry, 1, 3, 6, 
and 12 months and patients with MMN and MGUSP at entry, 3, and 12 months of 
follow-up. All patients with GBS were treated at entry; 23 with IVIg, 6 with plasma 
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exchange, 5 with IVIg combined with prednisolone and 2 with IVIg after plasma 
exchange. All but one of the CIDP patients have been treated during follow-up, most 
of them (18) with IVIg, the others receiving corticosteroids (6), plasma exchange 
(1), immunosuppressive drugs (3) or a combination of IVIg with corticosteroids 
and/or plasma exchange (6). Of the 11 MGUSP patients, 5 have been treated (2 
with IVIg, 3 with Rituximab). All MMN patients except 1 were treated with IVIg; in 
one patient IVIg was combined with cyclophosphamide interval therapy.
All patients with GBS, CIDP, and MMN met the international criteria for their 
illness.16-18 The diagnosis of MGUSP was established after excluding all other 
possible causes for gammopathy and polyneuropathy.19
Standard protocol approvals, registrations, and patient consents
The local medical ethics committee in each participating centre approved the 
protocol. Written informed consent was obtained from all participants.
Outcome measures applied
The selection of outcome measures was based on recommendations given at 
a workshop on outcome measures in immune-mediated neuropathies.20 The 
following impairment and disability measures were selected for the patients with 
GBS, CIDP, and MGUSP:
• The MRC sumscore comprises the following six muscle pairs: upper arm 
abductors, elbow fl exors, wrist extensors, hip fl exors, knee extensors, and foot 
dorsal fl exors.21 These muscles were examined and scored using the Medical 
Research Council grades that range from 0 (paralysis) to 5 (normal strength).22
• The modifi ed INCAT sensory sumscore (mISS) embraces pinprick, vibration, light 
touch, and joint position senses assessed separately in the arms and legs plus 
the two-point discrimination only assessed at the index fi nger (using a sliding 
aesthesiometer with curved sharp tips).23 Except for the two-point discrimination, 
all sensory qualities were scored separately using response options that range 
from 0 (no sensory defi cit at the index fi nger or hallux) to 4 (highest sensory 
defi cit at acromioclavicular joint or anterior superior iliac spine). Two-point 
discrimination was scored as normal (grade 0) or disturbed (grade 1) based on 
age-dependent normative values.24
• The Rasch-built overall disability scale (R-ODS) consists of 24 daily and social 
activity items that are scored as 0 (‘impossible to perform’), 1 (‘performed with 
diffi culty’), or 2 (‘easily performed, without diffi culty’).25 This outcome measure 
at the interval level was specifi cally designed to capture activity limitations and 
participation restrictions in patients with GBS, CIDP, and MGUSP.
• For the patients with MMN, the modifi ed MRC sumscore was assessed of the 
following muscle pairs: shoulder abductors, elbow fl exors, elbow extensors, wrist 
extensors, wrist fl exors, fi nger extensors, fi ngers spreaders, fi nger fl exors, thumb 
adductor, thumb adductor, and thumb opponent. Also, a 25- items MMN specifi c 
R-ODS (R-ODS-MMN) was applied.
Study procedures
All selected measures were applied according to the previously published 
requirements.25, 26 All participating centres as part of the PeriNomS study (n=26) 
were trained in 2007 (by IM and SvN) at the Peripheral Nerve Society meeting 
(Utah, USA) aiming to standardise the assessment procedures for all scales as part 
of this study. In addition, participants received a research manual that included a 
thorough description and pictures illustrating how to assess the various sensory 
modalities for the MRC sumscore and the mISS. Patients also received standardised 
instructions for the completion of their illness-specifi c R-ODS.
Rasch analyses and statistical aspects
Creating interval measures through Rasch
The Rasch methodology has been described thoroughly elsewhere, also specifi cally 
for neurologists (see also chapter 3.1).8, 12, 13 The collected data for all selected 
outcome measures were subjected to Rasch analyses using the software Rasch 
unidimensional measurement models (RUMM).27 Data of MMN patients were 
collected and analysed separately, because all measures applied in MMN are 
illness-specifi c. The RUMM software enables the transformation of ordinal obtained 
scores into interval scores, and provides an estimate of each patient location with 
a corresponding SE on the same logit (log-odds unit) scale. 
Determining MCID-SE based on the clinical picture
Various methods have been proposed to capture clinically relevant changes in 
patients receiving interventional therapies.28-30 However, there is no consensus 
on how to quantify the importance and magnitude of such changes. Also no 
study in immune-mediated neuropathies has considered the possibility that the 
magnitude of clinical relevant change can vary, dependent on the clinical picture 
of the diagnosis and variable SE corresponding to the ability of the patient. Defi cit 
in GBS and CIDP is characterised by an acute or subacute onset, mainly driven by 
motor dysfunction and less by sensory disturbances.31 Therefore, it is conceivable 
to hypothesise that in GBS and CIDP motor changes as assessed with the MRC 
sumscore will be of a higher magnitude than sensory changes using the mISS. In 
contrast, the clinical picture of MGUSP and MMN tends to be more indolent with 
less vigorous changes. MMN generally presents with only motor defi cits, whereas 
in MGUSP, sensory disturbances are more prominent than weakness. Clinical 
changes in MGUSP and MMN will probably be less pronounced.  
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Responsiveness at the individual person level
Referred to as minimum clinically important difference-standard error (MCID-
SE) score based on the previously described signifi cant change (SigChange).14 In 
brief, MCID-SE was calculated by computing for each participating patient at each 
assessment and for each scale applied:
• their own change (person location at i month - person location at entry; where i = 
1, 3, 6 or 12 months of follow-up in patients with GBS and CIDP or 3 or 12 months 
in patients with MGUSP and MMN), 
• the corresponding SE of difference related to their individual change (SE
diff 
= 
square-root (SE
entry
2+SE
i month
2)), and 
• the fi nal MCID-SE calculations by dividing the individual change scores by 
corresponding SE
diff
 (MCID-SE = (person location at i month - person location at 
entry)/SE
diff
).13
Since there is no consensus on the magnitude of MCID-SE, we have decided to 
perform two separate classifi cations using cut-off values for the MCID-SE scores 
at 1x SE or 1.96x SE for each outcome measure applied in the various illnesses. 
The degree of uncertainty associated with the ability estimate is expressed by the 
standard error, and can be seen as an estimate of the standard deviation of the 
ability of a patient. Thus, using 1 SE gives 68% certainty that the ability is in this 
range; using 1.96 SE gives 95% confi dence. 
Five different subgroups were created, based on the MCID-SE scores: 
• subgroup 1 (clinically important improvement): MCID-SE ≥ 1 (or 1.96)
• subgroup 2 (clinically unimportant improvement): 0 < MCID-SE < 1 (or 1.96)
• subgroup 3 (no change): MCID-SE = 0
• subgroup 4 (clinically unimportant deterioration): -1 (or -1.96) < MCID-SE < 0
• subgroup 5 (clinically important deterioration): MCID-SE ≤ -1 (or -1.96)
Since a reduction in mISS score refl ects improvement, the MCID-SE cut-offs were 
reversed for the mISS scale (subgroup 1 defi ned as clinically important improvement: 
MCID-SE ≤ -1 (or -1.96); subgroup 2 defi ned as clinically unimportant improvement: 
-1 (or -1.96) < MCID-SE < 0 ; subgroup 3 defi ned as no change: MCID-SE = 0; 
subgroup 4 defi ned as clinically unimportant deterioration: 0 < MCID-SE < 1 (or 
1.96), and subgroup 5 defi ned as clinically important deterioration: MCID-SE ≥ 1 
(or 1.96).
Software
Rasch analyses were performed with the partial credit model as default (RUMM2030). 
Graphs were constructed using Stata 11.0 for Windows XP.
Results
General aspects study population
The general characteristics of participants are described in table 1. 
Table 1. General characteristics of the participants
Total GBS CIDP MGUSP MMN
Number of patients 92 36 35 11 10
Age (years), mean (SD), 
range
55.9 (19.2), 
19-90
53.3 (14.0), 
18-74
60.7 (12.6), 
45-85
46.5 (9.2), 
32-60
Gender, n (%)
Male 65 (71) 25 (69) 26 (74) 6 (55) 8 (80)
Female 27 (29) 11 (31) 9 (26) 5 (46) 2 (20)
Country of assessment, 
n (%)
Netherlands 40 (43) 19 (53) 15 (43) 3 (27) 3 (30)
USA 22 (24) 6 (17) 9 (25) 3 (27) 4 (40)
Italy 13 (14) 6 (17) 3 (9) 2 (18) 2 (20)
Canada 4 (4) 2 (6) 2 (6) - -
Belgium 5 (5) 1 (3) 2 (6) 2 (18) -
France 3 (3) - 1 (3) 1 (9) 1 (10)
UK 2 (2) 1 (3) 1 (3) - -
Spain 1 (1) - 1 (3) - -
Brazil 2 (2) 1 (3) 1 (3) - -
Variable SE with changing patient locations
The mISS and the MRC sumscore were subjected to RUMM software, hereby 
creating interval measures with corresponding locations and SE for each individual. 
Figure 1 illustrates the variable SE with changing patient locations on the Rasch-
built outcome measures. As can be seen, a somewhat ‘U-shape’ dot-pattern is 
shown, with lower SE scores in the mid-section and increasing SE values towards 
the extremes of patients’ability levels in all metrics applied. The highest variation 
in SE was seen in the Rasch-built MRC sumscore for patients with GBS, CIDP, 
and MGUSP (fi vefold). The SE varied twofold in the Rasch-built modifi ed MRC 
sumscore for patients with MMN, threefold in the Rasch-built mISS, in the R-ODS 
for GBS, CIDP, and MGUSP patients, and in the R-ODS-MMN (fi gure 1).
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Figure 1. The ‘U-shape’of the variable standard errors (SE) with changing patient loca-
tions on the various interval outcome measures applied in patients with immune-medi-
ated neuropathies
Legend to fi gure 1. GBS = Guillain-Barré syndrome, 
CIDP = chronic infl ammatory demyelinating polyra-
diculoneuropathy, MGUSP = monoclonal gammop-
athy of undetermined signifi cance related polyneu-
ropathy, MMN = multifocal motor neuropathy, SE = 
standard error, MRC = Medical Research Council, 
mISS = modifi ed INCAT sensory sumscore, R-ODS 
= Rasch-built overall disability scale.
Determining clinically relevant changes 
Tables 2 and 3 provide the MCID-SE categorisation results of all individual 
patients depending on the magnitude of clinical changes seen plus the direction 
(deterioration, stable, improvement) of such changes. Setting the MCID-SE cut-
off at ≥ 1, patients with GBS demonstrated a much faster and consistently higher 
percentage of clinically important improvement when compared to patients with 
other immune-mediated neuropathies. The highest scores were seen for the R-ODS, 
followed by the Rasch-built MRC sumscore (respectively 100% and approximately 
83% responders at 12 months follow-up). The Rasch-built mISS also demonstrated 
higher values in the GBS group, but only half of the patients showed clinically 
important improvement (table 2A). 
Rasch-built MRC sumscore
R-ODS for GBS/CIDP/MGUSP
Rasch-built modifi ed MRC sum-
score for MMN
Rasch-built mISS
R-ODS-MMN
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Figure 2. Percentage of GBS and CIDP patients reaching clinically important changes ap-
plying the concept of minimum clinically meaningful changes using different cut-offs (SE 
1x and SE 1.96x) (MCID-SE) in various interval outcome measures
Legend to fi gure 2. Patients with GBS consistently demonstrated higher scores when compared to 
patients with CIDP. The R-ODS demonstrated the highest percentages of responders in both GBS 
and CIDP. MCID-SE = minimum clinically important difference using varying individual standard 
errors (MCID-SE). GBS = Guillain-Barré syndrome, CIDP = chronic infl ammatory demyelinating 
polyradiculoneuropathy, MRC = Medical Research Council, mISS = modifi ed INCAT sensory 
sumscore, R-ODS = Rasch-built overall disability scale. 
Setting the MCID-SE cut-off at ≥ 1.96 still demonstrated a similar pattern, with 
a high percentage of clinically important improvement when assessing changes 
with the R-ODS in GBS (table 2B). A gradual increase of responders was seen in 
the GBS patients when assessing strength with the Rasch-built MRC sumscore 
(41.7% reaching the cut-off vs. 83.3% reaching a cut-off of ≥ 1 SE at 12 months of 
follow-up). The changes in patients with CIDP were lower, with only 6% showing 
clinically important improvement at 12 months on the mISS in contrast to 25% of 
the patients with GBS. Between 0-14.3% of patients with CIDP showed clinically 
important deterioration during follow-up (table 2). 
The magnitude of clinically important improvement for all selected measures 
applied in patients with GBS and CIDP is illustrated in fi gure 2. As shown, 
consistently higher values were obtained for GBS patients. Especially the R-ODS 
refl ected clinically important changes in time. 
Setting the MCID-SE cut-off at ≥ 1.96 patients with MGUSP and MMN 
demonstrated the least clinically important improvement (table 3B). 
Approximately 86% of the patients with MMN demonstrated a clinically 
unimportant improvement on the R-ODS-MMN. At a MCID-SE cut-off of ≥ 1, 
clinically important improvement on the R-ODS-MMN was seen in 11.1-37.5% of 
patients during follow-up (table 3). Using this cut-off of ≥ 1 , half of the patients 
with MGUSP demonstrated clinically important improvement on the R-ODS at 
3 months of whom half still maintained this level of improvement at 12 months 
of follow-up (table 3A). 
Table 3. Categorising the minimum clinically important difference using the variable SE 
values (MCID-SE) of each longitudinally examined patient with MGUSP and MMN ac-
cording to the size and direction of changes seen for all outcome measures applied, A: 
cut-off value at 1x SE and B: cut-off value at 1.96x SE
A: Cut-off value of 1x SE
MGUSP (n=11)
(%) of patients per subgroup
MMN (n=10)
(%) of patients per subgroup
Subgroup classifi cation 
Rasch-built 
MRC sumscore
Rasch-built 
mISS
R-ODS
Rasch-built 
modifi ed MRC 
sumscore
R-ODS-MMN
Follow-up period (months) Î 3 12 3 12 3 12 3 12 3 12
1: Clinically important improvement 11.1 0 22.2 0 50 25 22.2 37.5 11.1 28.6
2: Clinically unimportant improvement 22.2 0 55.6 66.7 0 25 22.2 0 11.1 57.1
3: Stable (unchanged) 44.4 33.3 11.1 33.3 25 25 33.3 12.5 44.4 14.3
4: Clinically unimportant deterioration 11.1 33.3 11.1 0 25 0 11.1 50 22.2 0
5: Clinically important deterioration 11.1 33.3 0 0 0 25 11.1 0 11.1 0
B: Cut-off value of 1.96x SE
MGUSP (n=11)
(%) of patients per subgroup
MMN (n=10)
(%) of patients per subgroup
Follow-up period (months) Î 3 12 3 12 3 12 3 12 3 12
1: Clinically important improvement 0 0 0 0 37.5 0 0 12.5 11.1 0
2: Clinically unimportant improvement 33.3 0 77.8 66.7 12.5 50 66.7 25 11.1 85.7
3: Stable (unchanged) 44.4 33.3 11.1 33.3 25 25 0 12.5 44.4 14.3
4: Clinically unimportant deterioration 22.2 33.3 11.1 0 25 0 33.3 50 33.3 0
5: Clinically important deterioration 0 33.3 0 0 0 25 0 0 0 0
Legend to table 3. Minimum clinically important difference using varying standard errors 
(MCID-SE); MGUSP = monoclonal gammopathy of undetermined signifi cance related 
polyneuropathy, MMN = multifocal motor neuropathy, SE = standard error. MRC = Medical 
Research Council, mISS = modifi ed INCAT sensory sumscore, R-ODS = Rasch-built overall 
disability scale. The white cells refl ect clinically important improvement.
232 233
DEFINING A RESPONDER: DYNAMIC THROUGH RASCH ANALYSES
Chapter
5.3
CHAPTER 5.3
Discussion
This study illustrates that the Rasch method reveals variable SE values depending on 
patients’ ability levels for the selected impairment and disability interval measures in 
immune-mediated neuropathies. These variable SE values enable the defi nition of a 
responder at the individual person level and may therefore have major implications 
for future trials in these conditions by defi ning clinically meaningful change for 
interval outcome measures.
Although it has been generally accepted to analyse ordinal (Likert) outcome 
measures as interval measures, the true distance between the different response 
options remains unknown, thereby making calculations with sumscores less 
meaningful. In addition, these ordinal outcome measures are used to calculate 
a group level SE that remains equal for all patients regardless their changing 
ability level. Modern clinimetric methods like Rasch analysis not only transform 
ordinal scores into interval scores, but also calculate the precise SE for each person 
location. The Rasch method demonstrates that the SE is related to the ability level 
of the patients, thereby varying across the range of the scale.14, 15
Furthermore, when establishing a cut-off value for clinically important change, 
the natural course of the disease needs to be taken into account. For example, 
the high percentage of GBS and CIDP patients reaching the 1.96 MCID-SE cut-off 
value for the R-ODS indicate that this outcome measure is capable of capturing 
the dynamic changes seen during the course and treatment of these illnesses. 
In addition to general aspects like being valid and reliable, and fulfi llment of the 
Rasch model expectations, the R-ODS has shown to be responsive when using 
the MCID-SE method for defi ning a responder in these conditions. Therefore, this 
outcome measure is proposed as the preferred outcome measure to capture activity 
limitations and participation restrictions in patients with GBS and CIDP.25 
In contrast, both MMN and MGUSP in general have a more indolent disease 
course. Only limited responders could be found at the 1.96xSE cut-off. Therefore, 
a cut-off value of 1xSE might be more consistent with the clinical course in these 
conditions. Additionally, sensory change in immune-mediated neuropathies 
is usually less prominent than motor alteration; as a consequence, the mISS is 
expected to vary less justifying choosing 1xSE as a cut-off value when using this 
outcome measure.32
As stated previously, the cut-off values of 1xSE and 1.96x SE as minimal clinically 
important difference (MCID) are defi ned arbitrarily. Although the change observed 
with a cut-off of 1xSE could also incorporate measurement error, for patients with 
an indolent clinical course a cut-off value of 1.96xSE might not capture small but 
relevant changes as clinically important. 
Data of the MRC sumscore and the mISS were analysed using the Rasch method, 
however, without a complete correction for Rasch requirements such as item bias, 
local dependency and fi t statistics. Even though it was our aim to improve fi t to the 
model, some incomplete corrections of the outcome measures were accepted in 
order to preserve to the ordinal construction of the scales. 
We have shown that the SE is not a fi xed value, but varies across the range of 
an outcome measure enabling the calculation of individual change using the 
concept of MCID-SE. Furthermore, to determine MCID-SE cut-off values the speed 
of progression of the disease course and the expected magnitude of relevant 
change of the quality examined should be considered. Consequently, for physicians 
a paradigm shift is needed towards the use of outcome measures with a linear 
construct taking into account the dynamic changing pattern of defi ning a responder 
through the concept of MCID using variable SE values. Therefore the MCID-SE 
method is suggested to be used in future trial in order to establish cut-off values to 
defi ne a responder in immune-mediated neuropathies. 
Based on the fi ndings in this study, the R-ODS questionnaires have demonstrated 
in addition to fulfi lling modern clinimetric requirements, to have relatively high 
responsiveness patterns in patients with immune-mediated neuropathies 
compared to other general measures applied. Further exploration of the various 
responsiveness entities are warranted aiming to establish a core set of outcome 
measures for standardised use in future trials and follow-up clinical studies in 
these conditions.
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General discussion and summary
 
In this thesis, the outline and results of the fi rst part of the Peripheral Neuropathy 
outcome measures Standardisation (PeriNomS) study are described. The primary 
aim of the studies described in this thesis was to improve and standardise 
assessment of patients with immune-mediated neuropathies with the fi nal aim to 
present a neuropathy-specifi c core set of high quality outcome measures for future 
immune-mediated neuropathy studies (aim of the PeriNomS study). Starting with 
the PeriNomS study we could not imagine how much we would be infl uenced by 
the changing insights in the fi eld of clinimetrics. This thesis refl ects these changing 
insights by transforming selected ordinal outcome measures to interval measures 
using the Rasch method before performing the actual comparison studies. 
Furthermore, changing insights on how to defi ne a responder using the concept 
of minimum clinically important difference (MCID) infl uenced the performed 
comparison studies. Not only in immune-mediated neuropathies, but also in other 
chronic illnesses the use of the Rasch method and the concept of MCID will be 
relevant improving assessment of patients.
Chapter 1 (general introduction) highlights the various forms of immune-mediated 
neuropathies, ranging from an acute onset of motor (-sensory) defi cit in Guillain-
Barré syndrome (GBS), to more chronic forms such as chronic infl ammatory 
demyelinating polyradiculoneuropathy (CIDP), and (far) more slowly 
progressive neuropathies such as monoclonal gammopathy of undetermined 
signifi cance related neuropathy (MGUSP), and multifocal motor neuropathy 
(MMN). Furthermore, an overview of all outcome measures applied in clinical 
trials involving patients with these disorders is presented, highlighting their 
strengths and weaknesses. Since many different outcome measures have been 
used, thus hampering the comparison of the obtained results, a strong plea for 
standardisation was made: the use of a standardised set of outcome measures 
in future studies. The clinimetric essentials, from a classic approach to more 
modern approaches like item response theory (IRT) and Rasch methodology 
are discussed. 
Finally, the Peripheral Neuropathy outcome measures Standardisation 
(PeriNomS) study is presented, a large clinimetric study carried out by 26 
centres worldwide. Its aim is to obtain a core set of neuropathy-specifi c 
outcome measures, representing the various levels of assessing outcome, 
to be used in future clinical studies in immune-mediated neuropathies. The 
studies underlying this thesis contribute to realising this aim by improving and 
standardising assessment of patients with immune-mediated neuropathies. 
Chapter 2 (normative value studies) presents the revised normative values for the 
2-point discriminator and the Jamar dynamometer, after having examined large 
cohorts of healthy controls. Normative values for the 2-point discriminator 
were needed to improve the assessment of this quality as part of the INCAT 
sensory sumscore. Until now arbitrarily chosen cut-off values for the 2-point 
discrimination quality at the index fi nger have been used. The revised normative 
values of the Jamar dynamometer were obtained using similar statistical 
techniques as have been used to calculate normative values for the Vigorimeter, 
enhancing comparison.1
Chapter 3 (Rasch-built outcome measures), the core of this thesis, refl ects a new era 
in constructing and evaluating outcome measures. It starts with an introduction 
aiming to explain and simplify the method of Rasch analysis. An example of how 
to use Rasch to improve traditional ordinal scales by translating them to interval 
scales is given by the revision of the fatigue severity scale (FSS). Furthermore, 
the construction of two neuropathy-specifi c activity and participation measures 
is described (R-ODS questionnaires), demonstrating the possibilities of using 
Rasch to create new measures with a linear construct, enabling the use of 
sumscores. A specifi c R-ODS was constructed for patients with GBS, CIDP, 
and MGUSP, fulfi lling all Rasch model expectations. Since patients with MMN 
may substantially differ in their clinical features and as a result differ in activity 
and participation restrictions, a MMN-specifi c R-ODS was constructed, also 
fulfi lling all Rasch model expectations. Compared to the currently most often 
used ordinal scale in immune-mediated neuropathy studies to refl ect disability, 
the overall disability sumscore (ODSS), the R-ODS for GBS, CIDP and MGUSP 
represents a wider range of item diffi culties thereby better targeting patients 
with different ability levels. For the R-ODS-MMN already some responsiveness 
analyses are presented (based upon a limited dataset) comparing traditional 
techniques such as effect size with more dynamic responsiveness analyses 
using Rasch-generated individual standard errors depending on the ability level 
of a patient. 
Chapter 4 (comparative validity, reliability, and responsiveness) presents the 
comparison between the Jamar dynamometer and the Vigorimeter for the 
assessment of grip strength in patients with GBS, CIDP, MGUSP and MMN. 
Based on the comparative validity and reliability analyses of these two linear 
measures, no difference was seen between both tools. Their responsiveness 
needs further evaluation. The preliminary results described in this thesis 
demonstrated a questionable low ability to detect clinically relevant change 
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for both tools. However, these results were based on a rather low amount of 
patients with incomplete follow-up data. These data will be reanalysed when 
the entire group of longitudinally studied patients included in the PeriNomS 
study has fi nalised the follow-up phase. Most patients preferred the use of the 
Vigorimeter over the Jamar dynamometer for various reasons such as ‘being less 
heavy’ or ‘less painful to squeeze a bulb’. Therefore, if both devices are equally 
valid, reliable and responsive, the use of the Vigorimeter will be suggested in 
future clinical studies. 
Also, a comparison was made between the sensory subset of the neuropathy 
impairment score (NISs) and the modifi ed INCAT sensory sumscore (mISS). 
The ISS was modifi ed by incorporating joint position and touch sense in a 
standardised manner and improving the 2-point discrimination assessment 
by using our revised age matched normative values. Both ordinal measures 
were successfully translated to interval measures fulfi lling Rasch requirements 
in general, and still maintaining their original structure. Despite the apparent 
similarity, the results of the clinimetric comparative studies are in favour of 
the mISS, because this scale demonstrated a larger targeting range, less fl oor 
effect, and better responsiveness scores. Nevertheless, these analyses will be 
repeated after closing the longitudinal part of the PeriNomS study. Presuming 
no relevant change when including more data, the use of the mISS is suggested 
as part of the future standardised core set of outcome measures.
Chapter 5 (minimum clinically important difference (MCID)) introduces the concept 
of MCID, a concept defi ning the minimum change score necessary to refl ect 
clinically relevant change. Defi ning MCID may be complex. There are many 
different methods to calculate MCID, such as anchor-based and distribution-
based methods, however, there is no consensus on the best calculation 
method. Furthermore, different interested parties (e.g., patients, clinicians, the 
community) will defi ne MCID in a different manner. 
Using data from the largest trial ever performed in patients with CIDP, 
the ICE study, the effi cacy of intravenous immunoglobulin over placebo was 
reconfi rmed, shifting hereby from statistical signifi cant to clinically relevant 
changes. Since no consensus on the use of MCID methods exists, a suggestion 
is given to defi ne a responder as a patient that fulfi ls at least one anchor-based 
and one distribution-based MCID method. The presented MCID cut-offs derived 
from the ICE study suggest a static MCID over the whole range of an outcome 
measure. However, ‘defi ning a responder’ seems to have a dynamic changing 
pattern. As has been reported by others, we noticed that the magnitude of Rasch-
generated individual standard errors depend on the ability of a patient refl ected 
by their location on the linear metric used, increasing at the fl oor and ceiling 
parts and decreasing at the middle part.2 Thus, the corresponding MCID cut-off 
calculated using these individual variable standard errors, the MCID-SE, is also 
changing per patient. This approach was subsequently applied in the currently 
available interval measures for patients with immune-mediated neuropathies. 
Comparative responsiveness studies of these measures were performed by 
determining the percentage of serially examined patients reaching a pre-defi ned 
MCID-SE cut-off. In patients with GBS and CIDP the R-ODS turned out to 
be more responsive than the Rasch-built MRC sumscore and the Rasch-built 
mISS.
Main fi ndings described in this thesis
• The fatigue severity scale (FSS), the sensory subset of the neuropathy 
impairment score (NISs) and the modifi ed INCAT sensory sumscore (mISS), 
all existing ordinal outcome measures used in patients with immune-
mediated neuropathies, were successfully transformed to measures with a 
linear construct using the Rasch method. 
• Two new interval measures capturing activity and participation limitations 
in immune-mediated neuropathy patients were created using the Rasch 
method, the Rasch-built overall disability scale (R-ODS) for patients with 
GBS, CIDP and MGUSP and the R-ODS specifi cally for patients with MMN 
(R-ODS-MMN).
• The dynamics of being a responder were demonstrated for Rasch-built 
outcome measures using individual standard errors provided by Rasch.
• The possibilities of using the concept of minimum clinically important 
difference (MCID) in defi ning a responder based on a predefi ned clinically 
relevant change instead of a statistical signifi cant change were illustrated 
with data from the ICE study. The effi cacy of intravenous immunoglobulin 
over placebo in CIDP was reconfi rmed using MCID.
• The Jamar dynamometer and the Vigorimeter are both valid and reliable 
tools. Since their responsiveness seems to be similar as well, the use of the 
Vigorimeter as the standard tool to assess grip strength in patients with 
immune-mediated neuropathies is suggested based on patients’ preference 
for the Vigorimeter.
• Clinimetric comparative studies of the sensory subset of the neuropathy 
impairment score (NISs) and the modifi ed INCAT sensory sumscore (mISS) 
are in favour of the mISS, since this scale demonstrated a larger targeting 
range, less fl oor effect, and better responsiveness scores. However, the 
comparative responsiveness studies were based on a rather low amount of 
patients with incomplete follow-up data, thus needs reconfi rmation before 
selecting the mISS for the standardised minimum core set of outcome 
measures to be used in future neuropathy studies.
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• Normative values were provided for the two-point discriminator improv-
ing and standardising the mISS. Revised normative values for the Jamar 
dynamometer were provided to enhance its applicability in clinical practice.
Clinimetric essentials
Outcome measures should be simple, communicable, valid, reliable and respon-
sive prior to their use.3-5 Currently, clinimetric properties of outcome measures are 
often examined during clinical trials. However, whether their strict in- and exclu-
sion criteria refl ect a representative study population to evaluate these properties 
is doubtful. To overcome this limitation the PeriNomS study includes patients inde-
pendent from their level of functioning. Furthermore, only simple outcome meas-
ures were selected for the comparative PeriNomS studies thereby aiming to create 
a core set of high quality outcome measures not only suitable for future clinical 
trials but also for daily clinical practice.
Linearity
Ordinal scales based on the classical test theory (CTT) do have disadvantages. 
Generally, patients are requested to complete all items of CTT-based scales, even 
though some may be irrelevant for their level of ability. Furthermore, a sum of item 
scores is often calculated assuming equal relevance and hence weighting of each 
item which is highly unlikely.6, 7 The Rasch method overcomes these limitations and 
enables the construction of interval outcome measures showing the true distance 
between patients and items on a linear ruler. When all data fulfi l the Rasch model 
expectations meaningful sumscores and change scores can be obtained suitable 
for conventional statistics. 
The calibration of items (item locations on the linear ruler representing their 
item diffi culty) is based on the characteristics of the study population. Some items 
might be easy to perform for patient with disease A (e.g., MMN), but diffi cult for 
patients with disease B (e.g., GBS). Therefore, the construction of disease-specifi c 
interval outcome measures should be considered.
Future perspectives
The studies and new insights described in this thesis contribute to improving and 
standardising assessment of patients with immune-mediated neuropathies. How-
ever, there are numerous aspects that still need to be accomplished and these are 
addressed in the following: 
• PeriNomS study: the longitudinal part is still on-going. Data collection has to 
be fi nished before performing the fi nal comparative responsiveness studies. 
Results of comparative validity and reliability studies of the cross-sectional part 
will be combined with these responsiveness analyses to present a neuropathy-
specifi c minimum core set of high quality outcome measures for future stud-
ies and clinical practice (fi nal aim of the PeriNomS study). The comparative 
responsiveness analyses of the Jamar dynamometer vs. the Vigorimeter and the 
NISs vs. the mISS will be recalculated.
• Medical Research Council (MRC) grading system versus NIS motor subset: as 
demonstrated for the modifi ed ISS versus NIS sensory subset in chapter 4.2, an 
equivalent comparison should be part of future clinimetric studies between the 
MRC grading versus the NIS motor subset using Rasch analyses. 
• MRC grading system: the MRC grading system, with its 6 scoring options from 
paralyses (0) to normal strength (5), has served for more than 7 decades as 
an apparently easy and reliable tool to assess strength of the various muscle 
groups in neuromuscular illnesses, despite being criticised due to the unequal 
width of its response categories.8-11 However, previous reports have suggested 
humans inability to differentiate between more than 3 to 4 response options.12, 13
Based on these observations, we examined the applicability and discrimina-
tive capacity of physicians using the MRC grades in patients with various neu-
romuscular illnesses with different degrees of muscle weakness. Discriminative 
capacity can be visualised through Rasch analyses by examining the ordering of 
thresholds. Many disordered thresholds were found, therefore a modifi cation of 
the MRC grading system was suggested.14
• EMG: its value as part of international guidelines on the diagnosis of various 
immune-mediated neuropathies has been established. However, there is no 
consensus whether EMG examination is a useful tool to evaluate treatment 
effect in clinical trials, and if so, which standardised EMG parameters should 
be assessed during follow-up for each immune-mediated neuropathy.15 Further 
research is necessary to evaluate the relation between improving EMG param-
eters and relevant clinical improvement from patient’s perspective.
• Skin biopsy: Skin biopsy as a new diagnostic tool is gaining recognition as a 
possible outcome measure in patients with peripheral neuropathies.16 Through 
skin biopsy, the intraepidermal nerve fi bre density (IENFD) can be determined 
and values can be compared with reported age and gender matched normative 
cut-off scores.17 In a recent paper, morphometric studies have demonstrated an 
expansion of the use of skin biopsy as a possible marker for large nerve fi bre 
neuropathies.18 Small nerve fi bres related dysfunction has been demonstrated in 
patients with peripheral neuropathies including those with GBS and CIDP. 19-22
Pan and associates were the fi rst that reported on the use of skin biopsy counting 
the intraepidermal nerve fi bre density in patients with GBS and stated that this 
244
CHAPTER 6
245
Chapter
6
GENERAL DISCUSSION AND SUMMARY
illness should be seen as a more global neuropathy, with the involvement of large 
and small nerve fi bres. This has also been investigated in a Dutch prospective 
clinical study in GBS.22 However, additional studies are needed to determine the 
clinical applicability of skin biopsy parameters as possible outcome measures 
in future clinical trials and to evaluate their prognostic value. 
• MCID: the concept of minimum clinically important difference (MCID) should 
have a more central role in defi ning future goals in trials and follow-up studies in 
patients with immune-mediated neuropathies, as well as in neurology in general. 
MCID is a rather complex concept with many ways to defi ne and to calculate 
its content.23 Different cut-offs might be necessary for the various neuropathies 
based on different courses of disease (rapidly progressive versus rather indolent), 
based on different baseline characteristics or based on the direction of change 
(improvement versus deterioration). Experts in the fi eld of immune-mediated 
neuropathies, patient representatives as well as statisticians/clinimetricians 
should join forces in order to establish the minimum requirements to defi ne 
clinically meaningful changes for every selected scale of the fi nal core set of 
outcome measures for each immune-mediated neuropathy separately.
To conclude, the studies described in this thesis can be considered as the basis 
and the fi rst part of the PeriNomS study. When also the longitudinal part of 
the PeriNomS study is fi nished and analysed, the results will be presented and 
discussed in an additional workshop in 2012/2013. This will be the fi nal step of the 
PeriNomS study to reach consensus and to present a fi nal minimum core set of 
high quality outcome measures to be used in future trials and follow-up studies 
in patients with GBS, CIDP, MGUSP and MMN. The European Neuromuscular 
Centre (ENMC) could serve as a platform for such a meeting.
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Hoofdstuk 1 (algemene introductie) belicht de verschillende uitingsvormen 
van immuun-gemedieerde neuropathieën, variërend van acuut beginnend 
krachtsverlies (veelal gecombineerd met gevoelsstoornissen) bij het Guillain-Barré 
syndroom (GBS) tot meer chronische varianten zoals chronische infl ammatoire 
demyeliniserende polyradiculopathie (CIDP), en (zeer) langzaam progressieve 
neuropathieën zoals polyneuropathie geassocieerd met een monoklonale 
gammopathie (MGUSP) en multifocale motore neuropathie (MMN). Vervolgens 
wordt een overzicht gegeven van alle testen en vragenlijsten (uitkomstmaten) 
die gebruikt zijn in wetenschappelijk onderzoek bij deze patiëntengroepen, 
inclusief een sterkte-zwakte analyse. Omdat zoveel verschillende uitkomstmaten 
worden gebruikt, is de vergelijking van onderzoeksresultaten vaak niet goed 
mogelijk. Daarom wordt gepleit voor standaardisatie: het gebruik van een 
gestandaardiseerde set van uitkomstmaten in toekomstige onderzoeken. De 
kwaliteitsvoorwaarden waar deze uitkomstmaten aan moeten voldoen worden 
toegelicht, waarbij zowel de traditionele begrippen binnen de klinimetrie als ook 
de plaats voor moderne technieken zoals de item respons theorie (IRT) en de 
Rasch methode worden besproken. 
Uiteindelijk wordt de Perifere Neuropathie uitkomstmaten Standaardisatie 
(PeriNomS) studie gepresenteerd, een grote klinimetrische studie waaraan 
wereldwijd 26 centra deelnemen. Doel is het vaststellen van een basisset 
neuropathie-specifi eke uitkomstmaten, welke de verschillende niveaus van 
meten weergeven, en die geschikt is voor de dagelijkse praktijk en voor toekomstig 
wetenschappelijk onderzoek bij patiënten met een immuun-gemedieerde 
neuropathie. De studies in dit proefschrift dragen bij aan het realiseren van dit 
doel door het verbeteren en standaardiseren van het onderzoek van patiënten 
met een immuun-gemedieerde neuropathie.
Hoofdstuk 2 (normaalwaarden studies) geeft de gereviseerde normaalwaarden 
voor de 2-puntsdiscriminator en de Jamar dynamometer, verkregen door het 
onderzoeken van grote groepen gezonde vrijwilligers. Normaalwaarden voor de 
2-puntsdiscriminator waren onder meer nodig om de INCAT sensory sumscore 
te verbeteren. Tot nu toe werden arbitrair gekozen afkappunten gebruikt om het 
vermogen tot het onderscheiden van 2 punten op de wijsvinger als normaal 
of abnormaal te classifi ceren. De gereviseerde normaalwaarden voor de Jamar 
dynamometer werden verkregen door gebruik te maken van dezelfde statistische 
technieken als waarmee de normaalwaarden voor de Vigorimeter zijn berekend 
dat het vergelijken van de twee instrumenten vergemakkelijkt.
Hoofdstuk 3 (uitkomstmaten ontwikkeld met behulp van de Rasch methode), de 
kern van dit proefschrift, laat nieuwe mogelijkheden zien met betrekking tot 
het creëren en evalueren van uitkomstmaten. In de introductie wordt de Rasch 
methode in begrijpelijke taal uitgelegd. De revisie van de fatigue severity scale 
(FSS) laat zien hoe de Rasch methode gebruikt kan worden om bestaande ordinale 
schalen om te zetten in intervalschalen. Vervolgens wordt de constructie van 
twee neuropathie-specifi eke vragenlijsten gericht op het meten van beperkingen 
in dagelijkse en sociale activiteiten beschreven (R-ODS vragenlijsten). Hierbij 
wordt de Rasch methode ingezet om nieuwe uitkomstmaten met lineaire 
eigenschappen te creëren. Voordeel hiervan is dat scores opgeteld kunnen 
worden. Er kon één R-ODS worden gemaakt voor patiënten met GBS, CIDP 
en MGUSP, welke voldoet aan de eisen van het Rasch model. De klinische 
verschijnselen van MMN patiënten zijn anders met als gevolg andere beperkingen 
in dagelijkse en sociale activiteiten, daarom werd een aparte MMN-specifi eke 
R-ODS vragenlijst ontwikkeld welke eveneens voldoet aan alle eisen van het 
Rasch model. In vergelijking tot de overall disability sumscore (ODSS), de voor 
wetenschappelijk onderzoek momenteel meest gebruikte ordinale schaal om 
beperkingen te meten bij patiënten met een immuun-gemedieerde neuropathie, 
heeft de R-ODS voor patiënten met GBS, CIDP en MGUSP een groter bereik van 
makkelijke tot moeilijke vragen. Daardoor sluit de R-ODS beter aan bij patiënten 
met verschillende niveaus van functioneren. In het R-ODS-MMN stuk worden 
al enige responsiviteitsanalyses getoond, gebaseerd op beperkt beschikbare 
data. Traditionele technieken als ‘effect size’ worden vergeleken met moderne, 
dynamische technieken waarbij met behulp van Rasch verkregen individuele 
standard errors (meetfouten) worden gebruikt. Deze hangen af van het niveau 
van functioneren van de patiënt. 
Hoofdstuk 4 (vergelijking van validiteit, betrouwbaarheid en responsiviteit) 
presenteert de vergelijking van de Jamar dynamometer en de Vigorimeter voor 
het bepalen van de knijpkracht van patiënten met GBS, CIDP, MGUSP en MMN. 
Op basis van de analyses van de validiteit en de betrouwbaarheid van beide 
lineaire instrumenten is er geen belangrijk verschil. De responsiviteit van beide 
instrumenten vergt nader onderzoek. De voorlopige resultaten beschreven 
in dit proefschrift wijzen erop dat beide instrumenten matig in staat zijn om 
klinisch relevante veranderingen weer te geven. Dit is echter gebaseerd op data 
van een relatief klein aantal patiënten waarvan de follow-up gegevens deels 
onvolledig zijn. Deze analyses zullen dan ook worden herhaald zodra de follow-
up fase van de hele groep met longitudinaal gevolgde patiënten geïncludeerd in 
de PeriNomS studie is afgerond. De meeste patiënten gaven de voorkeur aan 
de Vigorimeter boven de Jamar dynamometer om redenen als ‘minder zwaar’ 
250
CHAPTER 7
251
Chapter
7
NEDERLANDSE SAMENVATTING
of ‘minder pijnlijk om in ballon te knijpen’. Als beide instrumenten even valide, 
betrouwbaar en responsief blijken te zijn, dan zal, gezien de voorkeur van de 
patiënten, het gebruik van de Vigorimeter worden voorgesteld voor toekomstige 
klinische studies. 
Ook worden de resultaten beschreven van de vergelijking tussen het 
gedeelte van de neuropathy impairment score dat betrekking heeft op 
gevoelsstoornissen (NISs) en de gemodifi ceerde INCAT sensory sumscore 
(mISS). De mISS werd afgeleid van de ISS door toevoeging van de op een 
gestandaardiseerde wijze onderzochte kwaliteiten positiezin en tastzin en door 
de score van de kwaliteit 2-puntsdiscriminatie te baseren op onze gereviseerde 
leeftijdgebonden normaalwaarden. Beide ordinale uitkomstmaten konden met 
behulp van de Rasch methode worden omgezet naar intervalschalen die aan 
het Rasch model voldoen, met behoud van hun originele structuur. Ondanks de 
ogenschijnlijke overeenkomsten, liet vergelijkend onderzoek zien dat de mISS 
een aantal gunstigere kwaliteiten heeft dan de NISs: de mISS lijkt een betere 
weerspiegeling te geven van de gevoelsstoornissen zoals aangegeven door deze 
patiëntengroepen, de ondergrens van de schaal wordt minder snel bereikt en het 
geeft beter de verandering van de gevoelskwaliteiten in de tijd weer. Ook deze 
analyses zullen worden herhaald als het longitudinale deel van de PeriNomS 
studie is afgesloten. Indien door het toevoegen van data de resultaten niet 
noemenswaardig veranderen, dan zal voorgesteld worden de mISS onderdeel 
te laten uitmaken van het toekomstige basisset van gestandaardiseerde 
uitkomstmaten.
Hoofdstuk 5 (minimum clinically important difference (MCID)) introduceert het 
concept MCID, een concept dat betrekking heeft op het defi niëren van het verschil 
in score dat minimaal nodig is om klinisch relevant te zijn. Het kan lastig zijn 
om de MCID te defi niëren. Voor het berekenen van MCID bestaan verschillende 
methodes, zoals anker-gebaseerde methodes en verdeling-gebaseerde 
methodes. Er is echter geen consensus over de beste berekeningsmethode. 
Daarnaast zullen verschillende partijen (bv. patiënten, dokters, de maatschappij) 
een andere visie hebben op wat een klinisch relevant verschil is. 
Door data te gebruiken van de grootste klinische trial ooit uitgevoerd bij 
patiënten met CIDP, de ICE studie, is opnieuw aangetoond dat intraveneuze 
behandeling met immunoglobulines superieur is aan placebo behandeling. Dit 
keer niet alleen op basis van statistisch signifi cante verschillen maar ook door 
het aantonen van klinisch relevante verschillen met behulp van het concept 
MCID. Omdat er geen consensus is welke MCID methode het beste kan 
worden gebruikt wordt voorgesteld om in toekomstige klinische trials patiënten 
als ‘responsief’ te beschouwen als de opgetreden verandering minstens 
voldoet aan 1 anker-gebaseerde en 1 verdeling-gebaseerde afkapwaarde. De 
gepresenteerde MCID afkapwaarden in de ICE studie suggereren een statische 
MCID, gelijk over het hele bereik van de uitkomstmaat. Echter het defi niëren 
van een patiënt als wel of niet responsief lijkt een dynamisch patroon te hebben. 
Zoals al gerapporteerd werd door anderen, merkten ook wij op dat de grootte 
van de individuele meetfout (standard error = SE), gegenereerd met behulp van 
Rasch, afhangt van de locatie op de schaal: de SE neemt toe als de schaal zijn 
ondergrens of bovengrens bereikt, in het middengedeelte is de SE lager. De 
corresponderende MCID afkapwaarde, berekend met deze variabele individuele 
SE, de MCID-SE, verandert dus ook per patiënt. Deze aanpak werd vervolgens 
toegepast op de inmiddels beschikbare intervalschalen voor patiënten met een 
immuun-gemedieerde neuropathie. De responsiviteit van deze schalen werd 
vergeleken door het percentage patiënten te bepalen dat per schaal de van 
tevoren gedefi nieerde MCID-SE afkapwaarde bereikte. Bij patiënten met GBS 
en CIDP bleek de R-ODS vragenlijst responsiever dan de met behulp van Rasch 
getransformeerde versies van de MRC sumscore en de mISS.
Hoofdstuk 6 (samenvatting en toekomstperspectieven) geeft een samenvatting van 
de verschillende studies die in dit proefschrift zijn beschreven, de resultaten 
worden ter discussie gesteld en er worden suggesties gedaan voor toekomstig 
onderzoek.
Epilogue
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List of abbreviations 
AAN American Academy of Neurology
A-CIDP acute onset CIDP
AIDP acute infl ammatory demyelinating polyradiculoneuropathy
AIDS acquired immunodefi ciency syndrome
ALDS AMC linear disability score
AMAN acute motor axonal neuropathy
AMC Academic Medical Centre Amsterdam
ANOVA analysis of variance
CASS composite autonomic scoring scale
CIDP chronic infl ammatory demyelinating poly(radiculo)neuropathy
ClinJSc clinical judgment score
CMAP compound muscle action potential 
COPM Canadian occupational performance measure
CSF cerebrospinal fl uid
CTT classical test theory
DF degrees of freedom
DIF differential item functioning
DIP distal interphalangeal
EFNS European Federation of Neurological Societies
EMG electromyography
ENMC European Neuromuscular Centre
ES effect size
EuroQoL-5D EuroQoL group-5D scale 
f-score Hughes’ functional grading scale
FSS fatigue severity scale
GBS Guillain-Barré syndrome
HIV human immunodefi ciency virus
HMSN hereditary motor and sensory neuropathy
ICC intraclass correlation coeffi cient
ICC item characteristic curve
ICE trial IGIV-C CIDP effi cacy trial
ICF International Classifi cation of Functioning, Disability and Health
ICIDH International Classifi cation of Impairments, Disabilities, and Handicaps
IENF intraepidermal nerve fi bre 
IENFD IENF density
IGIV-C immune globulin intravenous, 10% caprylate/chromatography purifi ed
INC Infl ammatory Neuropathy Consortium
INCAT Infl ammatory Neuropathy Cause and Treatment
IRT item response theory
ISS INCAT sensory sumscore
IVIg intravenous immunoglobulins
kPa kilopascal
MADSAM multifocal acquired demyelinating sensory and motor neuropathy
MAG myelin-associated glycoprotein
MCID minimum clinically important difference
MCID-SE MCID using variable individual standard errors
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MCS mental component score 
mD-COMPASS modifi ed Dutch composite autonomic symptom scale
MGUS  monoclonal gammopathy of undetermined signifi cance
MGUSP  MGUS-related polyneuropathy
mISS modifi ed ISS
MMN  multifocal motor neuropathy
MRC  Medical Research Council
MS multiple sclerosis
MTX  methotrexate
NHP Nottingham health profi le 
NIS  neuropathy impairment score
NISs neuropathy impairment score - sensory subset 
ODSS  overall disability sumscore
ONLS overall neuropathy limitations scale
PCS physical component score 
PE plasma exchange
PeriNomS Peripheral Neuropathy outcome measures Standardisation
PI-NRS pain intensity - numerical scale
PN  peripheral neuropathies
PNS Peripheral Nerve Society
PPCM personal patient-centred measures 
PSI person separation index
Qol quality of life
RHS Rotterdam handicap scale 
RMC trial randomised methotrexate CIDP trial
RMI  Rivermead mobility index
R-mISS Rasch-built mISS 
R-NISs Rasch-built NISs
R-ODS  Rasch-built overall disability scale
R-ODS-MMN  Rasch-built overall disability scale for patients with MMN
RUMM Rasch Unidimensional Measurement Models
SAIDP  subacute infl ammatory demyelinating polyradiculoneuropathy
SD standard deviation
SDD smallest detectable difference 
SE standard error
SEM standard error of measurement 
SF-36 short form 36-item health survey
SFFS short-form fatigue scale
SIP sickness impact profi le
SRM  standardised response mean
VAS  visual analogue scale
VSN Vereniging Spierziekten Nederland
WEST Weinstein enhanced sensory test
WHO  World Health Organisation
WHO-QoL bref short form of the WHO quality of life scale
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